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Piscine orthoreovirus (PRV) causes heart- and skeletal muscle inflammation (HSMI) in 
farmed Atlantic salmon (Salmo salar). HSMI causes significant economic losses to the 
salmon aquaculture industry, and there is currently no vaccine available. In the trial this 
master thesis is based on, Atlantic salmon were injected with PRV-1, PRV-2, PRV-3 and 
inactivated PRV-1 to explore cross immunity and protection. In this thesis work, the focus 
was on detecting PRV specific antibodies (i.e., an IgM response). For the detection of PRV 
specific antibodies a multiplexed bead-based immunoassay was used to detect antibodies 
targeting the antigens PRV-1 σ1, PRV-μ1C, PRV-3 σ1 and PRV-3 μNS. PRV specific 
antibodies targeting PRV-1 σ1 were detected in Atlantic salmon immunized with PRV-2 and 
PRV-3, and PRV specific antibodies targeting PRV-1 σ1 and PRV-μ1C were detected in 
Atlantic salmon infected with PRV-1. There was also detected an increase in unspecific 
antibodies binding to controls after PRV-1 infection. No specific antibodies were detected in 
fish injected with InPRV-1. The PRV-3 µNS and PRV-3 σ1 antigens did not bind antibodies 
in this assay and could not be used as a reliable detection method. Immunization with PRV-3 
induced anti-PRV antibodies and completely blocked a secondary PRV-1 infection and 
protected against HSMI. PRV-2 produced low levels of anti-PRV antibodies, but did not 
block PRV-1 infection or efficiently protected against HSMI. No antibodies were detected 
after immunization with inactivated PRV-1, but an intermediate protection was still obtained. 
Multiplexed bead-based immunoassay is a sensitive and fast method that can be used as a 














The Norwegian aquaculture industry has been the world-leading producer of Atlantic salmon 
(Salmo salar L.) for the last decade. The industry plays an important role for the global food 
market and the Norwegian economy, where approximately 95 percent of produced salmonids 
are exported (1). In 2020, Norway exported seafood for over 105 billion NOK (2), and in 2050 
it is estimated that the Norwegian Aquaculture production will be traded at 550 billion NOK. 
However, there are many uncertain assumptions forming this prediction including fish health, 
disease and environmental challenges, innovation in breeding, cage engineering and fish feed 
(3).  
According to the Norwegian Veterinary Institute (VI) the average mortality rate for farmed 
Atlantic salmon was 14.8 percent in 2020 and 16.1 percent in 2019 (4). A survey performed by 
“matfiskgenerasjoner” in 2011 also registered a total loss of 16.3 percent of farmed salmon 
from 288 locations in Norway. The latter survey concluded that the largest loss was due to 
infectious virus diseases (5). Another conducted survey from 2017, reported 53 million fish as 
lost in Norway, from which 88 percent (of the lost fish) died due to diseases and handling (6).  
One of the best measures against viral diseases in fish farming are vaccines. Most virus 
vaccines for fish in Norway are based on inactivated viruses and these have limited protection 
compared to vaccines directed against bacterial diseases. As a result, there is a need for more 
effective vaccines to be developed to combat pathogenic viruses in the salmon aquaculture 
industry (7). 
 
The introduction of this master thesis is divided into three parts: A, B and C.  
• Part A describes the situation of viral diseases in the Norwegian aquaculture industry, 
closing in on heart and skeletal muscle inflammation (HSMI) and vaccination. 
• Part B describes the immune system of Atlantic salmon focusing on B-lymphocytes (B-
cells) and antibodies. 
• Part C describes the structure, subtypes, and immune responses to Piscine 




1.2 Viral diseases in the Norwegian aquaculture industry, focusing on 
Atlantic salmon 
Viral diseases represent a large problem for the fish welfare and economy as it can increase 
mortality and reduce slaughter yield. If the Norwegian Aquaculture industry is to increase its 
production in a sustainably manner, solutions must be developed that prevent viral diseases 
from infecting Atlantic salmon (8). For the last two decades, the most common and serious 
viral diseases reported to affect Atlantic salmon have been heart and skeletal muscle 
inflammation (HSMI) with a disease outbreak of 161 per locality in 2020, pancreas disease 
(PD) with a disease outbreak of 158 per locality in 2020, cardiomyopathy syndrome (CMS) 
with a disease outbreak of 154 per locality in 2020, infectious salmon anemia (ISA) with a 
disease outbreak of 23 per locality in 2020, and infectious pancreatic necrosis (IPN) with a 
disease outbreak of 22 per locality in 2020 (9, 10).  
HSMI caused by Piscine orthoreovirus subtype 1 (PRV-1) (11), PD caused by the Salmonid 
alphavirus (SAV) (12) and CMS caused by Piscine myocarditis virus (PMCV) (13) are all 
heart related diseases that commonly affect different regions of the heart of Atlantic salmon. 
HSMI is characterized by inflammation in the heart and red skeletal muscle, whereas the white 
muscle is unharmed to mildly infected (14, 15). For PD, the damage to the heart is mainly 
necrosis rather than inflammation, and in addition, most of its exocrine pancreas is missing (12, 
16, 17). The pancreas is not damaged during HSMI, and by including the pancreas in the sample 
material for histopathology it is easy to distinguish between HSMI and PD (18). For CMS there 
are mostly observed degeneration and necrosis in the heart (19, 20). CMS can be distinguished 
from PD and HSMI since it normally causes changes in neither the pancreas nor skeletal muscle 
(19, 21). Histopathology of the heart might be challenging if co-infections of PD, CMS and 
HSMI occur in the same individual, where PD can mask histological HSMI and CMS, while 
HSMI can mask histological CMS. However, other methods like revers transcription real time 
polymerase chain reaction (RT-qPCR) are used to distinguish the viruses (22). ISA is caused 
by the Infectious salmon anemia virus (ISAV) and are related to circulatory disorder (ascites), 
and infects the endothelial cells causing severe anemia and pale organs (23, 24). Infectious 
pancreas necrosis (IPN) is caused by Infectious pancreas necrosis virus (IPNV) and infects 
exocrine pancreas and causes haemorrhagic enteritis (25, 26).  
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The Norwegian government has created measures to prevent the development of viral diseases 
in the aquaculture industry. These measures are described in regulations which includes 
prevention of outbreaks, minimizing outcome of outbreaks and fight against spread of 
contagious viral diseases (27, 28). One of the measures stated in the regulations is to report on 
any increased fish mortality or suspicion of disease to the Norwegian Food Safety Authority 
(FSA). As a result, the diseases can be detected early on and defeated at an early stage before 
they spread to adjacent farms or the environment (27). Another measure is the laws associated 
with the list of infectious diseases provided by the World Organization for Animal Health 
(OIE), diseases that are mandatory to report on to the FSA. There are three lists for infectious 
diseases. The European Union (EU) directive determines the diseases on list 1 (exotic diseases, 
e.g. epizootic haematopoietic necrosis) and list 2 (non-exotic diseases, e.g. ISA, viral 
haemorrhagic septicaemia (VHS) and infectious haematopoietic necrosis (IHN)), while the 
Norwegian government determines the diseases on list 3 (national diseases, e.g. PD) (29). 
Unlisted infectious diseases (HSMI, IPN,CMS) are not mandatory to report to FSA and are 
often left unreported when diagnosed by private companies.  
The occurrence of viral diseases over the years is shown in fig.1.1 (9, 10). For the unlisted 
diseases, HMSI, CMS and IPN, there may be more outbreaks than reported in the yearly fish 
health report from VI. In 2020, the numbers of outbreaks reported by private laboratories was 
included in the outbreak collection examined at VI and resulted in an increase of reported 
outbreaks of HMSI and CMS. Therefore,  the 2020-report, most likely,  reflects the number of 
HSMI and CMS more truthfully than earlier years reports (10). Although the Norwegian 
government has strict regulations in regards to viral diseases within the aquaculture industry, 
companies often enforce additional actions to prevent disease outbreaks (30). 
 
Figure 1.1. Development of HSMI, PD, CMS, ISA and IPN from 2002 – 2020. From 2002 – 2019, not listed 
diseases are based on sample data examined by the veterinary institute (VI). For 2020, data from private 
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1.3 Heart and skeletal muscle inflammation (HSMI)  
HSMI is a disease that affects Atlantic salmon, and was first diagnosed in 1999 (18), whereas 
the link between PRV-1 and HSMI was proven experimentally in 2017 (11). Mortality from 
HSMI usually varies from insignificant to 20 percent in farms (31), while the morbidity is 
almost 100 percent in affected cages (32). Stressors such as grading, delousing, and transport 
are reported to increase mortality of HSMI infected fish (31, 33). The disease  is described to 
primarily harm the heart, in addition it cause inflammation to the skeletal muscle (11, 34). 
Atlantic salmon that die from HSMI often had significant circulatory disorders (ascites), pale 
heart with coagulated blood in the pericardial cavity, a large spleen and a grey film/veil 
(fibrinous layer) over the liver (fig.1.2) (18).  
 
Figure 1.2. Heart and skeletal muscle inflammation (HSMI) in Atlantic salmon. Macroscopic symptoms of 
HSMI in Atlantic salmon with a) pericardial cavity with coagulated blood, b) large/swollen spleen, c) pale 
heart, and d) fibrinous layer over liver. In addition to mentioned symptoms, blood or transparent liquid (ascites) 
are often observed in the abdominal cavity (14). 
 
PRV-1 is predominantly observed in farmed Atlantic salmon and to a much lower extent in 
wild Atlantic salmon (35). For farmed Atlantic salmon PRV-1 is mainly observed in the 
seawater phase (36), and is ubiquitous in the seawater phase in aquaculture, often without 
showing clinical signs (14, 36). However, PRV-1 has also emerged in freshwater facilities. 
Diagnostics of HSMI are therefore performed using histopathology as seen in fig. 1.3 (37). 
Common findings are inflammatory changes in the heart and in pronounced cases also in the 
red skeletal muscle (14, 38). For the heart pathology, the inflammation is more severe in the 
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epicardium and compact myocardium of the ventricle in early stages to a greater involvement 
of the spongy myocardium and atrium in later stages where it develops to panmyocarditis (14, 
15). There are also observations of degeneration and necrosis with loss of transverse stripes. 
Atlantic salmon with pronounced cardiac pathology may show same type of degeneration of 
myocytes in the red skeletal muscle and degeneration and necrosis of hepatocytes (14). 
Persistent PRV-1 infection has also been reported to play a role in development of black spots 
(melanin) in the white skeletal muscle (39, 40), an economical problem as it downgrades the 
fillet quality (41).  
 
 
Figure 1.3. Histopathology of Atlantic salmon infected with heart and skeletal muscle inflammation (HSMI). 
Histopathology of heart (ventricle) and red skeletal muscle of Atlantic salmon with HSMI showing massive 
inflammation in ventricle (specially epicard and compact myocardium) and red skeletal muscle. Histology 
pictures taken by Monica Nordberg during pathology course at UiT. 
 
Outbreaks of HSMI seems to be independent of region and type of farms, where some farms 
experience major problems with HSMI, while others experience few or no problems (33). 
There are indications of repeated HSMI outbreaks at some farms. This could be related to high 
stability of PRV-1 as it is a naked virus (no lipid membrane). This makes the virus more 
equipped to survive in the environment and more challenging to remove with wash (42). 
Another reason for repeated outbreaks may be related to the possibility of PRV-1 to circulate 
asymptomatically in the fish and then to infect other fish (33). The high prevalence of PRV-1 
and most viral findings not being associated with clinical disease, led to HSMI being removed 
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from the OIE list in 2014 (33). There has been reports of functional feed and fatty acid 
component (tetradecylthioacetic acid) reducing the extent of HSMI, and hence increase 
survival during an outbreak (43, 44). However, this has not curbed the outbreaks of HSMI in 
Norway. 
1.3.1 Current situation of HSMI  
In 2020, data from private laboratories was included in the data from VI. Therefore, a higher 
number of HSMI outbreaks were reported than recent years (fig. 1.1) (9, 10). Data that are not 
reported represents a problem in relation to accuracy in occurrence and prevalence of the HSMI 
outbreaks.   
HSMI outbreaks were reported on 161 locations with Atlantic salmon in 2020, where 153 
outbreaks were reported from ongrowing farms, 7 outbreaks from smolt farms and 1 outbreak 
from a broodstock farm. In addition to this, there were PRV-1 detected on 89 farms without 
HSMI. From a survey completed by fish health specialists, HSMI was strongly associated with 
mortality at ongrowing farms, where only CMS was considered more serious when comparing 














1.4 Vaccination of Atlantic salmon  
Atlantic salmon is vaccinated before transfer to on-growing farms (46). Vaccination prepares 
the immune system against a particular disease by mimicking the pathogenic microorganism 
(47).  There are different types of vaccines used in the aquaculture industry. In this section, 
attenuated and inactivated vaccination, delivery route and earlier PRV-vaccine trials will be 
covered.  
 
1.4.1 Attenuated vaccines, inactivated vaccines and DNA vaccines 
An attenuated live vaccine contains a weaker, non-pathogenic version of the pathogen. 
However, the pathogen is still able to enter and replicate in cells, and thereby trigger both the 
humoral and cellular part of the immune system. This results in a strong and long-lasting 
immune response in the host. Compared to inactivated vaccines, lower doses are required and 
there is no need for adjuvants and boosters. Nevertheless, there is a small risk of reversion to a 
more virulent pathogen due to replication (48).  
An inactivated vaccine contains a non-living version of the pathogen that upon chemical or 
thermal treatment no longer replicate and cannot cause disease in its host (e.g., no risk of 
reversion). Inactivated vaccines are less efficient in providing an immune response and hence 
they cause lower protection in the host when compared to attenuated live vaccines (48). Some, 
but not all inactivated vaccines need booster and adjuvants to trigger the immune system to 
provide long lasting protection (49-51). Adjuvants improve immune responses towards vaccine 
antigens, where there are two types: depot (oil-based adjuvants) and immune stimulants (52).  
DNA vaccines are genetic vaccines that encodes for one or several specific proteins (antigens) 
from a virus or bacteria to stimulate the immune system (53). A plasmid with encoded antigens 
is inserted into the muscle or skin and taken up by host cells which start producing the foreign 
proteins. The intracellular production of foreign proteins mimics an infection and the DNA can 
itself stimulate both the humoral and cellular part of the immune system offering long lasting 
immunity (54, 55).  
 
1.4.2 Vaccine delivery routes  
The three major ways of vaccine delivery are injection, oral and immersion. Oral vaccination 
is beneficial as it does not require handling of fish, but the amount of vaccine (feed) is difficult 
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to control. Amount of vaccine is also difficult to control during immersion vaccination as fish 
is kept dipped or bathed in the vaccine solution. An injection vaccine is administered to the 
fish either intramuscularly (i.m.) or intraperitoneally (i.p.) (fig. 1.4). There are major advantages 
using injectable fish vaccines such as longer protection period (over a year for some vaccines) 
(56), more than one antigen can be given in one  shot (most complex vaccines given in aquaculture 
today contains up to 7 pathogens) (57), all fish are sure to get vaccinated and receive the correct 




Figure 1.4. Injection of vaccine intermuscular (A) and intraperitoneal (B). Retrieved from 
https://www.hi.no/filarkiv/2016/03/laks_er_mer_utsatt_for_pd_nar_den_moter_virus_i_nye_farvann.pdf/nb-no 
 
1.4.3 PRV vaccines 
Presently, there are no commercial PRV-1 vaccines on the marked. The ongoing attempts to 
develop PRV-1 vaccines are demanding as PRV-1, cannot be cultivated and produced in 
available fish cell lines (58). In addition, PRV-1 establishes a persistent infection in Atlantic 
salmon, which increases the probability that PRV-1 may spread and mutate after vaccination 
(39, 59). Although there are challenges, two partly protective experimental vaccine candidates 
have been tested (60, 61). For the first vaccine candidate, PRV-1 was isolated from infected 
salmon erythrocytes, inactivated by formalin, and combined in an adjuvant formulation. The 
vaccine preparation and quality assurance were carried out by PHARMAQ AS. Upon i.p. 
injection in Atlantic salmon, this vaccine candidate demonstrated reduced heart lesions and 
viral loads in Atlantic salmon. However, it did not prevent PRV-1 infection (60). In the second 
vaccine trial, a DNA plasmid vaccine encoding the non-structural PRV-1 protein µNS, σNS 
and the cell attachment protein σ1 was i.m. injected into Atlantic salmon. The DNA vaccination 
delayed the infection of PRV-1 and induced moderate protection against HSMI. However, 




Part B:  
1.5 Immune system – an overview 
The main task of the immune system is to maintain homeostasis and protect the host against 
foreign materials and pathogenic microorganisms. To eliminate foreign invaders, it is crucial 
that the immune system can recognise self from non-self. The immune system is comprised by 
lymphoid organs forming defined anatomic sites that are dispersed through the body.  At these 
sites, the immune cells develop from stem cells into mature immune cells, that are competent 
to respond to antigens. And then, upon encountering antigens the matured immune cells 
become functionally activated. The lymphoid organs are divided into the primary organs, 
which are the producers of T-lymphocytes (T-cells) and B-lymphocytes (B-cells), and the 
secondary organs, where immune responses are initiated  through uptake of antigens and 
interaction between innate and adaptive immune cells (47). Teleost lacks bone marrow and 
lymph nodes that serves as lymphoid organs in mammals. Instead, thymus and head kidney 
(HK) function as their primary organs, while the kidney (including HK), spleen and mucosal 
associated lymphoid tissue (MALT) are their secondary lymphoid organs. The HK consist of 
hemopoietic tissue, developing B-cells and has antigen sampling ability. The thymus consist 
of developing T-cells (62).  
 
1.5.1 The physical and chemical barrier – the body’s first line of defence 
The physical barriers of the fish are the skin, gills, and gut. They prevent infections by blocking 
the pathogens from entering. The barrier contains mucus with antimicrobial peptides/molecules 
and immunoglobulin (Ig) secreted by MALT that capture, alert the immune system and kill the 
microorganisms (63).  
 
1.5.2 The innate immune system   
The innate immune system provides the first, immediate response to an infection, but does not 
remember prior encounters with a pathogen. The innate immune system consists of 
macrophages/monocytes1, dendritic cells (DC-cells), Natural Killer cells (NK-cells) and 
 
1 Develop from monocytes (patrols the blood) to macrophages (stationed in the tissue) 64. Lea T. 
Immunologi og immunologiske teknikker: Fagbokforlaget Vigmostad & Bjørke AS; 2006. 393 p.. 
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granulocytes (neutrophil, eosinophil, basophile). The system is activated when cells of the 
innate immune system recognize pathogen associated molecule patterns (PAMPs) on the 
microorganisms. These patterns are essential for survival and infectivity of microorganisms 
and represents a large variety of molecular signatures that has been conserved though evolution 
(i.e. ss/ds RNA, CpG DNA, flagella). The PAMPs are recognized by pattern recognition 
receptors (PRRs). PRRs are evolutionary ancient receptors expressed by innate immune cells, 
of which some are expressed on B-cells. PRRs are non-clonal (identical receptors on all cells 
of the same lineage), and includes RIG-like receptors (RLR), Toll-like receptors (TLR) and 
Nod-like receptors (NLR) that are all identified in Atlantic salmon and represent a greater 
expansion of PRR families than in mammals (47, 65-67). Upon PAMPs recognition, most 
PRRs leads to upregulation of various immunogens, including cytokines, chemokines and type 
I interferons (IFN) (47).  
Phagocytosis:  
Phagocytes are cells performing phagocytosis. Phagocytosis is a special form of endocytosis 
where the pathogen is engulfed, fused together with lysosomes containing hydrolytic enzymes 
(i.e. lysozyme) and broken down (47). The phagocytic cells in salmonids are the DC-like cells 
(68-70), macrophages, neutrophils (71-73), and phagocytic B-cells (74-76). The capability of 
phagocytosis by B-cell varies between teleost species and are relativly high in Atlantic salmon 
compared to Atlantic cod (Gardus morhua) (76).  
Degranulation:  
Degranulation is a strategy where reactive substances are released from cells. One type of 
degranulation is release of perforins and granzymes by natural killer (NK) cells or cytotoxic T 
cells to trigger apoptosis in virus infected cells (47). Non-specific cytotoxic cells (NCC) are 
identified in teleost and are seen as the evolutionary precursor of NK cells (Greenlee et al., 
1991). The NCCs spontaneous kills infectious pathogens that infiltrates the fish without any 






Opsonization and complement activation:  
Opsonization is a process where microorganisms are tagged for recognition. Antibodies, 
complement factors and soluble recognition molecules (i.e. pentraxins and collectins) opsonise 
microorganism. This facilitate the binding to specific receptors on the phagocytes. where they 
induce a cellular response (phagocytosis, degranulation, activation of complement system. 
There are three complement pathways: named the alternative, the classic and the lectin. The 
complement system consists of series of complement proteins, where cleavage of one protein 
result in a cascade of reaction. The activation of these pathways either opsonize or result in 
lysis of pathogens by forming membrane attack complexes (MACs). Alternative pathway is 
activated by complement protein 3 (C3) which are cleaved to C3b and have high affinity to 
pathogenic surfaces (47). To activate the classical pathway, antibodies (IgM) are required. IgM 
can be produced before or after antigen stimulation (78). IgM bind to pathogen and bind 
complement protein 1 (C1). The lectin pathway recognizes carbohydrates (mannose) on 
bacteria and bind mannose-binding-lectin (MBL), activating the complement system (47). 
 
1.5.3 The adaptive immune system  
Teleost lack lymph nodes, follicular structures, and germinal centre (GC) (79), and there is no 
class switching and a modest antibody affinity maturation. Teleost therefore rely on the innate 
immune system for an extended period until the adaptive immunity is kicked off (80, 81). The 
adaptive immune system consists of T-cells and B-cells. These lymphocytes recognize antigens 
ty heir T-cell receptor (TCR) and B-cell receptor (BCR). Each TCR and BCR are unique since 
they are obtained by point mutations (AID) and somatic recombination of gene segments (VDJ 
genes) where recombination activating genes 1/2 (RAG 1/2) are central. When the correct 
antigen is recognized by BCR and TCR, the cells after additional cytokine signals can develop 







1.6 Cell-mediated adaptive immune responses 
Cell-mediated adaptive immunity is organized by T-cells with their TCR complex. The TCR 
interacts with cells though Major Histocompatibility Complex (MHC) (47). Teleosts possess 
αβ TCR and γδ TCR, where the latter is not well studied in teleosts (82). Most T-cells are αβ 
TCR and divided into two groups: T-helper (Th) lymphocytes (CD4+) and T-cytotoxic (CD8+) 
lymphocytes (CTL). CTL recognize endogenous antigens and Th-cells recognize exogenous 
antigens, by interacting with MHCI and MHCII, respectively (83-85). MHCI are expressed by 
all cells, while MHCII are expressed by so-called antigen presenting cells (APC). APCs in 
salmonids include macrophages, B-cells, and DC-like cells. The latter share characteristics 
with the mammalian DCs and are so called professional APC and have the ability to present 
antigen and activate naïve T-cells (70, 86-88). 
Th-cells (CD4+) can be activated by APC where they, in mammals, differentiate into Th1, Th2 
or Th17. Th1, Th2 and Th17 secrete cytokines that target host defence against intracellular 
pathogens, parasites and extracellular pathogens, respectively (47). Teleosts secrete cytokines 
that are signatures for Th1, Th2 and Th17 in mammals. This indicates that different Th 
populations resemble those in mammals (89). Teleost possesses cytotoxic cells that are 
functionally equivalent to CTL (CD8+) in mammals (83, 89). CTL (CD8+) are effector cells 
that causes cytotoxic responses. The TCR and CD8 interacts with MHCI and kills virus infected 
cells and cancer cells either through FAS ligand or degranulation (47).  
In non-vaccinated salmonids, mature T-cells are abundant in thymus, MALT (gills and 
intestine) and in the interbranchial lymphoid tissue in the gills. In addition, lower number of 
mature T-cells are dispersed throughout the body of salmonids in organs such as kidney, spleen, 
peripheral blood (PBL), liver and heart (90, 91). Activated T-cells can differentiate into “long 
lived” memory cells that survive post-infection. Memory T-cells are reported in kidney of 









1.7 Humoral adaptive immune responses 
Humoral adaptive immune responses consist of antibodies secreted by plasma cells. B-cells 
differentiate to plasma cells upon binding of antigens with their B-cell receptor (BCR), a 
membrane-bound immunoglobulin (Ig). Antibodies and BCRs consist of an Fc-part and a Fab-
part (fig.1.5). The variable region of the Fab-part binds to the antigen, while the Fc-part binds 
to phagocytic and cytolytic cells and to different immune effector molecules (47). 
 
Figure 1.5. The structure of an antibody and BCR (Ig). The Fab-part with one variable and one constant 
region. The Fc-part with two constant regions. Retrieved from 
https://www.memorangapp.com/flashcards/28659/Antibody+Structure/#review 
 
1.7.1 Subtypes of B-cells based on Ig expression 
So far only three types of functional Igs; IgM, IgD, IgT/IgZ (IgT) have been identified in 
teleosts, where the isotype is determined by the constant (C) regions in the heavy chain: Cμ for 
IgM, Cδ for IgD and Cτ for IgT (93). IgM is evolutionary the most ancient Ig and is produced 
from early embryotic development in salmonids (94). IgM is the dominating Ig subset in the 
systemic (spleen and kidney) and peripheral sites (PBL and peritoneal cavity) in teleosts (95-
97).  IgM exist as a monomer when membrane bound and as a tetramer when secreted in serum 
(98, 99). IgM therefore has higher avidity (binding strength) when secreted (8 binding sites) 
compared to membrane bound (2 binding sites) (47, 98). Secreted IgM can bind epitopes 
closely or far apart due to their flexibility (100, 101). IgM has a role in both the innate (natural 
antibodies) and adaptive immunity (78). In Atlantic salmon, the concentrations of IgM in 
plasma vary  from 80 – 130 mg/100 mL (98, 102) and their half-life in serum of salmonids is 
from 1.3 days (103). High affinity (binding of IgM to antigen) and highly polymerized 
antibodies have a longer half-life than low affinity and low polymerized antibodies (104). IgT 
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is unique for teleost and is most likely the equivalent of IgA in humans. It is specialized for 
mucosal immunity in salmonids and has a 100-1000 fold lower concentration in plasma than 
IgM (105). Most teleosts express only membrane bound IgD, that are co-expressed with IgM 
on the same cell. Secreted IgD have been detected in rainbow trout, but not yet in Atlantic 
salmon (98). The role of IgD is however unclear (79). Atlantic salmon possess two Ig heavy 
chain loci resulting in two IgM sub variants, IgM-A and IgM-B, which both are present serum. 
However, the biological significance of having two IgM sub variants is incompletely 
understood. Like IgM, IgD has also been cloned in several teleost species including salmon 
(106, 107). The structure of membrane bound Ig (mIg) and secreted Ig (sIg or antibodies) are 
shown in figure 1.6 (99).  
 
Figure 1.6. Secreted immunoglobulins (sIg or antibodies) and membrane bound immunoglobulins (mIg) in 
teleosts. The heavy chain variable regions are shown by yellow ovals, and constant regions are represented by 
coloured ovals: baby blue, bright pink and bright green, respectively for Cμ, Cτ and Cδ (99). 
 
1.7.2 Teleost B-cells has similarities with the mammalian B-1 cells 
Three independent B-cell progenitors are known to exsist in mammals giving rise to the three 
B cell phenotypes: B-1a, B-1b and B-2 (conventional B-cells). Conventional B-cells are T-cell 
dependent and secrete antibodies upon activation (47, 108). B1 cells can be T-cell independent 
and secrete natural antibodies without contact with antigen (109). Teleost B-cells are long-
lived cells that based on the expression of B1 cell marked CD5 (110) and functional 
characteristics, resemble and is considered as a homologue of the mammalian B-1 cell. These 
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includes maintained innate functions like expression of PRRs (111), high phagocytic capability 
(74, 76), as APC where they activate T-cells (87), and secretion of natural antibodies (81). 
Natural antibodies are polyreactive (unspecific) antibodies with low affinity and can opsonize 
two or more unrelated antigens (100, 112). Their role is unclear, where they have been found 
in serum of fish (113), and are often measured as background noise in assays (101). 
Polyreactive antibodies can self-react to a number of unrelated antigens and cause 
autoimmunity (100, 114, 115). Polyreactive antibodies are also highly cross-reactive and can 
bind different antigens (78).  
Teleost B-cells are considered to be antibody-making machines secreting IgM both 
independently (natural antibodies) and dependently of external antigenic stimulation (81, 116). 
Continuous stimulation by the same external antigen can result in B-cells to become more 
specific towards antigen (100, 117). The repeated encounters with the same antigen results in 
point mutations in the variable regions of Ig through the help of activation-induced cytidine 
deaminase (AID). Thereby increasing the affinity of antibody towards the antigen. This process 
is termed affinity maturation (47). AID is identified in teleost, but where the affinity maturation 
process is happening and mechanism around are not well understood teleost (118). 
 
1.7.3 Development and distribution of B-cells 
There is a maturation gradient of B-cells in the kidney, where the HK mostly consist of 
developing pro-/pre-B-cells (rearranging of BCR) in the process of maturation. The naïve B-
cells migrate to the sites of activation; the HK, posterior kidney, spleen and periphery and 
become plasma cells which in turn may circulate back to the HK (63, 119).  
Teleost B-cells possess two types of memory: memory B cells and long-lived plasma cells. 
Memory cells have been through affinity maturation and therefore they react faster and better 
upon a secondary response (47, 120). Long-lived plasma cells are non-dividing cells that 
secrete high affinity antibodies. Long-lived plasma cells  enter into a compartment (niches) in 
the HK in teleost (120, 121). HK is a reservoir for long-lived plasma cells where these  with 
the help from other immune cells are kept alive for a long time and maintain persistent antibody 
secretion (fig. 1.7) (122). A recent study also discovered prolonged local B-cell responses in 
the peritoneal cavity of Atlantic salmon for up to nine weeks after i.p injection with SAV3, 
indicating that the peritoneal cavity also could serve as a immunological site by providing a 





Figure 1.7. B-cell development in HK and migration to/from spleen. Naïve B-cells are distributed through 
peripheral tissue through blood. Upon antigen encounter B-cell are activated and mature to plasma cells. 
Plasma cells can migrate back to the HK where they can enter a survival niche compartment and become long-
lived plasma cells (123). 
 
1.8 Antiviral immune responses 
In the aquatic environment, fish are in constantly contact with pathogens, where viruses 
outnumber other pathogens (124). The first encounter with viruses takes place  in the mucosal 
tissue, where antiviral peptides, enzymes and mucosal antibodies (IgT) fight off the pathogen 
(63, 125). The immune response against viruses are firstly combated by innate antiviral 
immune responses (i.e type 1 IFN) and secondly by adaptive immunity (47).     
 
1.8.1 Innate immune responses 
In teleosts, recognition of virus occurs through PRRs (i.e. cytoplasmic RIG-1 like receptors, 
TLR) and result in secretion of type I IFN (126). Type I Interferons (IFN α, β and others) are 
the most important antiviral defence molecules in the innate immune system. Cells that are 
infected by virus will start producing and secreting IFN and alarm other nearby cells. The 
secreted IFNs bind to  specific receptors on neighbouring cells and turn on interferon stimulated 
genes (ISG). This will lead to production of antiviral proteins (Mx protein, ISG15, viperin etc) 
that inhibit viral replication (degrade genome, inhibit virus assembly etc) (47).  
 
1.8.2 Adaptive immune responses 
The adaptive immune system provide immunological memory based on specific antigen 
recognition and memory development during the second exposure to the antigen. This is the 
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very basis for vaccination (84, 127). Naïve T-cells are activated by professional APCs and to 
differentiate into T helper cells (Th) and cytotoxic T lymphocytes (CTL). Th cells produce 
cytokines (e.g. IFN- γ and IL-2) which are critical in humoral and cellular immune responses 
against viruses. Th1 stimulates phagocytosis, antigen presentation and increase cytotoxic 
activity by CTL (47). Teleost lack true germinal centers (GC) and follicles which are important 
for B-cell proliferation and differentiation to plasma cells in mammals. The lack of follicular 
structures, point of T-cell and B-cell meeting, makes the role of T-cells towards B-cells 
uncertain in teleost (47, 80, 81). Activation of teleost B-cell through Th-cells is therefore still 
a pending question. Melanomacrophage centres observed in the HK and spleen of salmonids 
contain lymphocytes and macrophages, and might function as the equivalent of GC in 
mammals. These macrophages might present antigens to B-cells, and thereby take part in B-
cell activation and affinity maturation of antibodies (128). The adaptive immune system of 
teleosts are weaker than that of mammals, as it has  limited repertoire of antibodies, a weaker 
affinity maturation and a slower memory response (80, 81).  
 
1.8.3 The anti-viral effector functions of IgM   
The anti-viral effector function of IgM in teleost includes neutralization, agglutination for 
phagocytosis, opsonization, complement activation and antibody-dependent cell-mediated 
toxicity (120, 129, 130). Neutralizing antibodies bind specific epitopes (attachment protein) on 
the virus. The antibodies  then prevent the virus from entering the host cell and do harm, thereby 
neutralizing it (47, 120). Specific IgM with neutralizing properties towards many different 
viruses  have been demonstrated in serum of salmonids (131, 132). Agglutination occurs when 
IgM link viruses together as a “clump”. This prevents the virus to infect more cells. In addition, 
these “clumps”  are more effectively phagocytosed and removed by phagocytic cells (120). 
IgM can activate the complement system (classical pathway) and contribute to lyse and 
opsonize pathogens (78, 130, 133). NK-like cells (NCC)  are activated by IgM through 
antibody-dependent cell-mediated cytotoxicity (ADCC) and degranulate and kill infected host 









1.9 Piscine orthoreovirus (PRV) 
1.9.1 The PRV particle with its protein components 
Piscine orthoreovirus (PRV) is a common virus in salmonid fish, with three recognized 
subtypes (PRV1-3) which differ in host tropism and are linked to different diseases (134). The 
virus belongs to the genus Orthoreovirus in the family Reoviridae (135). PRV is a naked virus 
with two layers (capsid) of icosahedral structures with a size of approximately 70 – 80 nm in 
diameter (11, 136). The virus particle contains 10 double stranded RNA (dsRNA) segments; 
three λ (L), three μ (M) and four σ (S) with a total size of 23,320 nucleotides (nt) that encodes 
for at least 11 proteins (34). There are 8 proteins assumed to be structural and form the inner 




Figure 1.8. Piscine orthoreovirus (PRV).  The structural (outer and inner capsid) and non-structural (ns) 
proteins of Piscine orthoreovirus (PRV) (137). Illustrates only six of the twelve turrets (138). 
 
Mammalian orthoreovirus (MRV) is a virus related to PRV that has been extensively studied 
and is currently used as a model for predicting structural and functional properties of PRV 
(135). In MRV, the outer capsid consists of σ1, μ1 and σ3 proteins. The σ1 protein is a trimer 
attachment protein with serotype determination (139, 140). Antibody mediated protection has 
shown neutralizing functions towards the σ1 protein and an induced production of neutralizing 
antibodies when σ1 protein is presented (141, 142). The σ1 protein binds to the receptor 
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junction adhesion molecule-A (Jam-A) in mammalian cells (139, 143), but this is yet to be 
discovered for PRV. The μ1 protein is the major outside capsid protein, where three subunits 
of μ1 protein and three subuntis of σ3 protein form a heterohexamer (138). The μ1 and σ3 
proteins are proteolytic cleaved in the endosome after viral uptake and are important for viral 
entry and infectivity. The μ1 will be cleaved into μ1C and a shorter μ1n peptide and release the 
virus from the endosome to the cytoplasm (144). The viral proteins σ1 has been identified in 
serum using monoclonal antibodies (132). The cytoplasmic σ3 protein protects and binds 
dsRNA and prevents translational shutoff. The inner capsid consists of λ1/σ2, λ2, λ3 and μ2 
proteins. Here, 12 turrets/spikes are formed by the λ2 and σ1 protein (138). The non-structural 
proteins in PRV are the σNS, μNS and p13. The σNS and μNS are not part of the viral particle 
itself but serve a role in replication and host interaction (145). The μNS is the main protein 
involved in the viral factory formation (globular inclusions) as it recruits the newly replicated 
PRV proteins for virus assembly (146). Viral factories are produced to shield virus replication 
from cytoplasmic and endosomal nucleic acid sensing by PRRs (146-148).  
 
1.9.2 Piscine orthoreovirus subtype 1 (PRV-1) 
PRV-1 has been predominantly identified in salmonid species. Infection by PRV-1 is common 
for Atlantic salmon, and widely spread geographically as it has been identified in Europe 
(Norway, Denmark, Faroe Islands, Sweden, Iceland, Ireland, United Kingdom, Germany, 
France), North America (Canada, United States) and South America (Chile) (149). PRV-1 was 
first identified in Norway in 2010 through genome sequencing (34) and was connected to 
HSMI in Atlantic salmon when purified PRV-1 gave illness (11).  
 
Pathogenesis – Atlantic salmon: 
PRV-1 infects horizontally (150), and can infect Atlantic salmon though the intestinal wall 
when given anally. However, the actual route of infection is not well studied, and can be over 
the gills, orally, fin base e.g. (151).  
PRV-1 replicates after a week post-infection (wpc) in erythrocytes. Erythrocytes are seen as 
the main target cell for PRV where more than 50 percent of all erythrocytes can be infected 
(136, 152). The spleen has been shown to reflect the levels of PRV infection in blood (136). 
High plasma viremia was observed and gave massive infection in the erythrocytes. The RNA 
viral load peaked for around a week in plasma following erythrocytes (153, 154). The viral 
RNA in serum after decreased and stabilized, establishing a persistent infection. PRV-1 
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establishes a persistent infection in Atlantic salmon, as the fish fails to eliminate PRV-1 virus 
(39).  
The release mechanism from infected erythrocytes are still unknown for PRV-1 in Atlantic 
salmon, but anemia is not a clinical sign for PRV-1. However, the presence of µNS in plasma 
suggest that there is some degree of lysis of erythrocytes. Following the replication of 
erythrocytes and peak plasmic viremia (154), PRV-1 sheds from faeces to water (151) and can 
be detected in different cells including cardiomyocytes, macrophages and hepatocytes (154). 
The infiltration of inflammatory cells in the heart are dominated by CTL, which are the 
hallmark of HMSI (155, 156). Following infection of cardiomyocytes, PRV-1 can also infect 





Figure 1.9. Pathogenesis of PRV-1 in Atlantic salmon. Virus uptake through the intestinal wall, where 
erythrocytes (RBC) are infected (151). Inflammation in the heart (ventricle) and later the muscle causing HSMI 
(18). The regeneration/healing process of tissue take place with a persistent infection of PRV-1 (39). Histology 
pictures taken by Monica Nordberg during pathology course (BIO-2605) at UiT. 
 
1.9.3 Other subtypes of PRV 
There are two additional subtypes of PRV known as PRV-2 and PRV-3 which also infect 
salmonids but results in different diseases. PRV-2 causes erythrocyte inclusion body syndrome 
(EIBS) in coho salmon (Oncorhynchus kisutch). A disease characterized by acute anemia 
(157). PRV-3 (also called virus Y or PRVOm) causes HSMI‐like lesions (heart inflammation) 
and anemia in rainbow trout (Oncorhynchus mykiss) (158-160). PRV-3 is reported to be 
successfully cleared in rainbow trout and not move into persistence like PRV-1 in Atlantic 
salmon (159, 160). For PRV-3, the main host species for infection may be wild brown trout 
(Salmo trutta L.) due to infection prevalence (161). PRV-3 infection has been experimentally 
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injected into Atlantic salmon to assess the causal relationship between the virus and heart 
inflammation. During the 10 week long trial, slower transmission, less heart pathology and 
lower antiviral responses was observed compared to PRV-1  (159). There has never been 
reports of PRV-3 or PRV-2 infection in Atlantic salmon in the wild, and no trials on PRV-2 
infection in Atlantic salmon prior to the one my thesis is based on (162). 
 
1.9.4 The basis of cross-protection of PRV-1 
The PRV subtype similarity has to some extent resulted in infection between species with 
different disease development (163). PRV-3 is closer related to PRV-1 than PRV-2 when 
comparing amino acids composition and nucleotide composition. PRV-1 and PRV-3 have an 
amino acid resemblance of 90.5 percent, while PRV-1 and PRV-2 have an amino acid 
resemblance of 80.3 percent. Cross protection by cross-binding antibodies (PRV specific 
antibodies) rely on resemblance of amino acid composition between the PRV subtypes. Earlier 
studies showed that monoclonal antibodies protective against one reovirus also was protective 
against other reoviruses when targeting the outer capsid proteins (141, 164). The outer capsid 
protein PRV-1 σ1 has an amino acid resemblance of 81.6 percent and 66.7 percent towards 
PRV-3 σ1 and PRV-2 σ1, respectively. The PRV-1 outer capsid protein μ1 has an amino acid 
resemblance of 91.5 percent and 85.1 percent towards PRV-3 μ1 and PRV-2 μ1, respectively. 
The non-structural protein PRV-3 μNS has an amino acid resemblance of 82.2 percent towards 
PRV-1 μNS (164).  
 
1.9.5 Immune responses to PRV-1 
Innate immunity: 
Innate antiviral responses are primarily studied in erythrocytes, as they are the main target cell 
for infection in salmonids (165). Erythrocytes sense and respond to PRV-1 by the upregulation 
of innate effector genes resulting in a high IFN-mediated innate antiviral response (59, 166). 
The interferon stimulated genes (ISG) turned on by IFN in neighbouring cells has shown in 
mammalian host cells to block MRV (59). However, MRV may continuous its own virus 
protein production by avoiding the host`s translation block by interacting with PKR (167). This 
is not the case for PRV, where it is seen a long-lasting production of ISG. The regulation of 
these genes therefore do not indicate a blockage of IFN signal (168).The observed long lasting 
secretion of IFN from PRV-1 infected cells may trigger cross-protection against other unrelated 
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secondary viral infections (IHNV and SAV) as it induces a protective innate antiviral response 
that might last for several weeks after primary PRV-1 infection (169-171).  
 
T-lymphocytes (T-cells) response: 
The recruitment of immune cells parallelly decreases virus levels in heart and suggest that there 
is a specifically directed immune response towards myocytes. PRV-1 does not directly lyse the 
cell it infects (136, 172), and the pathogenic potential of PRV-1 can be linked to an adaptive 
(CTL mediated) immune response by the host (155, 173). Identification of transcript markers 
of CTL (granzyme A and CD8+) have been found in spleen, HK and heart, indicating a CTL 
attack on PRV-1 infected cardiomyocytes (174). Furthermore, the heart seems unaffected by 
PRV-1 infection until the recruitment of immune cells into the epicardium and the compact 
layers occur. The influx of CTL in the heart (inflammation) is characteristic for HSMI, 
followed by lysis and necrosis of cells (17, 19, 155).  
 
B-lymphocytes (B-cells) response: 
Following a PRV-1 infection, soluble and membrane-bound IgM gene expression was induced 
in HK (174). Chemokine (CCl19) attracting dendritic cells, T-cells and B-cells with their 
expressed chemokine receptor CCR7 was found in spleen and HK. In response to PRV-1 
infection, both specific antibodies and polyreactive antibodies are induced (116). The increase 
in polyreactive antibodies is observed as binding to control antigens in immunoassays and was 
neither observed in rainbow trout infected by PRV-3 nor in Atlantic salmon infected with SAV. 
Therefore, this seemed like a phenomenon typically induced by PRV-1 in Atlantic salmon (175, 
176).  
 
1.9.6 Specific antibody responses against PRV 
PRV specific plasma IgM in Atlantic salmon targeting the PRV-1 outer capsids σ1 and μ1c and 
the viral factory protein μNS, have previously been detected using bead based multiplex 
immunoassays (116). The PRV-specific antibodies were associated with protective effects, 







1.10 Aims of the study  
1.10.1 Main goal  
This master thesis is a part of the research project VivaAct, which focus on characterizing 
immune responses triggered by attenuated and inactivated viruses in Atlantic salmon (2018-
2021). The main goal of this thesis is to find out if a primary infection with PRV-2 and PRV-
3 can result in specific antibodies (i.e., an IgM response) against PRV in Atlantic salmon. This 
is done through 5 sub-goals.  
 
1.10.2 Sub-goals   
Sub-goal 1: 
Measure the PRV specific plasma immune response (IgM) in Atlantic salmon over an 18-week 
period post infected with PRV-1. 
 
Sub-goal 2: 
Measure the PRV specific plasma immune response (IgM) in Atlantic salmon over a 10-week 
period post immunization with PRV-2, PRV-3, and inactivated PRV-1.  
 
Sub-goal 3: 
Measure the PRV specific plasma immune response (IgM) after introduction of PRV-1 
shedders to Atlantic salmon immunization with PRV-2, PRV-3, and inactivated PRV-1.  
 
Sub-goal 4: 
Compare the PRV specific plasma immune response (IgM) in Atlantic salmon over an 18-week 
period post immunization with PRV-2, PRV-3 an inactivated PRV-1, using PRV-1 infection 
as a positive control and Mock as negative control. 
 
Sub-goal 5: 
Perform PRV specific antibody analyses on two different Bio-Plex 200 machines. 
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2.0 Material & Methods 
2.1 Description of vaccine trial  
The vaccine trial in Atlantic salmon was planned as part of the RCN-funded ViVaAct project, 
aiming to compare the effect of live, attenuated vaccines with inactivated vaccines against PRV 
and SAV. The trial lasted for 18 weeks and was divided into two periods. Period I was defined 
by the 10 first weeks of the trial. Here, the focus was on the immune response of the inactivated 
PRV-1 vaccine (InPRV-1) and the two viruses acting as attenuated “live” vaccines: PRV-2 and 
PRV-3. Period II was defined by the last 8 weeks of the trial and focused on the effect of the 
vaccines on a secondary infection (fig. 2.1).  
 
Figure 2.1. Timeline of the ViVaAct project. The trial lasted 18 weeks where there were six different 
tanks/groups; PRV-1, PRV-2, PRV-3, inactivated PRV-1, Negative controls and Naïve fish (later used as 
cohabs/shedders). Shedders were added 10 weeks post challenge (wpc) and split the experiment in two periods. 
Period I was the first 10 weeks of the trial (0-10 wpc) before PRV-1 shedders were introduced. Period II was 
the last 8 weeks of the trial (10-18 wpc) after PRV-1 shedders were introduced. 
 
Atlantic salmon were placed in six different 50 L freshwater tanks (groups), where group 1, 2 
and 3 contained 75 fish injected with three different PRV variants; PRV-1, PRV-2, PRV-3, 
respectively. PRV-1 was isolated and prepared from blood cells of infected Atlantic salmon 
from a previous trial (11), and originated from an outbreak of HSMI in mid Norway in 2012. 
PRV-2 was isolated from spleen tissue of coho salmon transported from Japan (157). PRV-3 
was isolated from blood cells originating from infected rainbow trout sampled during an 
outbreak in Norway in 2014 (158). Tank 4 contained 75 fish injected with formalin inactivated 
PRV-1 with adjuvants prepared by PHARMAQ/ ZOETIS. The adjuvant was a water-in-oil 
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formulation (60). Tank 5 contained 125 uninfected fish (negative controls) with injected blood 
without PRV infection (negative blood/mock), and tank 6 stored 190 naïve fish later used as 
cohabitants or shedders. At 5 wpc, 15 naïve fish were introduced to each of the groups 1, 2 and 
3 to check if the viruses were transmitted to cohabitants. Three and five weeks after addition 
(8 and 10 wpc), cohabitants were sampled/examinated for virus and at 10 wpc PRV-1 infected 
shedder fish were introduced to group 2, 3, 4 and 5b which was separated from group 5a (mock) 
to check immunity towards PRV-1 and protection from HSMI. To differentiate between 
immunized and introduced fish (cohab/shedder), the introduced fish were tattooed with a blue 
dye on the ventral side. 
Atlantic salmon had an average start weight of 45 g (0 wpc) and an average end weight of 194 
g (18 wpc). Fish were fed Nutra Olympic (Skretting) and had optimal environmental conditions 
during the trial period with temperature of 10 degrees2, oxygen varying between 80-100 percent 
and 24 hours of light. There was no mortality in any groups during the trial. The trial was 
performed at Tromsø Aquaculture Research Station in Kårvika. 
For my master thesis, antibodies in blood plasma from all groups were analysed in week 0, 2, 
5, 8, 10, 12, 15 and 18. I participated in the last 11 weeks of the trial and joined sampling at 8, 
10 and 15 wpc at Tromsø Aquaculture Research Station in Kårvika. Antibody analysis from 
week 0-15 was conducted using the Bio-Plex 200 machine at the Norwegian University of Life 
Sciences (NMBU) and the Veterinary Institute (VI) in Oslo, together with PhD student Lena 
H. Teige (NMBU) and laboratory engineer Karen Bækken Soleim (NVI), respectively, while 









2 If temperature fell under with 0.5 degrees or above with 0.5 degrees, measures were initiated (procedure at 
Tromsø Aquaculture Research Station). 
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2.2 Immunization and sampling – Tromsø Aquaculture Research Station 
Blood samples were taken from 8 fish at 0 wpc (end of the acclimation period) before the 
immunization started. The fish in groups 1-4 were injected with 0.2 mL of immunization 
material, and group 5 with control material without virus. Blood sampling from i.p injected 
fish (groups 1-5) was performed week 2, 5, 8, 10, 12, 15 and 18, where 8 fish from each group 
were sampled. In addition, blood was sampled from 6 cohabitant fish (transmission controls) 
at 8 and 10 wpc. Each plasma sample were given a code of three numbers in excel. The first 
number defined what study week the plasma was sampled, the second number explained what 
experimental group the plasma sample was collected from, and the third number was the 
identification number of the fish (sec. 6.1 Appendix). 
 
2.2.1 Sampling 
The Aquaculture Research Station was a 30 minutes’ drive from Tromsø airport (28,9 km) (fig. 
2.2). At the Research station, infected and non-infected fish were divided into two separate 
rooms to avoid contamination of tanks and samples. For period I (0 – 10 wpc), group 1, 2 and 
3 (infected with replicating virus) was in an infection room, while group 4 and 5 was in a non-
infection room. Group 6 however, was moved into the infection room in week 8 and infected 
with PRV-1 to be used as shedder fish. In week 10, both group 4 and half of group 5 (5b) was 
moved to the infected room, and shedders were introduced in these tanks, while the other half 
of group 5 (5a) was left alone in the non-infected room as a control group.  
To avoid cross infection of different viruses between groups, sampling was first completed on 
group 5, followed by group 4, 2, 3 and 1. Therefore, groups in the non-infected room were 
sampled before groups in the infected room. To avoid contamination between groups and 
samples, gloves and equipment (scissors, tweezer, scalpel, table paper) was changed and the 
work bench was sterilized after each group. In addition, scalpel blades and needles were 
changed between each fish. After week 10, all groups (except 5a) were infected with shedders 
from PRV-1. It was therefore not as crucial to change and sterilize everything between infected 





Figure 2.2. The Aquaculture Research Station in Tromsø, Kårvika. To the left, road map from Tromsø airport 
to the sampling spot at Tromsø Aquaculture Research Station. Retrieved from google maps. To the right, 
Tromsø Aquaculture Research Station, site of trial. 
 
Upon sampling, the Atlantic salmon was netted into a bucked containing an overdose of 
benzocaine. Blood samples were drawn immediately post-mortem from the caudal vein 
(aorta/vena caudalis) (fig. 2.3). Blood was sampled into Li-heparin vacutainer tubes (4mL) 
and stored on ice. The blood samples were centrifuged for 10 minutes at 3000g and 4 degrees 
on Multifuge Heraeus 1 s-r (Id-Nr: 20057821-a) later the same day. The plasma samples were 
pipetted into a micro tube (700 µL) and temporarily stored on minus 20 degrees at the Artic 
University of Norway (UiT). The day after, the plasma samples were packed with cooler 
elements when transferred to NVI in Oslo. Here, the plasma samples were stored on minus 80 
degrees until further analysis.  
 
Figure 2.3. Blood sampling at Aquaculture Research Station in Tromsø, Kårvika  





2.3 Preparation of bead-based antibody assay 
2.3.1 The principal of Bio-Plex 
Bio-Plex (Luminex) assay is a sensitive bead based multiplex assay that enables results in a 
shorter time with less work, and precise results with less sample material, compared to other 
analytical techniques (i.e ELISA). The beads are magnetic and coloured internally with ten 
different colours of red and infrared fluorescence dye, which in combination makes up 100 
different beads (fig. 2.4). Each bead type can be coated with a protein (sec. 2.3.2). The beads 
can be distinguished from the other beads due to its different red and infrared fluorescens dye. 
Different proteins can therefore also be combined in the same analytical sample well, so called 
multiplexing (177). 
Plasma contains a pool of different polyclonal antibodies (178). Polyclonal antibodies are 
produced by different clones of plasma B-cells targeting the same antigen, but different 
epitopes (179). During analysis, plasma was heat treated to decrease binding of polyreactive 
antibodies before added to coated beads (116). The primary Mouse Anti-Salmonid IgH 
monoclonal antibody (Cedarlane/Nordic BioSite, cat. CLF004, size 250 µg) was added to 
plasma antibodies attached to beads (fig. 2.7). Monoclonal antibody is produced by identical 
B-cells that are cloned from a single parent cell. To produce monoclonal antibodies, mouse is 
injected with a specific antigen (salmonid antibodies), multiple times. Spleen cells are isolated 
and fused with myeloma cells. The hybrid cell (hybridoma) are selected and cultured to produce 
identical monoclonal antibodies against heavy chain of salmonid antibody (179). Monoclonal 
antibodies are specific and react only with its introduced epitope (in this case salmonid IgH) 
and not with any other antigen (100). The secondary biotinylated Goat Anti-Mouse-IgG2a 
polyclonal antibody (SouthernBiotech, cat. 1080-09, concentration of 0.5 µg/µL) was added 
after the primary antibody (fig. 2.7). Polyclonal antibodies are produced by goat being injected 
with a specific antigen (Anti-Mouse-IgG2a). A mixture of antibodies is produced from 
different clones of plasma B-cells, where they target the same antigen but different epitopes. 
These polyclonal antibodies are harvested and isolated from serum of goat (179). Streptavidin-
PE conjugate is added to the biotinylated secondary antibody (fig. 2.7). Streptavidin bind biotin 
and give a light signal (PE) which can be detected by the Bio-Plex 200 machine as mean 
fluorescence intensity (MFI). MFI signal is therefore correlated to plasma antibodies bound to 





Figure 2.4. Magnetic beads used for multiplex assay. To the left, the bead region/gate of 100 different coloured 
bio-plex beads with their bead number 1-100. The different beads can be in the same well and target up to 100 
different analytes at the same time. To the right, beads during the staining process. The dye contains a solvent 
that allow the beads to swell and coat the polymer layer of the bead. The removal of this solvent trap the dye 
inside the bead and results in many uniquely coloured beads (177). 
 
The beads are pushed through a detection chamber, which emits red (635 nm) and green (532 
nm) laser, where the red classification laser identifies the bead colour, and thereby the 
gate/region of the beads (fig. 2.4). The green reporter laser identifies the intensity of red 
fluorescence reporter signal (streptavidin-PE binding to biotin) (fig. 2.5). The maximum 
fluorescence of the green laser that can be obtained is 25000 mean fluorescence intensity 
(MFI). At 25000 MFI, all proteins (antigens) have analytes (antibodies) attached (177). 
 
Figure 2.5. Beads pushed though the detection chamber. Beads are identified by the red classification laser 




Bio-Rad recommended bead count to be set to 50 beads in each region. This would ensure that 
at least 50 beads per region would be acquired before next well could be analysed. A time limit 
to each well was set to ensure that the reading did not continue for an extended length of time 
(0-200 sec). The flow of beads, the bead count, the bead region, and the platform temperature 
were monitored. If the system detected a problem in any of these areas, it triggered sample 
errors (table 2.1) (180). 
 
Table 2.1. Different errors, error triggers and error causes during Bio-Plex 200.  Error 1, 2 and 4 was 
triggered during Bio-Plex run of plasma samples (180). 
Error: Error triggered Possible cause: 
1. Low bead 
number 
If there are less than 25 % 
of acquired beads per 
bead population 
Too few beads in the assay; buffer volume in well is too low; plate 




Above 50 percent of 
aggregation in well 




 Microbubbles in the cuvette; beads have become photobleached; 
percentage of beads outside the selected bead region is too high. 
4. Region 
selection 
If there are less than 20 
beads counted for each 
bead population 
Incorrect beads were selected in the Protocol or assay; too few 
beads are present in the assay 
5. Platform 
temperature 
 Platform temperature has fluctuated ±2ºC during the reading. 
   
2.3.2 The principle of bead coating 
The surface of beads is covered with carboxyl groups, which offers multiple attachment sites 
for proteins. The attachment of proteins to the beads is called “coupling” reaction. The carboxyl 
groups on the beads are reactive and it is therefore easy to couple a desired protein to the bead. 
The COOH groups exposed on the beads are activated by a simple two step carbodiimide 
reaction, where N-hydroxysulfosuccinimide (S-NHS) reacts with N-(3-
Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDAC) to form a S-NHS-ester 
intermediate (active ester). This active ester can react with the primary amine group (NH2) of 
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a protein and form a permanent covalent attachment between the protein and bead (fig. 2.6) 
(181). 
 
Figure 2.6. Coating of protein (antigen) to beads.  Coupling reaction where the carboxyl group is activated by 
S-NHS and EDAC to form an active ester which bind the primary amino group (NH2) in proteins. Retrieved from 
Bio-Rad`s instructions manual. 
  
Antibodies bind specific epitopes on the protein, and it is therefore important that the coated 
protein mimic the structure of the protein as it is presented in the fish. The higher similarity 
between the protein on the bead and the protein presented in the fish, the higher the chance that 
the antibodies bind to the protein. How the proteins are coated to the bead are therefore of 
importance for antibody detection in plasma of Atlantic salmon. The manufacturers for each of 
the proteins used in this master thesis are listed in table.2.2.  
Recombinant PRV-1 σ1 and PRV-1 μ1c proteins were produced in Escherichia coli (E.coli) 
(172). In 2019, lipid modified PRV-1 σ1 (σ1-LM) was discovered to be a sensitive and reliable 
antigen for detection of anti-PRV-1 antibodies in plasma of Atlantic salmon (116).  The lipid 
modification of the N-terminal of PRV-1 σ1 increased specific detection of anti-PRV IgM, 
whereas PRV-1 σ1 failed to bind antibodies without the lipid modification. This was proposed 
to be related to the way the PRV-1 σ1-LM was coated on the beads, where the lipid either made 
the protein more available for the antibodies to bind or stabilized its optimal structure (116, 
132). The viral PRV-1 μ1C and PRV-1 μNS proteins have also been used to detect antibodies 
infected with PRV-1 in Atlantic salmon (132), but the bead coating of these antigens to beads 
have not yet been identified to only bind specific antibodies (polyclonal) towards PRV-1 as 
PRV-1 σ1-LM (116). In this trial, PRV-1 μNS was not used, as the protein was not available 
at the time plasma samples were analysed. The PRV-3 proteins σ1 and μNS were tried out for 
the first time to check if they could detect specific antibodies from PRV-3 infected fish. In 
addition, three control proteins from the infectious salmon anemia virus (ISAV) were analysed 
with plasma samples. ISAV FP-LM worked as a control protein for PRV-1 σ1-LM as they were 
both outer capsid proteins that were lipid modified, while unmodified ISAV FP worked as a 
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control protein for PRV-1 μ1C, as both are endosome fusion proteins. The lipid modified ICP11 
(ICP11-LM), a protein from white spot syndrome virus that infect shrimp was added as an 
additional control protein that salmon could definitely not have been exposed to earlier. ICP11 
is a non-structural protein that acts as a DNA mimic (182).  
 
Table 2.2 Overview of the manufacturer of the antigens and protein concentration. 
Manufactured by Antigen w. concentration 
Kumar Subramani ILA FP (0.046 mg/ml) 
Kumar Subramani ILA FP-LM (0.054 mg/ml) 
Kumar Subramani ICP11-LM (0.2 mg/ml) 
Øystein Wessel PRV-1 µ1c (0.62 mg/ml) 
Kumar Subramani PRV-1 σ1-LM (0.12 mg/ml) 
Ingvild Berg Nyman PRV-3 σ1 (0.4 mg/ml) 
Ingvild Berg Nyman PRV-3 µNS (0.4 mg/ml) 
 
2.3.3 Bead coating 
The coupling reaction was performed according to the Bio-Rad`s instructions manual; Bio-
Plex ProTM Magnetic COOH Beads Amine Coupling Kit (BIO-RAD, cat.171-406001). The 
coupling kit contained wash buffer, bead activation buffer, phosphate buffered saline (PBS 
buffer), blocking buffer and storage buffer.  
Antigens used for bead coating: 
- Two PRV-1 proteins (σ1-LM and µ1C). 
- Two PRV-3 proteins (σ1 and µNS). 
- Three control proteins (ISAV FP, ISAV FP-LM and ICP11-LM). 
New Eppendorf tubes (bead tubes) were marked with bead number and protein. The COOH 
beads (beads) with a stock concentration of 1.25 x 107 beads/mL were vortexed for 30 seconds 
and stored into a floating rack added cold water and sonicated by sound waves for 15 seconds. 
Beads were added to bead tubes according to the amount of protein available at this time point. 
How many beads, how much protein in what volume during coating, and the ratio of protein to 




After beads were added, step 1-11 was completed:  
1. Tubes were placed on a plastic rack onto a magnetic separator, DynamagTM -2 (Thermo 
Fisher Scientific, cat. 12321D) for 30 – 60 seconds to allow the beads to attach to the 
magnet.  
2. The supernatant was pipetted away carefully to avoid removal of beads. Pipette tip was 
changed between each bead tube.  
3. The plastic rack was lifted away from the DynamagTM – 2. 
4. Each bead tube was added 100 µL wash buffer and vortexed for 30 sec. Step 1-3 was 
repeated.  
5. Bead tube was added 80 µL of bead activation buffer and vortexed for 30 seconds. The 
bead tubes were put in a drawer away from light. 
6. 10 mg of N-hydroxysulfosuccinimide (S-NHS) and 10 mg of N-(3-
Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDAC) was weighed into 
two new Eppendorf tubes. 200µl bead activation buffer was added to the S-NHS and 
EDAC tubes, and both tubes were vortexed for 30 seconds.  
7.  Bead tubes were added 10 µL S-NHS and vortexed for 30 seconds, followed by 10 µL 
of EDAC and vortexed for 30 seconds. To avoid light, the bead tubes were wrapped in 
aluminium foil and put in the HulaMixer – Sample Mixer (Thermo Fisher Scientific, 
cat. 15920D) at room temperature for 20 minutes.  
8. 150 µl of PBS buffer (pH 7.4) was added to bead tubes followed by 10 seconds vortex. 
Step 1–3 was repeated.  
9. Bead tubes were added 150 µL PBS buffer (pH 7.4) and vortexed for 10 seconds. Step 
1-3 was repeated.  
10. Bead tubes were added 100 µL PBS buffer (pH 7.4) and vortexed for 30 seconds.  
11. Finally, protein and PBS buffer were added to beads (Appendix sec. 6.3). The 
instruction manual noted that one coupling reaction equalled 1.25 x 106 beads and 
required 5-12 µg protein.  
Here, 12 µg protein were added for the 1st coupling reaction performed (table 2.3). Different 
coupling scale reactions were completed depending on amount of protein available at this time 
point. A x1 coupling reaction was completed for bead 27 and 28. A three-fold coupling reaction 
(x3) was completed for bead 29, 34, 44, 54 and 64. The protein coating had a concentration of 
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24 µg protein/mL, while the protein/bead – ratio in coating tube was 9.6 protein per million 
beads. Volume of protein and PBS buffer (pH 7.4) added is calculated in Appendix sec. 6.3. 
 
Table 2.3. 1st coating of beads used in Bio-Plex analysis. Beads and proteins added to bead tubes with final 
ratio. A single (x1) coupling reaction equalled 1.25 x 106 beads with 12 µg protein in a volume adjusted to 500 

















Coupling reaction: x1 x1 x3 x3 x3 x3 x3 
Beads added (number) 1.25 x106 1.25 x106 3.75 x106 3.75 x106 3.75 x106 3.75 x106 3.75 x106 
Protein added (µg) 12 12 36 36 36 36 36 
Final volume (mL) 0.50 0.50 1.50 1.50 1.50 1.50 1.50 
 
 
Final bead concentration 
(beads/mL) 2.5 x106 2.5 x106 2.5 x106 2.5 x106 2.5 x106 2.5 x106 2.5 x106 
Final protein 














9.6 µg/  
million beads 









There was also a second coating of beads performed, not used in further analysis. Here, 
different concentrations of protein were added when coating (table 2.4). Depending on amount 
of protein available at this time point. A x0.5 coupling reaction was completed for bead 27. A 
three-time coupling reaction (x3) was completed for bead 29, 34 and 44. Bead 27 and 44 had 
different protein/bead – ratio during coating. Volume of protein and PBS buffer (pH 7.4) 







Table 2.4. 2nd coating of beads used in Bio-Plex analysis. Beads and proteins added to bead tubes with final 
ratio. A single (x1) coupling reaction equalled 1.25 x 106 beads with 12 µg protein in a volume adjusted to 500 







PRV-1 µ1C  
(34) 
PRV-1 σ1-LM  
(44) 
Coupling reaction: x0.5 x3 x3 x3 
Beads added (number)  6.25 x105 3.75 x106 3.75 x106 3.75 x106 
Protein added (µg) 5.3 36 36 27.36 
Final volume (mL) 0.25 1.50 1.50 1.50 
Final bead concentration 
(beads/mL) 2.5 x106 2.5 x106 2.5 x106 2.5 x106 
Final protein concentration 
(µg/mL) 21.2 24 24 18.2 
Ratio  
(µg protein/beads) 
8.48 µg /  
million 
beads 
9.6 µg/  
million 
beads 
9.6 µg/  
million 
beads 




The bead tubes were vortexed, packed in aluminium foil and incubated for 2 hours at room 
temperature in the HulaMixer. After 2 hours, the bead tubes were unwrapped from the foil and 
step 1-3 was repeated. The bead tubes were then added 500 µL PBS buffer (pH 7.4) and 
vortexed for 30 seconds before step 1-3 was repeated. The bead tubes were added 250 µL 
Blocking buffer and vortexed for 15 seconds. The tubes were packed in aluminium foil and 
incubated in the HulaMixer at room temperature for 30 minutes. After 30 minutes, bead tubes 
were unwrapped from the foil and step 1-3 was repeated. The bead tubes were added 500 µL 
Storage buffer and vortexed for 20 seconds before step 1-3 was repeated. Finally, bead tubes 
were added 150 µL Storage buffer and placed into a new black Eppendorf tube (black tube).  
The bead concentration and aggregation of beads were checked. A 10 – fold dilution of the 
coated beads was made, where 18 µL Storage buffers and and 2 µL coated beads were added 
to a microtiter plate, respectively. Before pipetting beads, the black tube was vortexed and 
mixed by pipetting. The storage buffer and coated beads were mixed by pipetting and 10 µL of 
the diluted sample was taken onto a countess chamber and put in Countess II FL, invitrogen 
(Thermo Fisher Scientific, cat. AMQAF1000). The concentrations of coated beads are listed in 
sec. 6.3 Appendix table 2.17. How many beads at the start and at the end of the coating together 




The black tubes were stored in the fridge at 4 degrees. The proteins, S-NHS and EDAC 
solutions were stored at minus 20 degrees, while the uncoated beads and kit were stored in the 
fridge at 4 degrees.  
 
2.3.4 Flow buffer preparation 
Flow buffer was made from 50 mL of 10x Flow buffer added to an autoclaved bottle of 450 
mL distilled H2O. 8.3 mL of 30 % bovine serum albumin (BSA) was added to the solution and 
gave a final concentration of 0.5 % BSA. The lid was tightened, and the solution was mixed 
by shaking the bottle.  
 
2.3.5 Plasma preparation   
A 10-fold dilution of plasma samples was prepared at NVI. The plasma was taken from minus 
80 degrees onto ice for thawing. PBS buffer (pH 7.2) and a microtiter plate was placed on ice 
to ensure cold environment for the samples. 20 µL of plasma was pipetted into the microtiter 
plate according to the microtiter plate setup (sec. 6.1 Appendix). When all wells were filled 
with plasma, 180 µL PBS buffer (pH 7.2) was pipetted onto the microtiter plate. Air bubbles 
and volume in the pipette tips were checked to ensure that the same volume was pipetted each 
time. The diluted samples were resuspended three times to homogenize the solution and stored 













2.4 Execution of bead-based antibody assay  
In this section, the steps involved in the bead-based antibody analysis will be explained. An 
overview of the procedure is shown in fig. 2.7. The antibody assay was analysed on a black flat 
bottom 96 well plate (Bio-Rad), shielding the analytes from light.  
 
 
Figure 2.7. The lab preparation of the 96-well plate for Bio-Plex analyses. 
 
Seven 96-well plates were analysed on Bio-Plex. The un-used wells in the plate were covered 
by tape. The 96-well plate overviews of plasma samples analysed on Bio-Plex can be found in 
Appendix sec. 6.2. 
 
2.4.1 Mastermix added to the 96-well plate. 
Beads were vortexed and pipetted into a new 15 mL tube together with prepared flow buffer. 
Each sample (well) contained 2500 beads of each bead number and the mastermix volume was 
50 µL and had a concentration of 50 beads of each type/µL. Calculations can be seen in sec. 
6.4 in Appendix. 
Washing beads: 
200 µL flow buffer was added to each well, followed by 50 µL of bead mastermix (2500 beads). 
The mastermix tube was vortexed for 30 seconds and pipetted several times before and after 
transfer to the plate to ensure that all beads left the pipette tip. A black lid was placed on the 
plate to protect the beads from light and the plate was incubated on a Heidolph™ Titramax 
Vibrating Platform Shaker (Fisher scientific, cat. 13-889-871) at room temperature at 750 rpm 
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for 30 seconds. The plate was placed on a magnet for 1 minute. The magnetic beads were 
attracted to the magnet and the supernatant could therefore be emptied in the sink by force. The 
plate on the magnet was tapped three times on paper before the plate was discharged. 
 
2.4.2 Plasma samples  
Heat treatment of plasma samples: 
The premade 10-fold diluted plasma samples in the microtiter plates were thawed at room 
temperature. The plasma samples were heat treated on a Heidolph flat hood incubator 1000 
(Fisher scientific, cat. 544-12200-00-4) for 20 min at 48 degrees and 150 rpm to decrease 
binding of unspecific components to the beads (116). Heat treatment was only done once and 
not repeated for the microtiter plates with 10-fold diluted plasma.   
100-fold dilution of plasma samples: 
A 100-fold dilution was prepared from the premade 10-fold diluted plasma samples according 
to the 96-well plate overview in sec. 6.2 in Appendix. Flow buffer was emptied into a 
disposable box so a multi pipette could be used when pipetting 67.5 µL of flow buffer to a new 
microtiter plate. 7.5 µL of plasma was then added into each of the wells with flow buffer to a 
total of 75 µl.  
Plasma samples added to the 96-well plate: 
50 µL of the 100-fold diluted plasma samples was added to each well of the 96-well plate using 
a multi pipette. The pipette tips were changed for each plasma sample. A black lid was placed 
on top of the plate and the plate was incubated on a Heidolph™ Titramax Vibrating Platform 
Shaker at room temperature at 750 rpm for 30 minutes. The plate was washed three times (step 
1-4 below repeated three times).  
1. 200 µL flow buffer was added to each well.  
2. The plate with lid was incubated on a Heidolph™ Titramax Vibrating Platform 
shaker at room temperature at 750 rpm for 30 seconds.   
3. Plate was placed on a magnet for 1 minute. 
4. The supernatant was emptied in the sink and the plate was tapped three times on 




2.4.3 Primary antibody, secondary antibody, and streptavidin  
The primary Mouse Anti-Salmonid IgH monoclonal antibody (Cedarlane/Nordic BioSite, cat. 
CLF004, size 250 µg) was diluted 1:400 in flow buffer to a concentration of 0.62 µg/µL. The 
secondary biotinylated Goat Anti-Mouse-IgG2a polyclonal antibody (SouthernBiotech, cat. 
1080-09, concentration of 0.5 µg/µL) was diluted 1:1000 in flow buffer to a concentration of 
0.5 ng/µL. The reporter fluorochrome, streptavidin-PE conjugate (Invitrogen) was diluted 1:50 
in flow buffer to 20 µg/mL. The volume calculated for all 96-well plates can be seen in 
Appendix sec. 6.5.  
Flow buffer was added to three 15 mL tubes followed by primary antibody, secondary antibody 
and streptavidin in separate tubes. Tubes were vortexed for 30 sec and put in a drawer away 
from light. A volume of 50 µL of diluted primary antibody, secondary antibody and 
streptavidin was added to wells with three repetitive washing steps (step 1-4 below) between 
each step. For each step, a black lid was placed on top of the plate and it was put on 
Heidolph™ Titramax Vibrating Platform Shaker at room temperature at 800 rpm for 30 
minutes for primary antibodies and at 750 rpm for secondary antibody and streptavidin. 
1. 200 µL flow buffers to each well was added.  
2. The plate was incubated on a Heidolph™ Titramax Vibrating Platform Shaker at 
room temperature at 750 rpm for 30 minutes.   
3. Plate was placed on a magnet for 1 minute. 
4. The supernatant was emptied in the sink and the plate was tapped three times on 
paper. The plate was removed from the magnet.  
100 µL of sheet fluid was added to each well and the plate was placed on Heidolph™ Titramax 
Vibrating Platform Shaker at room temperature at 750 rpm for 5 minutes. The plate was then 







2.5 Bio-Plex 200: Antibody analysis 
The Bio-Plex 200 had to be turned on 30 min before analysing samples to warm up. The Bio-
Plex program, Bioplex manager, was opened on the computer and start up and calibration 
programs were performed before samples could be analysed.  
 
2.5.1 Start up and calibrate  
A Bio-Plex Calibration kit (Bio-Rad, cat. 171-203060) was taken out from the fridge and put 
in room temperature for 10 min before calibration. Bio-Plex beads, CAL1 and CAL2 were 
vortexed for 30 seconds, and 6 drops of each tube were added to an MVC plate. The MVC 
plate was also added distilled water and 70 % isopropanol before inserted into Bio-Plex 200. 
In the Bio-Plex program, “Start up & Calibrate” buttons in the quick guide was pushed, and a 
new window appeared with instructions for calibration (mentioned above). After the calibration 
process, sheath fluid was added to the fill line and the box with waste liquid was emptied. 
 
2.5.2 Run samples  
A new protocol was made where protein coated beads (identified by bead numbers) and plasma 
samples with control/blank wells were formatted into the Bio-Plex program. The gate valve 
(DD gate) was set to 5000 – 25 000. Bead region was set to 100 beads minimum for each bead 
population and sample timeout was set to 60 sec.  
When Bio-Plex reading was finished, raw data were exported to Excel and saved. The 96-well 
plate was placed in a magnet for 60 seconds, the supernatant was emptied in the sink and the 
plate was tapped three times on a paper. The plate was removed from the magnet and 100 µL 
of sheet fluid was added to each well. Plate 1-4 (Appendix sec. 6.2) was stored in the fridge 
and analysed on a different Bio-Plex 200 machine at NVI the day after, resulting in duplets of 
measurements. Before the plate was analysed, the plate had to be incubated on a 
Heidolph™ Titramax Vibrating Platform Shaker at room temperature at 750 rpm for 5 min. 
The machine was calibrated (sec. 2.5.1) and samples were run (sec. 2.5.2). The mean 
fluorescens intensity (MFI) values used in results originated from the 1st run at the same Bio-
Plex 200 machine at NMBU. After analysing samples, wash between plates and shut down 




2.5.3 Wash and adjust needle  
The Bio-Plex sample collection needle was washed once a month to avoid aggregation and 
slow count of beads. Distilled water was pressed through the needle with the use of a 50 mL 
syringe, followed by 10 percent bleach and a second round with distilled water. The needle was 
sonicated in cold water for 15 min and placed back into the Bio-Plex machine. The needle was 
adjusted to the wells.   
 
2.6 Statistical analysis  
GraphPad Prism 8 software was used for all statistical analysis. Different analyses were run 
according to whether data were compared within groups (paired) or between groups (unpaired), 
and according to number of groups compared, and samples (n) in each group.  
A parametric paired T-test was run to compare aggregation and bead count between two runs 
on two different Bio-Plex 200 machines in figure 3.2 where n = 96 in each group. A non-
parametric Friedman (paired) test was run to compare the effect on bead count on antibody 
measurements from three runs in figure 3.3 where n = 8. A non-parametric Wilcoxon (paired) 
test was run to compare antibody levels detected from fish in the four different experimental 
groups (PRV-1, PRV-2 PRV-3, InPRV-1) in figure 3.4-3.7 where n=8. When the number of 
samples per group were n = 8 as in figure 3.3 – 3.7, the test was non-parametric as it could not 
conclude that data were normally distributed. It was considered that a p-value of ≤ 0.05 were 
significant and asterisks were used to differentiate between p-values (table 2.5). 
 
Table 2.5. Symbols to show significance and no significance (ns) in accordance with P-value. Asterisks symbols 













P ≤ 0.05 
 
 
P ≤ 0.01 
 
 
P ≤ 0.001 
 
 







When interpreting the results in this section, significantly higher binding of antibodies to beads 
coated with PRV antigens (PRV-1 σ1-LM, PRV-1 µ1C, PRV-3 µNS, PRV-3 σ1) than to 
control beads coated with non-PRV antigens (ISAV FP, ISAV FP-LM) will be referred to as 
PRV-specific antibodies, based on previous work (116). Binding to PRV antigens have been 
compared with binding to their most relevant control antigen in the same fish, using paired 
statistical analyses: Binding to PRV-1 σ1-LM was compared with ISAV FP-LM, both being 
lipid modified. Binding to PRV-1 µ1C, PRV-3 µNS, PRV-3 σ1 were compared with ISAV FP, 
not lipid modified. Binding of antibodies to control beads are defined as unspecific antibodies 
(polyreactive antibodies) (116). These antibody data and additional data from this trial have 
been published (attachment 6.9) (162). Relevant discussion of the antibody results in relation 
to virus levels, disease pathology and effects of immunization will be further addressed in the 
discussion. 
 
3.1 Detection of Anti-PRV antibodies (IgM)  
The trial period was divided in two periods based on the introduction of shedders infected by 
PRV-1 at 10 wpc (fig. 2.1). Period I was defined as the first 10 weeks of the trial (0-10 wpc) 
before shedders were introduced to groups. Period II was defined as the last 8 weeks of the trial 
(10-18 wpc) where shedders infected with PRV-1 was introduced to group 2 (fish immunized 
with PRV-2), group 3 (fish immunized with PRV-3) and Group 4 (fish immunized with InPRV-
1).  PRV-1 (positive control) was not introduced for PRV-1 shedders.  
 
3.1.1 Detection of PRV specific antibodies (IgM) in plasma after PRV-1 infection   
Detection of PRV specific antibodies in plasma of Atlantic salmon infected with PRV-1 
(positive control) illustrated in figure 3.1. Detection of PRV specific antibodies binding to PRV 
proteins (PRV-1 σ1-LM, PRV-1 µ1C, PRV-3 µNS and PRV-3 σ1) were compared to control 
antigens (ISAV FP and FP-LM) at different weeks post challenge (wpc). The PRV and controls 





Figure 3.1. Antibody detection in Group 1 (PRV-1). Detection of antibodies against viral proteins in Atlantic 
salmon infected with PRV-1 from 0-18 weeks post challenge (wpc). Antibodies against (A) PRV-1 σ1-LM, (B) 
PRV-1 µ1C, (C) PRV-3 µNS and (D) PRV-3 σ1 shown as mean fluorescence intensity (MFI) for individual fish 
and bars as group mean. Statistical analysis comparing group mean MFI at each time point the control antigen 
(grey) being lower (asterisks above) or higher (asterisks below) than the PRV viral proteins using Wilcoxon 
test, results shown as p-values (* p ≤ 0.05, ** p ≤ 0.01). Raw data in Appendix 6.8.1. 
 
PRV specific antibodies were produced after infection with PRV-1. PRV specific antibodies 
were detected at 5-18 wpc after PRV-1 infection. Antibodies binding to PRV-1 σ1-LM 
increased sharply at 8 wpc and remained elevated throughout 12 wpc before gradually 
decreasing until 18 wpc (fig. 3.1 A). PRV-1 µ1C detected antibodies higher than control beads 
2-18 wpc (fig. 3.1 B). In general, antibody levels against PRV-1 µ1C appeared to be lower than 
observed for PRV-1 σ1-LM. Antibody levels detected on PRV-3 µNS were slightly higher than 
control levels 5 wpc and 10-15 wpc and could be considered PRV-specific (fig. 3.1 C). 
Antibody levels binding to PRV-3 σ1 were slightly higher than its control 12-15 wpc and could 
be considered PRV-specific (fig. 3.1 D).  
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Unspecific antibodies binding to control beads are still present after heat treatment of plasma. 
More antibodies bind to the ILAV FP-LM control than to the ILA FP control. Unspecific 
antibodies binding to control beads are visually detected at its highest at 8 wpc and gradually 
decreases towards 18 wpc for both controls.  
 
3.1.2 Detection of PRV specific antibodies (IgM) in plasma after PRV-2 immunization   
Detection of PRV specific antibodies in plasma of Atlantic salmon immunized with PRV-2 
(group 2) illustrated in figure 3.2.  
 
Figure 3.2. Antibody detection in Group 2 (PRV-2). Detection of antibodies against viral proteins in Atlantic 
salmon immunized with PRV-2 from 0-18 weeks post challenge (wpc) and shedders introduced 10 wpc. 
Antibodies against (A) PRV-1 σ1-LM, (B) PRV-1 µ1C, (C) PRV-3 µNS and (D) PRV-3 σ1 shown as mean 
fluorescence intensity (MFI) for individual fish and bars as group mean. Statistical analysis comparing group 
mean MFI at each time point the control antigen (grey) being lower (asterisks above) or higher (asterisks 
below) than the PRV viral proteins using Wilcoxon test, results shown as p-values (* p ≤ 0.05, ** p ≤ 0.01). Raw 
data in Appendix 6.8.2. 
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PRV specific antibodies were produced after immunization with PRV-2, and binding to PRV-
1 σ1-LM at 5-10 wpc (fig. 3.2 A). In contrast, no PRV specific antibodies were detected to 
bind to PRV-1 µ1C or PRV-3 σ1 at 2-10 wpc (fig. 3.2 B, D). Furthermore, no PRV specific 
antibodies were detected to bind to PRV-3 µNS, except a minor increase in specific antibodies 
binding at 10 wpc (fig. 3.2 C).  
Following introduction of PRV-1 shedder at 10 wpc, antibodies against PRV-1 σ1-LM were 
detected from 12-18 wpc. Interestingly, the antibody levels increased sharply at 18 wpc (fig. 
3.2 A). PRV-1 µ1C detected antibody levels higher than control beads 15 wpc after PRV-1 
shedder introduction. No PRV specific antibodies were detected to bind to PRV-3 σ1 after 
addition of PRV-1 shedders. A small significant increase in PRV specific antibodies binding 
to PRV-3 µNS was detected at 15 wpc (fig. 3.2 C).  
Minor amounts of unspecific antibodies were detected on control beads after PRV-2 
immunization. Detection of unspecific antibody levels visually increased 18 wpc after PRV-1 
shedder introduction.  
 
3.1.3 Detection of PRV specific antibodies (IgM) in plasma after PRV-3 immunization  
Detection of PRV specific antibodies in plasma of Atlantic salmon immunized with PRV-3 
(group 3) is illustrated in figure 3.3.  
PRV specific antibodies are produced after immunization with PRV-3, and binding to PRV-1 
σ1-LM at 5-10 wpc. Specific antibodies attached to PRV-1 σ1-LM were detected 5 wpc and 
increased 8 wpc where it remained elevated throughout 10 wpc (fig. 3.3 A). Even though PRV-
1 shedders were introduced 10 wpc, no increase in PRV-1 specific antibody levels were 
detected. PRV specific antibodies binding PRV-1 σ1-LM gradually decreased from 12-18 wpc.  
PRV specific antibodies were binding to PRV-1 µ1C at 2 wpc and 12 wpc (fig. 3.3 B). 
Significantly higher binding to PRV-3 µNS beads were detected at one time point (fig. 3.3 C). 
No PRV specific antibodies bound to PRV-3 σ1 (fig. 3.3 D).  
Minor amounts of unspecific antibodies, but somewhat higher than PRV-2, were detected on 
control beads after PRV-3 immunization. Detection of unspecific antibody slightly increased 





Figure 3.3. Antibody detection in Group 3 (PRV-3). Detection of antibodies against viral proteins in Atlantic 
salmon immunized with PRV-3 from 0-18 weeks post challenge (wpc) and shedders introduced 10 wpc. 
Antibodies against (A) PRV-1 σ1-LM, (B) PRV-1 µ1C, (C) PRV-3 µNS and (D) PRV-3 σ1 shown as mean 
fluorescence intensity (MFI) for individual fish and bars as group mean. Statistical analysis comparing group 
mean MFI at each time point the control antigen (grey) being lower (asterisks above) or higher (asterisks 
below) than the PRV viral proteins using Wilcoxon test, results shown as p-values (* p ≤ 0.05, ** p ≤ 0.01). Raw 













3.1.4 Detection of PRV specific antibodies (IgM) in plasma after InPRV-1 immunization  
Detection of PRV specific antibodies in plasma of Atlantic salmon immunized with InPRV-1 
(group 4) illustrated in figure 3.4.  
 
 
Figure 3.4. Antibody detection in Group 4 (InPRV-1). Detection of antibodies against viral proteins in Atlantic 
salmon immunized with InPRV-1 from 0-18 weeks post challenge (wpc) and shedders introduced 10 wpc. 
Antibodies against (A) PRV-1 σ1-LM, (B) PRV-1 µ1C, (C) PRV-3 µNS and (D) PRV-3 σ1 shown as mean 
fluorescence intensity (MFI) for individual fish and bars as group mean. Statistical analysis comparing group 
mean MFI at each time point the control antigen (grey) being lower (asterisks above) or higher (asterisks 
below) than the PRV viral proteins using Wilcoxon test, results shown as p-values (* p ≤ 0.05, ** p ≤ 0.01). Raw 
data in Appendix 6.8.4. 
 
PRV specific antibodies could not visually be detected in plasma of Atlantic salmon immunized 
with inactivated PRV-1 up to 10 wpc. Following the introduction of PRV-1 shedders at 10 wpc, 
the levels of PRV specific antibodies increased compared to the control antigen at 12-18 wpc 
(fig. 3.4 A). A similar tendency was also observed against the other PRV antigens tested. PRV 
specific antibodies were also detected to bind PRV-3 µNS and PRV-3 σ1 afer PRV-1 shedder 
introduction (fig. 3.4 C, D). No PRV specific antibodies bound to PRV-1 µ1C (fig. 3.4 B). 
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3.1.5 Detection of PRV-1 specific antibodies (IgM) between groups  
Detection of antibodies from plasma of Atlantic salmon binding to PRV-1 σ1-LM was 
compared between groups divided in period I (fig. 3.5 A) and period II (fig. 3.5 B). Negative 
control group was divided into two groups at 10 wpc, where one group was introduced to 
shedders (group 5b) and one group was not introduced to shedders (group 5a) (fig. 3.5 B). 
 
 
Figure 3.5. Antibody detection between groups. Detection of antibodies in period I before shedder introduction 
10 wpc (A) and period II after shedder introduction 10 wpc (B). Antibody detection shown as mean fluorescence 
intensity (MFI) for individual fish and bars as group mean. Positive control not added shedders 10 wpc. Raw 
data in Appendix 6.8. 
 
In period I, detection of PRV specific antibodies binding to PRV-1 σ1-LM was higher in fish 
infected with PRV-1 (positive control) compared to all other groups at 8-10 wpc. Fish 
immunized with PRV-3 had relatively higher detection of PRV specific antibodies binding to 
PRV-1 σ1-LM than fish immunized with 2 at 5-10 wpc. Antibodies first appeared to bind PRV-
1 σ1-LM at 2 wpc from two fish from positive control and one fish from fish immunized with 
PRV-3. At 5 wpc, PRV specific antibodies binding to PRV-1 σ1-LM from fish immunized with 
PRV-3 and PRV-2 was slightly higher visually than PRV specific antibodies binding to PRV-
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1 σ1-LM in positive control. Fish immunized with InPRV-1 and negative group had no visual 
detection of PRV specific antibodies binding to PRV-1 σ1-LM at 5-10 wpc. Interestingly, at 2 
wpc antibodies binding to PRV-1 σ1-LM were visually detected in one fish from fish 
immunized with InPRV-1. No PRV specific antibodies appeared to bind to PRV-1 σ1-LM 
before trial start at 0 wpc (fig. 3.5 A).  
For period II, introduction of PRV-1 shedders did not increase (boost) binding of PRV specific 
antibodies to PRV-1 σ1-LM in fish immunized with PRV-3. PRV specific antibodies binding 
PRV-1 σ1-LM in fish immunized with PRV-3 was reduced from 12-18 wpc. This was also 
seen for fish injected with PRV-1 in period I, which were not introduced to shedders. At 12 
wpc and 15 wpc, two fish and one fish had higher levels of antibodies binding to PRV-1 σ1-
LM than the rest of the samples in fish immunized with PRV-3. At 18 wpc, PRV specific 
antibodies binding PRV-1 σ1-LM from fish immunized with PRV-3 was relativly lower than 
the other groups. After week 10, only fish immunized with PRV-2 and InPRV-1 had an increase 





















3.2 Measurement of PRV specific antibodies on two Bio-Plex 200 machines  
3.2.1 Effect of aggregation on bead loss 
Plasma samples were run on two different Bio-Plex 200 machines to evaluate if the machines 
gave the same assay response to be able to transfer the PRV antibody assays to the Veterinary 
institute (VI). The reanalysis of the plates, 2nd run at VI, gave increased aggregation (fig. 3.6 
B) and a lower bead count (fig. 3.6 A).   
A higher aggregation and lower bead count from 2nd run resulted in plasma samples only from 
1st run at NMBU to be used in analysis in sec. 3.2. This because plasma samples run 1st time 
on Bio-Plex had a higher bead count and lower aggregation than 2nd run on Bio-plex.   
 
Figure 3.6. Aggregation and bead count after reanalysis on two different Bio-Plex 200 machines. Measuring 
the number of counted beads (A) and % aggregation of beads (B) for each plasma sample (well) at the 1st and 
2nd run at two different Bio-Plex 200 machines, 1st at NMBU (grey) and 2nd at Veterinary institute (VI) (brown). 
Statistical analysis comparing the group means of 1st and 2nd run using a paired T-test, results shown as p-









3.2.2 Effect of bead count on antibody measurement  
Plasma samples were run three times (NMBU, VI, VI) on two different Bio-Plex 200 machines 
to evaluate if a cut off on 10 beads per bead population would influence antibody measurement 
(MFI). The three runs showed no significant difference on antibody measurement (fig. 3.7 A), 
but differences in bead count as illustrated in fig. 3.6 A and 3.7 B. No significant difference in 
antibody measurement with an average bead count of 66, 37 and 8 for each bead population 
defended a bead count cut off on 10 beads of each bead population per well. Samples (wells) 
with 10 or more beads counted from each bead population was therefore included in results in 
sec. 3.1. 
 
Figure 3.7. Effect of bead count on antibody measurement in the different study groups. Mean fluorescence 
intensity (MFI) from PRV-1 bead 44 (PRV-1 σ1-LM) and PRV-1 bead 34 (PRV-1 µ1C) (A) and counted PRV-1 
beads 44 and PRV-1 bead 34 (B) during three runs on two different Bio-Plex machines, once at NMBU (blue) 
and twice at the Veterinary institute (VI) (green, orange). Statistical analysis compares the medians of the three 
runs using a Friedman test, results shown as p-values (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001). 




3.2.3 Investigating the bead loss during bead coating  
Bio-Rad do not offer premade bead kits with antigens against PRV. Therefore, our own bead 
was coated and bead loss during the coating process was investigated.  
Coating of antigen to magnetic beads was done twice, where only the 1st set of coating was 
used for the Bio-Plex analysis (fig. 3.7 A). The bead count after coating varied between bead 
populations and a bead loss range from 5 percent – 52 percent was observed. Around half (45 
percent - 52 percent) of bead numbers 27 from 1st set of coating and bead 34 from both sets of 
coating were lost during bead coating. The quality of coating is unknown as there are no 
methods for quantifying proteins coated to beads.  
 
Figure 3.8. Investigating the bead loss during bead coating. Beads at the start (grey) and at the end (green) of 
the bead coating with calculated bead loss (%). Different beads added at the start in regard to coupling 
reaction (x0.5, x1, x3) and available protein. One coupling reaction (x1) equalled 1.25 x 106 beads. Bead loss 
(%) during coating process for (A) 1st coating of beads used in Bio-Plex analysis and (B) 2nd coating of beads 







4.1 Detection of antibodies binding to PRV and control antigens  
4.1.1 Overview of antibody production in the immunization trial  
This trial was divided in two periods, period I and period II. Period I was the first 10 weeks of 
the trial (0-10 wpc) before shedders were introduced to any groups. This meant that antibodies 
measured in period I were produced after injection of PRV-1, PRV-2, PRV-3 and inactivated 
PRV-1. Period II was the last 8 weeks of the trial (10-18 wpc) where PRV-1 shedders were 
introduced to fish immunized with PRV-2, PRV-3, InPRV-1 and to non-immunized controls. 
This meant that antibodies measured in period II could derive from immunization by PRV-
2/PRV-3 but are most likely a result of infection with PRV-1. The level of antibodies produced 
at this stage will also be affected by protection from PRV-1. 
The PRV-1 infected group (group 1, Figure 3.1) was not introduced to PRV-1 shedders, and 
therefore showed the full 18-week time course of antibody production in response to PRV-1. 
This group acted as a positive control for the levels of PRV specific antibodies produced during 
a PRV-1 infection in Atlantic salmon, which is the natural host for PRV-1. In fish infected with 
PRV-1, antibodies were produced and detected by binding to the PRV-1 σ1-LM antigen at 5-
18 wpc and PRV-1 μ1C antigen already from 2 wpc. This could indicate a more rapid 
production of antibodies towards PRV-1 μ1C than towards PRV-1 σ1 (fig. 3.1 A, B) (sec. 
4.1.3).  
The production of PRV specific antibodies measured in plasma using this assay are free-
unbound antibodies, and the level seems to be stable 8-15 wpc. This means that the total amount 
of antibodies produced are not measured, as some antibodies are bound up in complexes or 
taken up in cells. The stable antibody level measured at 8-15 wpc may be due to a continuous 
production of PRV specific antibodies. Here, the production of antibodies and binding/uptake 
of antibodies to antigens/cells seem to be in equilibrium. However, membrane bound 
antibodies are also possible to identify and quantify by serological antibody analysis even 
though this wasn’t completed in this master thesis (183).  Binding/uptake of antibodies related 
to uptake into phagocytic cells, where antibody are degraded may also play a role (120). The 
antibody production appeared to dab off at 18 wpc. PRV specific antibodies binding to PRV-3 
antigens will be discussed in section 4.1.4.   
 
ISAV FP and ISAV FP-LM were added to the assay as control antigens. They worked as 
controls, as the fish immune system had never encountered ISAV before. For fish infected with 
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PRV-1 there was an increase in unspecific antibodies binding to ISAV FP and ISAV FP-LM. 
This will be more discussed in sec. 4.1.5. 
PRV specific antibodies produced in fish immunized with PRV-2 and PRV-3 was found to 
bind PRV-1 antigens (cross-binding antibodies). This will be more discussed in sec. 4.1.2.  
Fish immunized with PRV-2 (group 2) produced PRV specific antibodies binding to PRV-1 
σ1 at 5-10 wpc, and at 12-18 after PRV-1 challenge (fig. 3.2 A, B). No PRV specific antibodies 
binding to PRV-1 μ1C were detected from fish immunized with PRV-2, but PRV specific 
antibodies were detected at 15 wpc after PRV-1 challenge (fig. 3.2 B). The antibodies detected 
in period I to bind to PRV-1 σ1 indicated a specific, but low antibody response towards PRV-
2. After PRV-1 shedders were introduced, an increase in the production of antibodies detected 
by PRV-1 σ1-LM were seen (fig. 3.2 A).  
Fish immunized with PRV-3 (group 3) produced PRV specific antibodies binding to PRV-1 
σ1 at 5-10 wpc, and after PRV-1 challenge at 12-18 wpc (fig. 3.3 A, B). However, PRV specific 
antibodies binding to PRV-1 μ1C were only detected at 2 wpc after immunization, and after 
PRV-1 shedder challenge at 12 wpc (fig. 3.3 B). PRV specific antibodies did not bind to PRV-
3 μNS or PRV-3 σ1 after immunization with PRV-3 (3.3 C, D). One would expect even more 
antibodies to be produced and bind PRV-3 antigens (if working in this assay) than to PRV-1 
antigens, as PRV-3 was injected in fish. This indicated that the PRV-3 antigens coated on beads 
were not optimal for binding of PRV-specific antibodies (sec. 4.1.4).  
For immunization with inactivated PRV-1 (Group 4, fig. 3.4), PRV specific antibodies were 
only detected after PRV-1 challenge 10 wpc and not induced by immunization. This will be 
discussed in sec. 4.2.3. 
 
4.1.2 PRV-1 σ1-LM is suited to detect specific antibodies towards all subtypes of PRV 
Detection of specific antibodies towards PRV-1 σ1-LM was seen after PRV-1 (group 1), PRV-
2 (group 2) and PRV-3 (group 3) injection (fig. 3.1-3.3). PRV-1 σ1-LM has been confirmed in 
another trial to be well suited for detection of specific antibodies against PRV-1 in plasma 
(116). This was confirmed when PRV-1 σ1-LM showed similar binding of antibodies in heat-
treated plasma. For the control proteins used (ICP11-LM, ISAV FP, ISAV FP-LM), there was 
a lower antibody binding after heat-treatment of plasma compared to the non-heat-treated 
plasma. This indicated that the heat treatment decreased binding of unspecific/polyreactive 
antibodies on control beads. Therefore, PRV-1 σ1-LM was used as the main antigen for 
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detecting specific antibodies in this trial, and compared within (fig. 3.1-3.4) and between 
groups (fig 3.5) (116).  
In this thesis, antibodies induced by different PRV subtypes were shown to cross-bind PRV-1 
σ1-LM. Cross-binding antibodies rely on similarities in amino acid sequence and/or 3D 
structure and surface charges. PRV-3 have an amino acid resemblance  to PRV-1 of 90.5 
percent, while PRV-1 and PRV-2 have an amino acid resemblance of 80.3 percent (164). 
Antibodies are produced towards antigen based on both amino acid sequence (similar proteins) 
and structure of antigen. When similar antigens are presented to fish, antibodies produced may 
cross-bind as they do for PRV subtypes. The outer capsid protein PRV-1 σ1 has an amino acid 
resemblance of 81.6 percent and 66.7 percent towards PRV-3 σ1 and PRV-2 σ1, respectively 
(164).  
Despite that the amino acid resemblance of σ1 between PRV subtypes is lower than the overall 
similarity, PRV subtypes could cross-bind σ1. Probably because of the similarity in structure 
of σ1 when coated on beads (likely due to the lipid modification). The antibodies detected on 
PRV-1 σ1-LM could therefore be compared between groups in section 4.2 and 4.3 (fig. 3.5). 
However, PRV specific antibodies from fish immunized with PRV-2 and PRV-3 might have a 
lower ability to cross-bind antigen than PRV specific antibodies from fish infected with PRV-
1.  
 
4.1.3 Why did PRV-1 μ1C not pick up cross-binding antibodies? 
In this section, different points on why PRV-1 μ1C didn’t detect cross-binding antibodies from 
fish immunized with PRV-2 and PRV-3 will be discussed. 
PRV specific antibodies towards PRV-1 μ1C were detected at 2-18 wpc from fish infected with 
PRV-1 and at 2 wpc from fish immunized with PRV-3. In addition, PRV specific antibodies 
towards PRV-1 μ1C were detected after PRV-1 shedder introduction. Specific antibodies 
binding PRV-1 μ1C have been detected by Western blot in plasma from PRV-1 infected 
Atlantic salmon in another study (132). These specific antibodies were not detected in 
uninfected control fish. This is an additional proof that PRV specific antibodies, as detected in 
this assay, are present in plasma (132). Antibodies targeting PRV-1 μ1C and PRV-1 σ1 has 
also showed to recognize PRV-3 μ1C and PRV-3 σ1 during western blotting. Showing that 
antibodies produced towards PRV-1 μ1C and PRV-1 σ1 could cross-bind PRV-3 μ1C and 
PRV-3 σ1 (160). However, PRV-1 μ1C coated to beads did not show the same possibility in 
cross-binding throughout the trial for fish immunized with PRV-2 and PRV-3. There might be 
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many reasons for this, but knowing that PRV specific antibodies are produced (132) and can 
cross-bind PRV-3 μ1C (160) it indicates that the reason may be correlated to how PRV-1 μ1C 
is coated to beads (structure). Antigens coated to beads function best if they mimic antigens as 
they are presented in fish. This to make antibodies recognize the protein and to make antibody 
binding correlate to the number of free-unbound antibodies actually produced towards PRV-1 
μ1C in fish. Differences in detection of antibodies between groups immunized with different 
PRV subtypes might indicate several points.  
Firstly, the folding of PRV-1 μ1C in Atlantic salmon might be different than the folding of 
PRV-1 μ1C in rainbow trout, compared to the folding of PRV-1 μ1C produced in E.coli. This 
because antibodies produced towards PRV-1 μ1C was detected when produced in rainbow 
trout (160), but not in this experiment when produced in Atlantic salmon.  
Secondly, the quantity of protein coated to each bead could also affect levels of antibodies 
detected. Less PRV-1 μ1C coated to beads than PRV-1 σ1-LM will give less antibody 
detection. This will be more discussed in sec. 4.4.2.  
Thirdly, the PRV-1 outer capsid protein μ1 has an amino acid resemblance of 91.5 percent and 
85.1 percent to PRV-3 μ1 and PRV-2 μ1, respectively (164). Interestingly, this would in theory 
mean that PRV-1 μ1 should bind more cross-binding antibodies (if produced) than PRV-1 σ1. 
However, the structure of the antigens is of importance for antibodies to recognize antigens. 
The importance of lipid modification of PRV-1 σ1 and how it sits on bead is therefore again 
reflected (116).   
One can discuss if antibody production towards PRV-1 μ1C is actually lower than the antibody 
production towards PRV-1 σ1-LM in PRV-1 injected fish and none detected for PRV-2/PRV-
3 injected fish. However, it might also be because of the assay. Comparison between levels of 
different antibodies (MFI) detecting different antigens may therefore be impossible if detection 
is related to the assay, and not the actual level. The effect of heat treatment of plasma on 
antibody levels detected by PRV-1 μ1C could have been performed as Teige did with PRV-1 
σ1 in her study (116). If PRV-1 μ1C also were lipid modified, one could be able to evaluate 
how PRV-1 μ1C is presented on beads with and without modifications. This because one is 
uncertain about the level of binding compared to the actual level in plasma.  
 
To conclude, there might actually be less antibodies produced towards PRV-1 μ1C as detected 
in this assay. There might also be produced more antibodies towards PRV-1 μ1C but it is not 
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detected due to assay or the ability to cross-bind to PRV-1 µ1C (folding of protein in Atlantic 
salmon versus E. coli). A lower affinity is most likely triggered by the structure of the protein 
when it sits on beads, as amino acid resemblance is relatively high (164). It might also be that 
the active seat of antibodies target µ1, and when µ1 is cleaved to µ1C and μ1n (144), it 
decreases the ability of antibody to bind. 
It is hard to trust the significant findings at 2 wpc for fish immunized with PRV-3 because there 
at 8 wpc are shown that control beads bind significantly more antibodies than PRV-1 µ1C (fig. 
3.3 B). Because one is uncertain about the level of binding compared to the actual level in 
plasma in Atlantic salmon infected with PRV-2 and PRV-3, nothing can be concluded 
regarding PRV specific antibodies in plasma for these groups. For PRV-1 infected group PRV 
specific antibodies are binding to PRV-1 µ1C. However, one is uncertain how much is specific 
antibodies, how much is unspecific antibodies and if it is correlated to amount produced in fish.  
 
4.1.4 Why did PRV-3 antigens not pick up specific antibodies?  
PRV-3 proteins did not succeed at detecting PRV specific antibodies after immunization with 
PRV-3. Antibodies produced here should have bound to PRV-3 antigens and not only to PRV-
1 antigens. PRV-3 μNS and PRV-3 σ1 targeted antibodies is with high probability produced in 
plasma, as antibodies has been detected towards PRV-1 μNS and PRV-1 σ1 in Atlantic salmon 
previously (132, 160). The PRV-3 proteins used here are produced in insect cells and coated to 
beads. The folding of the proteins in insect cells might be different than the folding of protein 
in Atlantic salmon. Antibodies produced towards PRV-3 antigens in fish might therefore have 
problems binding to the PRV-3 proteins on beads, and this may hamper antibody binding from 
fish immunized also with PRV-2 and PRV-1. However, one expects the protein to be folded 
correctly. Firstly because PRV-1 μNS detecting antibodies in Teiges study was produced in 
insects cells (132). Secondly, because proteins are folded in a eukaryote cell and with a lower 
temperature than for production in E.coli (closer to the temperature of fish) (184).  
Another trial completed by Teige (116) revealed that PRV-1 σ1 could not bind PRV specific 
antibodies in plasma from fish infected with PRV-1. However, when PRV-1 σ1 was lipid 
modified (PRV-1 σ1-LM) it could bind PRV specific antibodies. This therefore indicated that 
the reason for why PRV-3 σ1 and probably PRV-3 μNS did not bind antibodies was because 
of how they were coated to beads. 
So, can significant differences observed in antibody binding between control beads and PRV-
3 antigen coated beads be trusted? At some time points PRV-3 coated beads bind low but 
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significantly more antibodies than control beads, and at other time points control beads bind 
significantly more antibodies. This makes it hard to trust the significant findings using the 
PRV-3 antigens.  
 
4.1.5 Unspecific antibodies binding ISAV FP and ISAV FP-LM 
There was visually a higher detection of polyreactive antibodies binding to ISAV FP and ISAV 
FP-LM in PRV-1 infected fish compared to the other groups (fig. 3.1). Fish had never 
encountered ISAV and therefore only unspecific antibodies were detected on the ISAV 
antigens. Teleost have unspecific natural antibodies that are presented without having 
encountered an antigen (81). Their role is unclear, where they have been found in serum of fish 
earlier (113), and stated to often measured as background noise in assays (101), as also been 
seen in this trial. Teleost have also unspecific antibodies (polyreactive antibodies) that can be 
secreted after encounter with pathogen. This is seen after PRV-1 infection in Teiges study  
(116) and also in this study after PRV-1 infection. The ratio between natural antibodies binding 
and how much polyreactive antibodies binding may be evaluated by looking at mock group. 
However, since plasma is heat treated as unspecific binding was something we did not want to 
measure, it is hard to discuss as one is unsure how much unspecific antibodies are removed 
during heat treatment.  
Teleost rely on the innate immune system for an extended period until the adaptive immunity 
is kicked off (80, 81). Atlantic salmon might produce polyreactive antibodies as affinity 
maturation process to produce PRV specific antibodies takes time (118). Also seen in this trial 
slightly detected at 5 wpc (fig. 3.1 A). To cope with PRV-1 in the meantime polyreactive 
antibodies are produced. Producing a lot of antibodies has its advantage. This is because 
antibodies can agglutinate viruses and label them for more effectively phagocytosis and 
removal (120). They can also opsonize pathogens for complement activation which can lyse 
and kill the virus, but this is more relevant for membrane-coated viruses (130, 133). In addition, 
NK-like cells can be activated by IgM through antibody-dependent cell-mediated cytotoxicity 
(ADCC), and degranulate and kill infected host cells (129). Antibodies can also neutralize and 
block the virus from entering the host cell and do harm (47, 120). These advantages are 
however only relevant if polyreactive antibodies bind PRV antigens. Polyreactive antibodies 




Interestingly, polyreactive antibodies are first seen to increase at the same time as specific 
antibodies detected at 8 wpc after PRV-1 infection (fig. 3.1 A). To compare, bacteria have 
many PAMPs that are recognized by polyreactive antibodies (185), while the most important 
PAMPs on viruses recognized by the immune system is its genome, which is dsRNA in PRV 
(34, 47). These polyreactive antibodies binding to ISAV-FP appear to increase because of 
PRV-1 infection. In addition, polyreactive antibodies from PRV-1 seem to follow the same 
time course as specific antibody produced increasing at 8 wpc.  
There were also minor levels of unspecific antibodies detected after PRV-2 and PRV-3 
immunization. This unspecific binding might be produced after immunization by PRV-2 and 
PRV-3 or it might represent natural antibodies that were there before infection (101). Antibody 
binding may also be induced by complement or other virus-binding molecules (i.e pentraxins 
and collectins) that are not removed after heat treatment (47). This type of binding has been 
checked for in negative group (group 5), which contains the same batch of fish expected to 




















4.2 PRV specific antibodies compared between groups – After immunization 
In this section, PRV specific antibodies binding to PRV-1 σ1-LM are compared between 
groups after immunization (fig. 3.5 A). This because antibodies produced towards PRV-2 and 
PRV-3 are found to cross-bind PRV-1 antigen, and because this is a reliable detection method 
for PRV-1 specific antibodies (sec. 4.1.2) (116). However, it is not certain that the cross-
binding of antibodies is as strong as the PRV specific antibodies from PRV-1 infection. Even 
though, it is well worth a comparison.  
More PRV specific antibodies binding to PRV-1 σ1-LM was detected from fish infected with 
PRV-1 compared to other groups in period I (fig. 3.5 A). This was probably because an 
injection of PRV-1 into its main host will cause a stronger infection/replication of virus. Strong 
infection by PRV-1 is shown to trigger a powerful antiviral response. A strong infection by 
PRV may therefore be a trigger for strong immunity (168) and may be correlated to higher 
levels of PRV specific antibodies compared to other groups.  
 
4.2.1 Comparing PRV specific antibodies from fish immunized with PRV-3 and PRV-2 
PRV specific antibodies (cross binding antibodies) were detected 5-10 wpc after immunization 
with PRV-3 and PRV-2 (fig. 3.2 A, 3.3 A, 3.5 A). However, PRV specific antibodies binding 
to PRV-1 σ1-LM were visually higher for fish immunized with PRV-3 than PRV-2, as shown 
in figure 3.5 A. The visually higher PRV specific antibodies detected on PRV-1 σ1-LM in 
PRV-3 immunized fish can have several causes that will be discussed in this section.  
Firstly, the higher antibody response from PRV-3 might correlate with higher replication and 
virus levels in fish. Both PRV-3 and PRV-2 replicated in Atlantic salmon. However, higher 
virus levels were detected in fish immunized with PRV-3 compared to fish immunized with 
PRV-2 (Attachment 6.9 in Appendix, fig. 2) (162). The article contains data on virus levels, 
histopathology, cellular immune responses (CD8α, Granzyme A, IFNγ) and innate antiviral 
immune responses (Mx, ISG15, Viperin), and includes data from this master thesis on PRV 
specific antibodies (162). A higher replication rate results in more virus produced and is 
expected to increase the antibody responses towards virus (186).  
Secondly, the injection dose was the same for all fish in the same group, but most likely not 
comparable between groups, as the virus infectivity could not be measured. PRV RNA 
measured by qPCR does not directly reflect the infectious dose. The infectivity of the virus 
preparation is correlated to how the material is treated with regards to temperature, storage, 
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sonication and what type of tissue (blood, organs), and at which time point of the infection 
organ/blood were sampled. Sonication is performed to lyse host cells to be able to isolate virus. 
Proteins from virus may also be affected and destroyed during sonication. This is probably in 
such small quantities that it is insignificant in the context of the experiment.  It is impossible 
to know how much infectious PRV-1, PRV-2 and PRV-3 are present in each of the doses. This 
is because qPCR only detects amount of genomes correlating to virus, but does not separate 
between infective and inactivated virus. More knowledge of virus properties are also required 
to be able to say more about the infectious dose between groups. If having a susceptible cell 
line that can be used to measure infectivity in lab, one could say more about infectious dose. 
The infectious dose within the same group are considered to be identical when injected 
(homogenized solution). However, biological differences between individuals in the same 
group may affect the capability of the infectious dose of viruses to infect host cells.  
Thirdly, antibodies produced will differ in specificity against PRV-1 σ1 when produced 
towards PRV-3 σ1 and PRV-2 σ1. Antibodies produced towards PRV-3 are likely to be more 
similar to antibodies recognizing PRV-1 due to amino acid composition (164). On the other 
hand, antibodies produced towards PRV-2 are likely to be less similar to antibodies recognizing 
PRV-1 due to amino acid composition (164) and therefore less antibodies might bind to PRV-
1 σ1-LM. A higher level of PRV specific antibody detected in PRV-3 seems realistic.  
PRV-3 is more closely related to PRV-1 than PRV-2, and more host cells may therefore be 
more susceptible to infection by PRV-3, resulting in more virus to replicate in host cells 
(Attachment 6.9 in Appendix, fig. 2) (162). Therefore showing an increased production of PRV 
specific antibodies (186).  
 
4.2.2 No PRV specific antibodies detected in fish immunized with InPRV-1  
PRV specific antibodies were not visually detected from fish immunized with InPRV-1. No 
statistical test were run between control beads and PRV antigen coated beads in period I (0-10 
wpc), as the controls ISAV FP and ISAV FP-LM were not run for InPRV-1 (fig. 3.4). 
Therefore, visual observations comparing antibody levels binding to PRV-1 σ1-LM in the 
InPRV-1 group and the negative control group was done in figure 3.5. However, at 2 wpc, a 
putative increase in PRV specific antibodies was detected in one fish only. This might be 
related to an individual difference in response to the immunization or just an accidental error 
in measurements.  
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Inactivated virus will not replicate in host cells, and therefore no virus levels were detected to 
replicate and therefore increase in fish from this group (162). In another trial studying 
immunization by inPRV-1, virus levels were detected and seen to decrease after injection as 
expected for inactivated viruses (60). No replication of virus is likely to give a weaker immune 
response (48), and less formation of antibodies (186). However, adjuvants were added to 
InPRV-1 to trigger both sides of the immune system (49-51). Adjuvants added in this trial 
might therefore not be as efficient in activating the adaptive humoral part of the immune system 
as no PRV specific antibodies were detected after immunization. Inactivation of PRV-1 can 
also have damaged outer surface proteins and therefore result in antibodies not binding to PRV-


















4.3 PRV specific antibodies produced after PRV-1 shedder introduction in 
period II of the trial 
In this section, PRV specific antibodies binding to PRV-1 σ1-LM are compared between 
groups after PRV-1 challenge in period II (12-18 wpc).  
 
4.3.1 Comparing protection from fish immunized with PRV-3 and PRV-2 
Even though PRV specific antibodies were detected after immunization by PRV-2 and PRV-
3, the responses after PRV-1 challenge 10 wpc differed. These antibodies could be derived 
from a PRV-1 infection or be absent because the fish were protected from PRV-1.  
The PRV specific antibody response from fish immunized with PRV-3 did not seem to be 
affected by the PRV-1 shedders introduced at 10 wpc (fig. 3.3). On the contrary, the PRV 
antibody response detected by PRV-1 σ1-LM appeared to decrease in period II (fig. 3.5 B, 3.3 
A). PRV-1 infection was not detected in most of the fish 12-18 wpc after PRV-1 shedder 
introduction (Attachment 6.9 in Appendix, fig. 5). This indicated that immunization with PRV-
3 protected against PRV-1 by completely blocking infection, and this was confirmed with 
histopathology and qPCR (162). This protection could partly be due to the PRV specific 
antibody response but could also be related to other immune protective mechanisms involving 
cellular immunity, or innate immunity. At 12 wpc and 15 wpc, two and one fish respectively 
had a higher PRV specific antibody response compared to the rest of the fish group (fig. 3.3). 
As already explained, this might be caused by biological differences between individual fish, 
the susceptibility and replication to virus (186).  
The PRV specific antibody response from fish immunized with PRV-2 was induced in period 
II (fig. 2.1) by the PRV-1 shedders introduced at 10 wpc (fig. 3.2, 3.5 B). Most fish immunized 
with PRV-2 showed an infection by PRV-1 at 15-18 wpc (Attachment 6.9 in Appendix, fig. 5). 
The increased production of antibodies was due to an infection of PRV-1, which was confirmed 
by histopathology and qPCR (162). The PRV specific antibody response visually ranged 
beyond the levels in the positive control (non-immunized fish infected with PRV-1 shedders in 
period II) (fig. 3.5 B), and the same did the amount of PRV-1 detected by qPCR compared to 
positive control (Attachment 6.9 in Appendix, fig. 5). Fish had however a delayed (high Ct 
value) and variable PRV-1 infection at 12 wpc after PRV-1 shedder introduction (Ct 10-24) in 
spleen (162), which is expected to reflect the virus levels in blood (136). The variable infection 
level was also reflected in levels of PRV specific antibodies produced.  Two fish did not 
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respond with an increase in production of PRV specific antibodies, and had a lower virus levels 
of PRV-1 (162). Five fish had a production of PRV specific antibodies higher than the positive 
control in period II (fig. 3.5 B). PRV-2 reduced the severity of HSMI in two individuals, but 
did not block PRV-1 infection (162). The PRV specific antibody response seen in period I was 
therefore not sufficient to cross-protect against PRV-1. There may however been produced 
antibodies towards other PRV antigens which are not analysed for in this assay.  
 
4.3.2 Protection of fish immunized with InPRV-1  
No PRV specific antibodies were detected to visually bind PRV-1 σ1 from fish immunized 
with inactivated PRV-1 (fig. 3.1). After introduction of PRV-1 shedders at 10 wpc, PRV 
specific antibodies were detected 12-18 wpc. Virus levels increased around the same time (15-
18 wpc) for all fish after introduction of PRV-1 shedders (Attachment 6.9 in Appendix, fig. 5) 
(162), but only six fish increased their production of PRV specific antibodies (fig. 3.4, 3.5 B). 
A partial protection of fish was seen in fish immunized with InPRV-1, where some fish had a 
lower viral load (Ct-value 30-35) (Attachment 6.9 in Appendix, fig. 5), and six out of eight fish 
were without heart lesions (162). This was in line with an earlier study performed on this 
InPRV-1 vaccine candidate, reporting reduced heart lesions but no prevention of PRV-1 
infection (60). Since there was no detection of PRV specific antibodies after InPRV-1 
immunization in our assay, another mechanism may have protected the heart and prevented 
HMSI in most fish (162). There may also have been produced antibodies towards other PRV 
antigens which are not analysed for in this assay.   
It is possible that InPRV-1 triggered a local immune response (humoral or cellular immunity) 
in the peritoneal cavity where the vaccine was injected. Analysis done before PRV-1 shedders 
were added found no indications of cellular and innate responses in spleen (162). Therefore, 
little reason to believe that a local non-systemic peritoneal response can protect the heart. The 
question is then, can B-cells and antibodies produced in peritoneum protect against an infection 
of PRV-1 and HSMI? Housing of B-cells in the peritoneal cavity might function as a local 
immune response in response to the InPRV-1 vaccine, as previously seen for a SAV infection 
(96), without triggering a systemic immune response. This local immune response may not be 
sufficient to protect from PRV infection and HSMI, since PRV infection is systemic (in red 
blood cells) (152). However, migration routes are unknown for the B-cells in the peritoneal 
cavity. It is unknown if the B-cells in the peritoneal cavity can migrate to internal organs or 
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just induce local immune responses (187). If they migrated, they should (if targeting these assay 
proteins PRV-1 σ1 and PRV-1 μ1C) have been detected as they would use the blood as a 
transportation medium to get to organs.  
 
4.4 Measurement of PRV specific antibodies on two Bio-Plex 200 machines 
The plasma samples were reanalysed on different Bio-Plex 200 machines, one at NMBU and 
one at the Veterinary Institute (VI). This was to evaluate if the machines gave the same assay 
response so PRV antibody assays could be transferred to the VI. 
4.4.1 Effect of aggregation on bead loss  
There was a lower bead count for the 2nd run of the plasma samples due to an increased 
occurrence of aggregation in each well (fig. 3.6). Aggregation from PRV-1 (group 1) and Mock 
(group 5a) from 2-15 wpc (Appendix 6.6) was merged to one figure as no difference in 
aggregation was seen between groups (not shown in results). A paired T-test was run to 
compare the mean of aggregation and bead count between the 1st and 2nd run. As the 2nd run 
gave high aggregation and problems related to low bead count only the 1st run of plasma 
samples was used as assay results.  
According to the Bio-Plex user guide, aggregation is defined as clumping of two or more beads. 
If beads overlap during Bio-Plex reading, this is calculated as percentage of aggregation of the 
already (total) counted beads. The light scattered from particles that flow past the red laser is 
directly proportional to particle size and therefore the machine identifies particles that are 
smaller (dust, air bubbles) or larger than a single bead (aggregation). If there are few 
microscopic air bubbles, they can also be read as aggregation. However, air bubbles will cause 
a sudden shift in the bead region and the reading will stop. This did not occur during assay run 
and therefore the aggregation detected in wells are most likely actual aggregated beads. In 
addition, use of lid avoided dust particles to enter the wells.  
There was same amount of aggregation of infected PRV-1 plasma and uninfected plasma (not 
shown in results), and therefore it is not only antibodies that bind antigens that crosslink. Beads 
aggregate because they in general bind impurities in plasma (lipids, proteins, polysaccharides 
etc.) that are sticky. They might also get sticky after coating as proteins that are coated are not 
100 percent pure.  
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Less beads were available in each well after 1st count as beads added to each well were limited 
to 2500 beads of each bead number. However, this should be more than enough to count the 
minimum limit of 100 beads of each population which Bio-Plex 200 was set to. From 1st and 
2nd run there were counted under 100 beads for several wells (fig. 3.6 B). Error 1, 2 and 4 was 
triggered during this analysis. Error 1 was triggered if there was fewer than 25 percent of the 
acquired beads per population. This meant that with an acquired bead count of 100 beads per 
population a low bead count would be triggered if less than 25 beads per population was read. 
Error 4 was triggered if less than 20 beads were counted from each well (table 2.1). Error 4 
indicated that the bead population selected (region selected) was incorrect or that there was 
actually too few beads in the wells (180). Error 2 was triggered if there was above 50 percent 
of aggregation in each well. There were no Error 2 triggered during the 1st run and most wells 
showed under 20 percent aggregation (fig. 3.6 B). For 2nd run there was an increase in 
aggregation. However, only two samples (wells) contained above 50 percent aggregation and 
triggered an Error 2 (fig. 3.6 B). Error 3 and Error 5 was not detected during the plate runs.  
A lower bead count than the limit of 100 beads set on the computer could correlate to pipetting 
skills at lab during preparation of the 96-well plate. This because aggregation for 1st run was 
below 20 percent for most wells and could therefore not be the only reason for a bead count 
lower than 100 for each bead population. In addition, 60 second is set as sample time. At this 
point, Bio-Plex 200 will not read more beads and go to next well. For the preparation of the 
96-well plate there was a magnet during the washing steps before adding plasma, primary 
antibody, secondary antibody, and streptavidin and the supernatant was emptied in sink by 
force. If magnet was too weak to hold on to beads it could be possible that some beads were 
lost in the sink during these washing steps, and vice versa if the magnetic beads were not strong 
enough to stay attached to the magnet during the emptying of supernatant.  
 
4.4.2 Sensitivity of detection in relation to bead counts and repeated runs 
The analyses were run three times on two different Bio-Plex 200 machines, once at NMBU 
and then twice at VI to compare the sensitivity of binding analyses at low bead counts. This 
was to evaluate if a cut off at 10 beads would influence antibody measurement (MFI levels). 
Bio-Rad recommended a minimum of 50 beads counted per bead population, and a lower bead 
count error would be triggered if below 20 beads per bead population was counted (180). The 
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reason for wanting to test a cut off on 10 beads was linked to problems explained in sec. 4.4.1 
related to error 2 and 4 (low bead count).  
There was no difference measured on MFI for the three runs even though they all showed a 
decrease in average bead count from 66, to 37 and to 8 beads counted per population (fig. 3.7). 
Therefore, a bead count cut off on 10 beads per population was possible.  
According to the Bio-Plex user guide, each well may be read twice without adversely affecting 
the results (180). This means that two runs should show a similar MFI value. In this trial, all 
three runs show similar MFI values. The stability in MFI between runs with decreasing bead 
count are likely correlate firstly to beads being coated with same amount of protein. Secondly, 
that plasma added outnumbers all the antigens coated to beads.  
Shaking of the plate at HulaMixer is important to homogenize the sample and decrease 
aggregation. Homogenizing sample increases the possibility that all attachment point of protein 
binds specific antibodies in plasma if available and produced (taking in account that proteins 
are coated in a correct manner mimicking the way it is presented in fish).  
The blocking buffer added at the end of the coating process make sure that carboxyl groups on 
beads do not bind unspecific antibodies. The side groups of antibodies were not blocked and 
therefore there is a chance of antibody side group to bind other plasma antibodies or 
primary/secondary antibodies when added. This would give a false MFI signal from bead if the 
biotinylated secondary antibody bound streptavidin. However, control wells disproved this as 
there was no issue concerning MFI from control wells during each of the seven 96-well plate 
runs.  
 
4.4.3 Investigating bead loss and quantification of proteins during bead coating  
Bio-Rad do not offer premade bead kits with antigens against PRV. Therefore, our own beads 
were coated, where quality and weak spots of coating had to be discussed. This included bead 
loss during coating, but also the quality of coating trying to specify the variables affecting the 
quantity of proteins coated to beads.  
A total bead loss of 5 – 52 percent occurred during bead coating (fig. 3.8). Bead numbers 27 
and 34 only had around half (45-52 percent) of their beads left after coating. Unequal pipetting 
techniques in each bead tube might explain the variation of bead loss from each bead 
population. Bead loss might also correlate to the magnetic separator which was used a couple 
of times for removal of supernatant. Even though protocol was followed, 30-60 sec in the 
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magnetic separator might be too little time to separate beads. Another reason for the high bead 
loss could also be related to the start bead count as this was only an estimated value and not a 
measured value at the Countess II FL. When transferring beads over to the bead tube it was 
important with a homogenic solution, so concentration of beads was equal in tube. Transferring 
beads by pipetting therefore had to be done right after beads were vortexed as beads sunk to 
the bottom.   
1st bead 27 (ISAV FP) was a little bit aggregated when observed in Countess II FL, but still 
functional to use during analysis. The other beads showed no visual aggregation. The 2nd round 
of coated beads was not used during analysis as different protein concentrations were used 
during coating, since the amount of proteins available wasn’t checked before starting the bead 
coating protocol. However, protein concentrations (21.2 µg/mL and 18.2 mg/µL) were within 
the recommended protein levels according to Bio-Rad`s instruction manual (5 – 12 µg protein 
or a concentration of 1 µg/mL – 24 µg/mL), but because of standardization they were not used 
in analysis.  
Unfortunately, we have no methods to check the quality or quantity of antigen binding to beads. 
Even though no methods are available, quantification could have been possible using a 
monoclonal antibody that can detect proteins on beads. This has been attempted but it was not 
successful. Therefore, beads might be unevenly coated with proteins within same bead 
population and between different bead populations. However, this is unlikely as we would see 
a different antibody measurement (MFI) between the three runs in figure 3.7 A if this was the 
case.  
Coating of beads can vary depending on reactions of S-NHS and EDAC to form an active ester. 
This is crucial as the active ester form a covalent bond between the amine group of the protein 
and is essential in the coupling reaction (181). The protein introduced to beads are of course of 
importance for the coating process, where there is a high range of protein (5 – 12 µg) that can 
be introduced to beads according to Bio-Rad`s instruction manual. To ensure enough protein 
for each active ester on bead population, the highest recommended amount of protein (12 µg) 
was added to beads. In addition to reaction time (2 hours for protein coating), vortex and mixing 
of bead tube affects the beads and solution homogenization and therefore the coating of beads. 
If there are carboxyl groups not bound by protein, blocking buffer was added as the last step 




4.4.4 Controls  
Several controls were added to assay to check for errors. Firstly, the plasma was run as duplets 
on two different Bio-Plex 200 machines. Secondly, control beads were added to assays. 
Thirdly, both positive (PRV-1 infected) and negative control (uninfected group) were run at 
each time point. Fourthly, control wells were added for each plate during each run.  
All plasma samples were run as doublets, first at NMBU and then at VI. This worked as a 
control to check if there were differences in measurement of antibodies binding to beads. The 
duplet runs also revealed that even though there is an increase in aggregation in the 2nd run and 
a lower bead count (down to a minimum of 10 beads per bead population), this doesn’t affect 
the measured level of antibodies (fig. 3.6, 3.7).  
Control beads ISAV FP and ISAV FP-LM detected unspecific antibody binding that were not 
inactivated by heat treatment. These unspecific antibodies may be produced as a result of PRV 
injection (polyreactive antibodies), produced due to antigens exposed to earlier, or be natural 
antibodies. Therefore, ISAV FP and ISAV FP-LM are important controls to check background 
in figure 3.1-3.4.  
The negative control group worked to check for antibodies in plasma that were already there 
without exposure to antigen (natural antibodies) and production of antibodies towards antigens 
the fish had been exposed to earlier. All fish from this trial were from the same batch, and most 
likely exposed to the same microorganisms earlier in life. Therefore, good controls for 
background antibodies. 
 
Control wells are crucial when running Bio-Plex to check that assay reagents and 
measurements are happening properly. Also, if unspecific background from secondary 
antibodies and detection reagents happens, it is an indicator for where this error happened in 
the protocol. Unfortunately, some of the control wells during analysis contained plasma which 
were not from the PRV-1 group (positive control) with the highest antibody levels. Plate 1 
controls were added plasma from the InPRV-1 group which didn’t show PRV specific antibody 
production in this assay. Plate 3 were added plasma from the PRV-2 group which also had 
visually low antibody levels. This weakens the assay, but during the Bio-Plex analysis none of 
the control wells, negative and positive controls showed any concerning results indicating that 




4.5 Future perspectives 
4.5.1 Protection of PRV-1 infection  
What will a vaccine against HSMI mean for the future?  
Mortality from HSMI usually varies from insignificant to 20 percent in farms (31). A growing 
world population increases the demand for food. An optimal vaccine against HSMI that could 
minimize mortality would therefore not only decreases suffering of fish and increases the 
economics of the companies. It also would increase the sustainability by ensuring that fish 
reach the dinner plate and contribute to three of the UN`s sustainability goals (goal 2-zero 
hunger, goal 8-economic growth and goal 14-life below water) (fig.4.1). 
 
Figure 4.1. An optimal PRV-vaccine would benefit three of UNs sustainability goals. More food would reach 
the dinner table decreasing hunger (goal 2) and increasing economics (goal 8) contributing to a more 
sustainable aquaculture industry (goal 14). An optimal PRV vaccine would decrease mortality of Atlantic 
salmon and therefore increase the value creation and profit by investing in fish welfare and health. Retrieved 
from The Global Goals. 
 
An optimal vaccine against HSMI should also protect against PRV-1 infection and avoid 
spreading PRV-1 to other fish. The vaccine should also be completely cleared from fish after 
injection. Fish were protected after immunization with PRV-3 and did not infect cohabs five 
weeks after immunization. However, PRV-3 was not completely cleared from fish at the end 
of the trial period, 18 wpc (162). Attenuated vaccines that are not completely cleared might 
cause some challenges as the fish might shed virus to the environment. The virus might then 
infect other species. It is especially problematic if the virus mutate and become more virulent 
(188). Brown trout have been found to have a high PRV-3 infection prevalence (161) and might 
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therefore have a higher susceptibility to the virus. It has also been speculated that PRV-3 can 
induce a severe disease in brown trout (189). Brown trout can therefore be infected by 
vaccinated farmed Atlantic salmon if not completely cleared after infection. However, there is 
no doubt that PRV-3 can be used to provoke specific immune responses towards PRV-1. The 
detection of PRV specific antibodies measured from fish immunized with PRV-3, may be one 
of many reasons that fish gained an efficient cross-protection against PRV-1. However, 
antibody levels do not necessarily correlate with the protection, which can be associated with 
other the long term protective immune responses (168).  
The mammalian orthoreovirus (MRV) is used as a model for predicting structural and 
functional properties of PRV (135). Therefore, antibodies binding to σ1 are believed to be 
neutralizing as PRV σ1 is predicted to be the receptor binding protein. Antibody mediated 
protection has also shown neutralizing functions towards the MRV σ1 protein and an induced 
production of neutralizing antibodies when MRV σ1 protein is presented (141, 142). The PRV 
σ1 might be a good vaccine component in the future. This because there was a high antibody 
response detected towards PRV-1 σ1 from groups injected with PRV-1-3.  
 
4.5.2 Multiplexed magnetic bead-based immunoassay for the Aquaculture industry 
Bio-Plex (Luminex) assay is a sensitive bead based multiplex assay. Results can be obtained 
in a shorter time with less work and sample material compared to comparable analytical 
techniques (i.e ELISA) (177). Multiplexing has in other words great advantages to offer the 
growing Aquaculture industry and will be discussed in paragraphs below.  
Antigens from several pathogens can be isolated and coated to beads and many antibodies 
screened for in the same well. This, however, is dependent on finding antigens that the immune 
system target, get the right coating of antigens to beads (right structure and quantity), and 
knowing how much binding is specific and unspecific using appropriate controls. There is a 
high level of unspecific antibody binding in fish and this is probably one of the biggest 
limitations of the Bio-Plex assay and other serological antibody assays as well. Most likely all 
the PRV antigens used have bound unspecific antibodies to some degree. However, if 
unspecific antibodies detected on control antigens are lower than antibodies detected on PRV 
antigens this would indicate a higher degree of specific antibodies than unspecific antibodies 
bound to PRV antigens.   
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As only small amounts of blood or mucus are needed for detection of analytes (antibodies, 
cytokine, chemokines, etc.), the sampling can potentially be completed with no lethal outcome. 
This also give the possibility to sample the same fish several times over a long period of time. 
Study of antibodies from one individual over a longer time frame could give important 
knowledge about development of how vaccines activate the adaptive humoral part of the 
immune system. It could also give knowledge about specific antibodies and unspecific 
antibodies produced before, during and after an infection of a bacteria or virus. Antibodies can 
also be detected after the pathogen is cleared from fish and diagnosed if fish has been infected 
by a pathogen. Bio-Plex might therefore be of importance for fish health biologist and 
veterinarians (fish or other animals) too identify exposed populations. In particular if pathogen 
circulates asymptomatic in fish, having an insignificant low mortality rate which is undetected 
by farmers, but still trigger a specific antibody response in fish.  
Furthermore, one could also differentiate how an infection would affect the antibody 
production during different seasons when placed in sea cages with and without infection. Also, 
checking variables as sea cages in the south and north, age of fish or other environmental 
variables. This would be interesting because it would tell and prepare farmers when fish might 
be more susceptible to the pathogens.  
A multiplex immunoassay targeting different antigens from different pathogens can therefore 
be used as a tool for screening and diagnostic purposes in the aquaculture industry. However, 
proper validation must be completed for each of the antigens before they can be used in a 
diagnostic tool. The aquaculture industry being one of the fastest growing industries in Norway 
need tools contributing to a faster diagnostics and thereby better surveillance of infectious 
diseases and immunity. Better surveillance of diseases and immune responses would also 









1) A primary infection with PRV-2 and PRV-3 resulted in a specific antibody response against 
PRV-1 in Atlantic salmon. PRV specific antibodies produced after injection with PRV-2 and 
PRV-3 could cross-bind PRV-1 σ1-LM. 
 
2) PRV specific antibodies were detected from 5-10 wpc after immunization by PRV-2 and 
PRV-3. No antibodies were visually detected in fish injected with inactivated PRV-1. PRV 
specific antibodies appeared highest after PRV-1 infection. 
 
3) After PRV-1 shedder challenge, the PRV specific antibody were detected 12-18 wpc for fish 
immunized with PRV-2, PRV-3 and inactivated PRV-1. The PRV specific antibody response 
was boosted for the inactivated PRV-1 and PRV-2 immunized group. The PRV specific 
antibody response decreased for PRV-3 immunized group. This reflected virus levels and 
protection in the PRV-3 group only. 
 
4) After PRV-1 infection specific antibodies targeting PRV-1 σ1 were detected from 5-18 wpc 
and antibodies targeting PRV-1 µ1C were detected 2-18 wpc. 
 
5) A polyreactive antibody response was detected in PRV-1 infected plasma despite heat 
treatment.  
 
6) PRV-3 µNS and PRV-3 σ1 antigens did not work in this assay and could not be used as a 
reliable detection method of PRV specific antibodies. 
 
7) Analysis on two different Bio-Plex machines revealed a higher aggregation in the second 
run and therefore a lower bead count. Bead counts as low as eight beads per bead population 
did not show any difference in antibody measurement (MFI). A bead count cut off on 10 beads 






6.1 Attachment: Plasma microtiter plate setup  
The plasma samples consisted of a three-digit system. The first number stated the week the 
plasma sample was take (week post challenge), the second number stated the group/tank and 
the last number explained the given identification number of fish.   
Example. 1014 (10 wpc, group 1, fish 4). 
 
Table 6.1. Plate 1 - Group 1 (2, 5, 8 and 10 wpc), where C stands for cohab. 
Plate 1 1 2 3 4 5 6 7 8 9 10 11 12 
A 211 511 811 811C 1011 1011C             
B 212 512 812 812C 1012 1012C             
C 213 513 813 813C 1013 1013C             
D 214 514 814 814C 1014 1014C             
E 215 515 815 815C 1015 1015C             
F 216 516 816 816C 1016 1016C             
G 217 517 817   1017               
H 218 518 818   1018               
 
Table 6.2. Plate 2 - Group 2 (2, 5, 8, 10 wpc), where C stands for cohab. 
Plate 2 1 2 3 4 5 6 7 8 9 10 11 12 
A 221 521 821 821C 1021 1021C             
B 222 522 822 822C 1022 1022C             
C 223 523 823 823C 1023 1023C             
D 224 524 824 824C 1024 1024C             
E 225 525 825 825C 1025 1025C             
F 226 526 826 826C 1026 1026C             
G 227 527 827   1027               






Table 6.3. Plate 3 - Group 3 (2, 5, 8, 10 wpc), where C stands for cohab 
Plate 3 1 2 3 4 5 6 7 8 9 10 11 12 
A 231 531 831 831C 1031 1031C             
B 232 532 832 832C 1032 1032C             
C 233 533 833 833C 1033 1033C             
D 234 534 834 834C 1034 1034C             
E 235 535 835 835C 1035 1035C             
F 236 536 836 836C 1036 1036C             




            




            
 
Table 6.4. Plate 4 - Group 4 and 5 (week 0, 2, 5, 8, 10 wpc) 
Plate 4 1 2 3 4 5 6 7 8 9 10 11 12 
A 1 241 251 541 551 841 851 1041 1051       
B 2 242 252 542 552 842 852 1042 1052       
C 3 243 253 543 553 843 853 1043 1053       
D 4 244 254 544 554 844 854 1044 1054       
E 5 245 255 545 555 845 855 1045 1055       
F 6 246 256 546 556 846 856 1046 1056       
G 7 247 257 547 557 847 857 1047 1057       
H 8 248 258 548 558 848 858 1048 1058       
 
Table 6.5. Plate 5 - Group 1, 2b, 3b, 4b, 5a, 5b (week 12 wpc) 
Plate 5 1 2 3 4 5 6 7 8 9 10 11 12 
A 1211 1221 1231 1241 125a1 125b1             
B 1212 1222 1232 1242 125a2 125b2             
C 1213 1223 1233 1243 125a3 125b3             
D 1214 1224 1234 1244 125a4 125b4             
E 1215 1225 1235 1245 125a5 125b5             
F 1216 1226 1236 1246 125a6 125b6             
G 1217 1227 1237 1247 125a7 125b7             




Table 6.6. Plate 6 - Group 1, 2b, 3b, 4b, 5a, 5b (week 15 wpc) 
Plate 6 1 2 3 4 5 6 7 8 9 10 11 12 
A 1511 1521 1531 1541 155a1 155b1 
      
B 1512 1522 1532 1542 155a2 155b2 
      
C 1513 1523 1533 1543 155a3 155b3 
      
D 1514 1524 1534 1544 155a4 155b4 
      
E 1515 1525 1535 1545 155a5 155b5 
      
F 1516 1526 1536 1546 155a6 155b6 
      
G 1517 1527 1537 1547 155a7 155b7 
      
H 1518 1528 1538 1548 155a8 155b8 
      
 
 
Table 6.7. Plate 7 - Group 1, 2b, 3b, 4b, 5a, 5b (week 18 wpc) 
Plate 7 1 2 3 4 5 6 7 8 9 10 11 12 
A 1811 1821 1831 1841 185a1 185b1  
     
B 1812 1822 1832 1842 185a2 185b2  
     
C 1813 1823 1833 1843 185a3 185b3  
     
D 1814 1824 1834 1844 185a4 185b4  
     
E 1815 1825 1835 1845 185a5 185b5  
     
F 1816 1826 1836 1846 185a6 185b6  
     
G 1817 1827 1837 1847 185a7 185b7  
     
H 1818 1828 1838 1848 185a8 185b8  




6.2 Attachment: Plasma samples analysed on bio-plex (96-well plate) 
96-well plate 1: 
Utilized 75 of the wells in the 96-well plate, where 71 wells contained plasma samples and 4 
wells worked each as control/blanks with no plasma, no primary antibody, no secondary 
antibody, and no streptavidin. The control wells 12F, 12G, 12H containing plasma from 
sample 1046, 1047, 1048, respectively (table 6.8). 
 
Table 6.8. Overview of plasma samples on 96-well plate 1.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1 241 251 541 551 841 851 1041 1051 
   
B 2 242 252 542 552 842 852 1042 1052 
   
C 3 243 253 543 553 843 853 1043 1053 
   
D 4 244 254 544 554 844 854 1044 1054 
   
E 5 245 255 545 555 845 855 1045 1055 
   
F 6 246 256 546 556 846 856 1046 1056 
  
No pri. Ab 
G 7 247 257 547 557 847 857 1047 1057 
  
No sec. Ab 




96-well plate 2: 
Utilized 93 of the wells in the 96-well plate, where 88 wells contained plasma samples and 5 
wells worked each as control/blanks with no plasma, no primary antibody, no secondary 
antibody, and no streptavidin. The fifth control, well 10G only contained flow buffer and 
streptavidin. The control wells 6G, 12G, 12H containing plasma from sample 818 (table 6.9).  
50 µL of 100-folds dilution of plasma samples was made and resulted in too little plasma in 
all wells since all wells should have been added 50 µL (mistake). In addition, control well 
12H did contain 30 µL mastermix instead of 50 µL mastermix as too little mastermix was 
made. Plate 2 was therefore not used in results, and plate was prepared for a second time 











Table 6.9. Overview of plasma samples on 96-well plate 2. Not used in analysis.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 211 511 811 811-co 1011 1011-co 231 531 831 831-co 1031 1031-co 
B 212 512 812 812-co 1012 1012-co 232 532 832 832-co 1032 1032-co 
C 213 513 813 813-co 1013 1013-co 233 533 833 833-co 1033 1033-co 
D 214 514 814 814-co 1014 1014-co 234 534 834 834-co 1034 1034-co 
E 215 515 815 815-co 1015 1015-co 235 535 835 835-co 1035 1035-co 
F 216 516 816 816-co 1016 1016-co 236 536 836 836-co 1036 1036-co 
G 217 517 817 
 
1017 No strepta 237 537 837 Flow + strepta 1037 No pri. Ab 




238 538 838 No plasma 1038 No sec. Ab 
 
96-well plate 3: 
Utilized 96 of the wells in the 96-well plate, where 95 wells contained plasma samples. There 
was one well with no plasma (blank), but no control wells as all wells were added primary 
antibody, secondary antibody, and streptavidin. The supposed control wells 4G, 4H, 6G 
containing plasma from sample 1028 (table 6.10). Control antigen ICP11 was not added and 
the plate was therefore prepared for a second time (plate 6). 
 
Table 6.10. Overview of plasma samples on 96-well plate 3.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 221 521 821 821-co 1021 1021-co 1211 1221 1231 1241 125a1 125b1 
B 222 522 822 822-co 1022 1022-co 1212 1222 1232 1242 125a2 125b2 
C 223 523 823 823-co 1023 1023-co 1213 1223 1233 1243 125a3 125b3 
D 224 524 824 824-co 1024 1024-co 1214 1224 1234 1244 125a4 125b4 
E 225 525 825 825-co 1025 1025-co 1215 1225 1235 1245 125a5 125b5 
F 226 526 826 826-co 1026 1026-co 1216 1226 1236 1246 125a6 125b6 
G 227 527 827 No pri. Ab 1027 No strepta 1217 1227 1237 1247 125a7 125b7 
H 228 528 828 No sec. Ab 1028 No plasma 1218 1228 1238 1248 125a8 125b8 
 
96-well plate 4: 
Utilized 62 of the wells in the 96-well plate, where 58 wells contained plasma samples and 4 
wells worked as control/blanks with no plasma, no primary antibody, no secondary antibody, 
and no streptavidin. The control wells 8F - 8H containing plasma from sample 1518 (table 
6.11). There was made a duplicate of 10 of the wells from 1A-1H and 3A-3B to 7A-7H and 
8A-8B, where mastermix 2 was added to compare 2nd coated beads with 1st coated beads to 
check the result and quality of coating. Plate 4 was run a second time due to low bead count 




Table 6.11. Overview of plasma samples on 96-well plate 4. Blue and green wells added mastermix 1 and 2, 
respectively. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1511 1521 1531 1541 155a1 155b1 1511 1531     
B 1512 1522 1532 1542 155a2 155b2 1512 1532     
C 1513 1523 1533 1543 155a3 155b3 1513      
D 1514 1524 1534 1544 155a4 155b4 1514      
E 1515 1525 1535 1545 155a5 155b5 1515 No plasma     
F 1516 1526 1536 1546 155a6 155b6 1516 No pri. Ab     
G 1517 1527 1537 1547 155a7 155b7 1517 No sek. Ab     
H 1518 1528 1538 1548 155a8 155b8 1518 No strepta     
 
96-well plate 5: 
Utilized 96 of the wells in the 96-well plate, where 92 wells contained plasma samples and 4 
wells worked as control/blanks with no plasma, no primary antibody, no secondary antibody, 
and no streptavidin. The control wells 12F - 12H containing plasma from sample 1018 (table 
6.12). There was made two mastermixes, where mastermix 1 was added to control wells and 
column 1-8 (blue), while mastermix 2 was added to 9-11 and 12A-12D (black).  
 
 Table 6.12. Overview of plasma samples on 96-well plate 5. Blue wells added mastermix 1, green wells added 
mastermix 2. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 211 511 811 1011 231 531 831 1031 1511 152b1 153b1 155b4 
B 212 512 812 1012 232 532 832 1032 1512 152b2 153b2 155b6 
C 213 513 813 1013 233 533 833 1033 1513 152b3 153b3 155b7 
D 214 514 814 1014 234 534 834 1034 1514 152b4 153b4 155b8 
E 215 515 815 1015 235 535 835 1035 1515 152b5 153b5 No plasma 
F 216 516 816 1016 236 536 836 1036 1516 152b6 153b6 No pri. Ab 
G 217 517 817 1017 237 537 837 1037 1517 152b7 153b7 No sec. Ab 
H 218 518 818 1018 238 538 838 1038 1518 152b8 153b8 No strepta 
 
96-well plate 6: 
Utilized 96 of the wells in the 96-well plate, where 92 wells contained plasma samples and 4 
wells worked each as control/blanks with no plasma, no primary antibody, no secondary 
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antibody, and no streptavidin. The control wells 12B – 12D containing plasma from sample 
1211 (table 6.13). 
 
Table 6.13. Overview of plasma samples on 96-well plate 6.   
 1 2 3 4 5 6 7 8 9 10 11 12 
A 221 521 821 1021 1211 122b1 123b1 124b1 125a1 125b1 154b1 No plasma 
B 222 522 822 1022 1212 122b2 123b2 124b2 125a2 125b2 154b2 No pri. Ab 
C 223 523 823 1023 1213 122b3 123b3 124b3 125a3 125b3 154b3 No sec. Ab 
D 224 524 824 1024 1214 122b4 123b4 124b4 125a4 125b4 154b4 No strepta 
E 225 525 825 1025 1215 122b5 123b5 124b5 125a5 125b5 154b5 155a2 
F 226 526 826 1026 1216 122b6 123b6 124b6 125a6 125b6 154b6 155a3 
G 227 527 827 1027 1217 122b7 123b7 124b7 125a7 125b7 154b7 155a4 
H 228 528 828 1028 1218 122b8 123b8 124b8 125a8 125b8 154b8 155a5 
 
96-well plate 7: 
Utilized 52 of the wells in the 96-well plate, where 48 wells contained plasma samples and 4 
wells worked each as control/blanks with no plasma, no primary antibody, no secondary 
antibody, and no streptavidin (table 6.14). 
 
Table 6.14. Overview of plasma samples on 96-well plate 7. Plate 7 was run by engineer Karen Bækken Soleim 
from NVI. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1811 182b1 183b1 184b1 185a1 185b1 No plasma      
B 1812 182b2 183b2 184b2 185a2 185b2 No pri. Ab      
C 1813 182b3 183b3 184b3 185a3 185b3 No sek. Ab      
D 1814 182b4 183b4 184b4 185a4 185b4 No strepta      
E 1815 182b5 183b5 184b5 185a5 185b5       
F 1816 182b6 183b6 184b6 185a6 185b6       
G 1817 182b7 183b7 184b7 185a7 185b7       
H 1818 182b8 183b8 184b8 185a8 185b8       
 
 
6.3 Attachment: Bead coating  
6.3.1. Calculation of protein and PBS buffer volume: 




Table 6.15. 1st coating of protein used in bio-plex analysis. Volume of protein and PBS (pH 7.4) buffer during 
coating. One scale (x1) coupling reaction equalled 1.25 x 106 beads (100 µL) with 5-12 µg protein in a volume 
adjusted to 500 µL by PBS buffer (pH 7.4) according to Bio-Rad`s instructions manual. 
1st coating of beads: 27 28 29 34 44 54 64 
Protein FP FP-LM ICP11-LM PRV-1 µ1C PRV-1 σ1-LM PRV-3 σ1 PRV-3 µ1C 
Concentration (μg/μL) 0.046 0.054 0.2 0.62 0.12 0.4 0.4 
Scale coupling 
reaction  x1 x1 x3 x3 x3 x3 x3 
 
12 μg / concentration 
(μg/μL) 
x  
scale coupling reaction 
 
= 




































Volume of protein 
(μL) 261 222 180 58 300 90 90 
 
Total volume  
- 




Volume of PBS buffer 
(μL) 






















































Table 6.16. 2nd coating of protein not used in bio-plex analysis. Volume of protein and PBS (pH 7.4) buffer 
during coating. One scale (x1) coupling reaction equalled 1.25 x 106 beads (100 µL) with 5-12 µg protein in a 
volume adjusted to 500 µL by PBS buffer (pH 7.4) according to Bio-Rad`s instructions manual. 
*For bead 27 there was added 5.3 µg protein, as protein quantity was not checked before coating.  
* For bead 44 there was added 27.36 µg protein, as protein quantity was not checked before coating. 
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2nd coating of beads: 27 29 34 44 
Antigen FP ICP11-LM PRV-1 µ1C PRV-1 σ1-LM 
Concentration (μg/μL) 0.046 0.2 0.62 0.12 
Scale coupling reaction  x0.5 x3 x3 x3 
 
12 μg / concentration 
(μg/μL) 
x  
scale coupling reaction 
 
= 




















Volume of protein 
(μL) 115 180 58 228 
 
Total volume  
- 




Volume of PBS buffer 
(μL) 


































6.3.2. Calculation of End beads and Bead loss (%): 
Beads at the start and end of coating with percentage of bead loss calculated in table 6.17. 




Table 6.17. How many beads at the start, at the end and the bead loss is calculated from the concentration of 
coated beads from Countess II FL. The protein coating for all beads had a concentration of 0.024 µg/µL. Only 
1st coated beads were used in Bio-plex analysis. 
*For bead 27 there was added 5.3 µg protein (concentration of protein coating: 21.2 µg/mL), as protein 
quantity was not checked before coating. 
* For bead 44 there was added 27.36 µg protein (concentration of protein coating: 18.2 µg/mL), as protein 
quantity was not checked before coating. 















1st 2nd * 1st 1st 2nd 1st 2nd 1st 2nd * 1st 1st 






















































coated beads from 
























Total volume when 
measured (mL) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
Bead loss (%) 
 
(End – Start) / Start * 









6.4 Attachment: Mastermix calculations  
Each sample (well) contained 2500 beads per bead population per well and the mastermix 





Table 6.18. Concentration of coated beads (beads/µL) retrieved from Countess II FL – only 1st coating used in 
analysis. 
* For bead 64, the concentration (C1) was 21 300 beads/µL on Countess II FL, but due to type error there were 
calculated with 21 000 beads/µL.  
*For bead 29, the concentration (C1) were 18 500 beads/µL on Countess II FL, but due to type error there were 
calculated with 18 000 beads/µL.  
Bead 27:  4605 beads/µL  
Bead 28:   5950 beads/µL 
Bead 29:  18 000* beads/µL 
Bead 34:  11 900 beads/µL  
Bead 44:   23 500 beads/µL  
Bead 54:   23 700 beads/µL  
Bead 64:  21 000* beads/µL  
 
To find total volume of mastermix for each 96-well plate, the number of utilized wells was 
multiplied with 50 µL and 1.1 (10 percent extra mastermix).  
To find volume of each coated beads, the dilution formula in equation 6.1 was used. This 
ensured same concentration (50 beads/µL) of each bead added to mastermix. 
 
𝑉𝑜𝑙𝑢𝑚𝑒(𝑉1) ∗ 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛(𝐶1) = 𝑉𝑜𝑙𝑢𝑚𝑒(𝑉2) ∗ 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛(𝐶2)                                   𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 6.1 
 
C1 was the concentration of the coated beads and received by the Countess II FL (table 6.18) 
C2 was 50 beads/µL and V2 was total volume of mastermix (depending on utilized wells). 





 =  
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑚𝑎𝑠𝑡𝑒𝑟𝑚𝑖𝑥 (µ𝐿)  ∗  50 𝑏𝑒𝑎𝑑𝑠/ µ𝐿 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑜𝑎𝑡𝑒𝑑 𝑏𝑒𝑎𝑑
 





Table. 6.19. Primary antibody, secondary antibody and streptavidin were added to all the 96-well plate. Both 
the volume and the formula for calculations are listed. Number of wells utilized can be found in appendix sec. 










6.6 Attachment: Raw data. Aggregation and bead count. 
Comparing aggregation of beads (%) and bead count in each plasma sample (well) from 
group 1 (PRV-1) and group 5a (mock group) during 1st (NMBU) and 2nd (VI) run on 96 well 
plate 1-4. 
96-well plate 1 2 3 4 5 6 7 
Need to make 
(Wells utilized *50 µL*1.15): 
4125 µL 5348 µL 5520 µL 3565 µL 5520 µL 5520 µL 2990 µL 
  
Primary antibody (Pri Ab) 
(Need to make / 400) 
 
Flow buffer 























Secondary antibody (sec Ab) 
(Need to make / 1000)  
 
Flow buffer 























(Need to make / 50) 
 
Flow buffer 

























Table. 6.20. Aggregation and bead count from group 1(PRV-1), positive control.  
  First run Second 
run 







Beads counted in 
well 
Bead count in each well  
211 8 29 559 233 
212 10 25 490 260 
213 10 22 491 263 
214 10 22 502 307 
215 9 31 239 149 
216 11 20 400 314 
217 9 21 535 332 
218 6 16 695 376 
511 11 33 343 126 
512 10 36 257 106 
513 15 39 188 100 
514 11 31 169 68 
515 13 31 170 88 
516 14 31 97 61 
517 12 24 341 193 
518 7 18 597 324 
811 8 29 353 150 
812 19 36 158 72 
813 10 36 114 67 
814 17 35 142 75 
815 18 40 82 52 
816 19 32 106 65 
817 14 33 171 119 
818 10 21 434 258 
1011 10 33 288 100 
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1012 19 47 73 55 
1013 23 54 28 9 
1014 18 42 69 29 
1015 19 51 46 19 
1016 16 41 72 39 
1017 10 31 180 91 
1018 9 22 291 223 
1211 10 10 820 443 
1212 13 16 364 195 
1213 13 20 173 107 
1214 19 22 161 80 
1215 15 19 252 128 
1216 15 25 130 61 
1217 14 18 342 177 
1218 10 9 738 405 
1511 9 13 944 525 
1512 8 9 947 534 
1513 12 10 713 423 
1514 14 11 654 356 
1515 15 11 506 311 
1516 13 13 628 309 
1517 13 15 765 419 





Table. 6.21. Aggregation and bead count from group 5a (Mock), negative control. 
  First run Second 
run 









Beads counted in 
well 
Bead count in each 
well  
251 8 29 645 272 
252 11 37 367 204 
253 15 46 227 86 
254 17 44 214 94 
255 20 43 135 63 
256 15 40 265 121 
257 11 37 421 202 
258 9 26 794 392 
551 10 29 652 248 
552 14 42 277 94 
553 19 44 131 71 
554 15 46 144 72 
555 12 44 140 80 
556 15 35 219 136 
557 13 31 241 162 
558 7 25 656 388 
851 8 23 638 328 
852 16 37 226 100 
853 13 40 163 70 
854 17 47 136 63 
855 18 42 178 104 
856 15 46 125 67 
857 12 32 371 200 
858 8 21 691 409 
1051 8 26 645 341 
1052 10 35 344 173 
1053 14 37 195 101 
1054 16 35 234 151 
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1055 14 36 211 136 
1056 15 42 202 106 
1057 10 25 471 261 
1058 8 18 643 505 
125a1 7 10 890 537 
125a2 9 9 383 285 
125a3 14 17 357 214 
125a4 11 13 368 226 
125a5 19 12 416 273 
125a6 11 10 441 331 
125a7 16 12 437 287 
125a8 7 9 807 467 
155a1 16 17 350 206 
155a2 18 14 149 116 
155a3 17 42 49 27 
155a4 17 28 105 58 
155a5 27 35 65 37 
155a6 20 24 120 69 
155a7 18 23 208 101 












6.7 Attachment: Raw data. MFI and bead count of PRV-1 beads. 
MFI and bead count from PRV-1 beads from three runs (NMBU, VI, VI) of the same 96-well 
plate 4. 
 
Table. 6.22. MFI with bead count in parentheses from PRV-1 σ1-LM from group 1-4 (PRV-1, PRV-2, PRV-3, 
InPRV-1) for three runs. Plasma samples from 96 well plate 4 (yellow). 
*** No beads counted from well. 
Plasma samples 1st 2nd 3rd 
1511 24582.5 (100) 24327,0 (55) 25137,0 (15) 
1512 23782.0 (89) 24681,5 (72) 23321,5 (8) 
1513 20535.0 (66) 20397,5 (34) 21213,0 (6) 
1514 21003.5 (60) 22328,0 (40) 22377,0 (4) 
1515 19080.0 (53) 19784,0 (26) 18195,0 (3) 
1516 15072.0 (51) 15344,5 (30) 16359,5 (6) 
1517 10448.0 (76) 10580,5 (44) 8134,5 (6) 
1518 19842.0 (89) 20997,0 (45) 21655,0 (7) 
1521 6640.0 (69) 6397,0 (41) 6097,0 (3) 
1522 940.0 (26) 941,0 (14) 820,0 (3) 
1523 470.0 (19) 374,0 (9) 350,0 (1) 
1524 6880.5 (26) 6586,0 (16) 7002,0 (6) 
1525 637.0 (13) 390,0 (17) 1216,5 (4) 
1526 1392.5 (22) 1009,0 (7) 777,0 (3) 
1527 8083.5 (32) 5130,0 (20) 5459,0 (5) 
1528 1085.0 (79) 961,0 (36) 725,0 (12) 
1531 5760.0 (25) 3810,0 (6) 5719,0 (1) 
1532 23957.0 (20) 24069,5 (8) *** 
1533 4298.0 (7) 4389,0 (8) *** 
1534 3277.5 (12) 2733,5 (12) 2315,0 (3) 
1535 3763.0 (6) 3858,5 (2) 1519,0 (2) 
1536 4924.0 (15) 4667,0 (10) 5489,0 (3) 
1537 8168.0 (14) 8730,5 (6) 7203,0 (6) 
1538 8913.5 (30) 9611,0 (38) 9025,0 (11) 
1541 941.5 (42) 846,5 (28) 570,5 (4) 
1542 1151.0 (23) 1050,0 (9) 964,0 (1) 
1543 1274.0 (10) 996,0 (10) 2031,5 (2) 
1544 1747.5 (8) 1640,0 (9) 1342,0 (1) 
1545 815.0 (9) 819,5 (6) 619,0 (3) 
1546 1129.0 (7) 986,0 (7) 940,0 (5) 
1547 1062.0 (23) 1059,0 (9) 1115,0 (3) 





Table. 6.23. MFI with bead count in parentheses from PRV-1 µ1C from group 1-4 (PRV-1, PRV-2, PRV-3, 
InPRV-1) for three runs. Plasma samples from 96 well plate 4 (yellow). 
*** No beads counted from well. 
Plasma samples 1st 2nd 3rd 
1511 17687.5 (208) 17586,0 (125) 18127,0 (21) 
1512 15831.0 (215) 13090,0 (107) 14535,0 (34) 
1513 8876.0 (171) 8489,5 (86) 9511,5 (16) 
1514 16130.0 (165) 15211,0 (84) 16739,0 (5) 
1515 12340.5 (114) 14642,0 (75) 13774,0 (12) 
1516 12197.5 (150) 11911,0 (68) 10284,0 (10) 
1517 9542.0 (165) 8831,0 (102) 8141,0 (8) 
1518 7025.0 (193) 7086,0 (105) 6817,5 (8) 
1521 2270.0 (163) 1962,0 (87) 1643,0 (13) 
1522 262.0 (81) 198,5 (44) 189,0 (6) 
1523 175.0 (57) 138,5 (28) 126,0 (5) 
1524 513.0 (59) 359,0 (24) 322,0 (4) 
1525 156.5 (50) 116,0 (25) 141,0 (11) 
1526 635.0 (42) 435,0 (23) 356,0 (5) 
1527 512.0 (69) 379,0 (39) 320,5 (14) 
1528 250.0 (187) 208,0 (100) 190,0 (30) 
1531 1364.0 (80) 1359,0 (37) 1367,0 (8) 
1532 2356.0 (53) 1711,0 (34) 1688,0 (5) 
1533 367.0 (39) 274,0 (11) 241,5 (6) 
1534 1457.5 (44) 1308,0 (27) 922,0 (8) 
1535 360.0 (22) 296,0 (5) 324,0 (3) 
1536 893.0 (34) 630,0 (15) 515,0 (10) 
1537 2335.5 (64) 1689,0 (40) 1765,0 (19) 
1538 310.5 (128) 291,0 (58) 249,5 (24) 
1541 489.0 (113) 456,0 (43) 430,0 (11) 
1542 285.0 (39) 244,0 (28) 178,0 (4) 
1543 518.5 (34) 409,0 (14) *** 
1544 1015.0 (29) 885,5 (20) 720,0 (7) 
1545 267.0 (19) 242,5 (14) 252,0 (3) 
1546 434.0 (33) 342,5 (16) 291,0 (9) 
1547 424.0 (58) 354,5 (40) 320,0 (9) 






6.8 Attachment: Raw data used in Bio-Plex analysis 
6.8.1 Group 1 (PRV-1) 
Table 6.24. Raw data from PRV-1/group 1 (positive control). Each colour represents a 96-well plate. Light grey 





Plasma sample PRV1 s1-LM (44) PRV1-u1c (34) PRV3 s1 (54) PRV3 uNS (64) ISAV FP (27) ISAV FP-LM (28) ICP11-LM (29)
1 197.0 (100) 55.0 (188) 76.0 (145) 61.0 (175) 108.0 (154)
2 281.0 (83) 74.0 (135) 116.0 (109) 74.5 (156) 218.5 (126)
3 400.0 (102) 94.0 (157) 111.0 (100) 78.5 (174) 259.0 (114)
4 255.0 (100) 72.0 (217) 106.0 (137) 72.0 (174) 155.5 (140)
5 197.5 (100) 53.0 (188) 88.0 (109) 61.0 (157) 158.0 (134)
6 237.0 (100) 59.0 (262) 87.0 (133) 54.5 (182) 221.0 (153)
7 562.0 (100) 77.0 (171) 128.0 (100) 85.0 (172) 187.5 (122)
No plasma
211 626.0 (59) 389.5 (102) 293.0 (50) 308.0 (79) 374.5 (78) 688.0 (92) 548.0 (59)
212 343.0 (50) 219.0 (91) 153.5 (50) 163.0 (87) 153.0 (85) 245.0 (84) 362.5 (58)
213 371.0 (105) 213.5 (158) 177.0 (100) 197.0 (181) 228.5 (166) 359.0 (172) 417.5 (116)
214 722.5 (100) 514.0 (167) 286.0 (109) 388.0 (157) 421.5 (138) 782.5 (144) 926.0 (104)
215 638.5 (100) 514.5 (182) 311.0 (136) 327.0 (189) 480.0 (177) 815.0 (161) 1308.0 (132)
216 1333.0 (100) 565.5 (190) 361.0 (103) 474.5 (182) 523.0 (157) 934.0 (155) 844.5 (130)
217 3090.5 (100) 1023.0 (158) 579.0 (112) 647.0 (150) 777.0 (165) 1530.0 (169) 1286.0 (125)
218 2247.0 (100) 488.5 (176) 337.5 (106) 360.0 (163) 308.0 (138) 616.0 (179) 751.0 (118)
511 3612.0 (100) 1023.0 (149) 628.0 (105) 998.0 (172) 966.0 (168) 1698.0 (139) 1714.5 (108)
512 1812.0 (100) 765.5 (202) 413.0 (118) 781.0 (196) 680.0 (197) 1074.5 (150) 1713.0 (141)
513 1691.0 (101) 777.5 (194) 375.5 (100) 765.0 (207) 493.5 (204) 780.0 (174) 1141.5 (132)
514 3836.0 (100) 1316.5 (200) 788.0 (107) 1783.0 (209) 1169.0 (174) 1828.5 (136) 2247.5 (106)
515 1104.0 (101) 600.0 (235) 382.0 (99) 623.0 (247) 548.0 (215) 902.5 (178) 1682.0 (107)
516 2367.5 (100) 977.0 (192) 477.5 (100) 841.0 (209) 750.0 (196) 1365.0 (147) 1847.0 (114)
517 3098.5 (100) 952.5 (222) 498.5 (126) 911.0 (213) 544.0 (213) 1143.0 (164) 2095.0 (150)
518 3737.0 (100) 1011.5 (156) 536.0 (126) 759.0 (164) 617.0 (145) 1381.5 (182) 1126.0 (114)
811 24101.5 (100) 13399.0 (166) 4544.0 (133) 8593.0 (172) 5007.5 (144) 7870.0 (161) 7904.0 (130)
812 22558.0 (109) 12933.5 (206) 8543.0 (110) 8027.0 (217) 8271.0 (198) 11929.0 (125) 12621.5 (100)
813 19366.0 (111) 10733.5 (172) 3300.5 (108) 6299.0 (176) 3987.0 (193) 7076.0 (145) 6692.0 (99)
814 23713.5 (84) 5310.0 (153) 3016.0 (88) 5948.0 (182) 2964.5 (172) 6013.0 (91) 11520.0 (66)
815 23068.0 (45) 6557.0 (117) 4555.5 (58) 7245.0 (113) 4440.0 (115) 8747.0 (46) 7531.0 (39)
816 23805.0 (85) 13604.5 (180) 13138.5 (86) 12693.0 (171) 15297.5 (176) 18122.0 (133) 17036.5 (92)
817 21306.5 (100) 8366.0 (219) 4289.0 (124) 8548.0 (268) 5316.5 (222) 8785.5 (200) 6957.0 (145)
818 22022.0 (102) 9080.0 (154) 3381.5 (100) 5665.0 (169) 3709.0 (136) 7540.0 (116) 6951.0 (112)
1011 24344.0 (109) 16225.0 (197) 4064.0 (100) 11953.0 (173) 6825.0 (173) 8805.0 (174) 11472.5 (134)
1012 24879.5 (100) 17215.5 (182) 11763.5 (124) 15944.0 (200) 12504.0 (181) 14860.5 (152) 17374.0 (105)
1013 20660.5 (84) 11187.5 (166) 3930.0 (98) 9293.0 (185) 5483.5 (164) 9753.0 (132) 11739.0 (99)
1014 19788.0 (55) 12205.0 (91) 5058.0 (59) 9054.0 (99) 4353.0 (110) 8904.0 (57) 8246.5 (62)
1015 23745.0 (53) 3878.5 (100) 1790.5 (70) 6960.0 (122) 1521.5 (118) 3603.5 (58) 6517.5 (48)
1016 25637.0 (51) 12532.5 (126) 5677.0 (64) 8158.0 (107) 3995.5 (132) 7467.0 (93) 7349.5 (62)
1017 24470.0 (91) 8278.0 (229) 3330.0 (115) 8001.0 (209) 3018.0 (218) 6311.0 (171) 5464.5 (136)
1018 20763.0 (100) 8256.0 (141) 1865.5 (110) 3736.0 (157) 1472.0 (133) 3014.0 (159) 2915.0 (104)
1211 23770.0 (111) 12849.0 (172) 3848.0 (100) 6667.0 (190) 1252.0 (169) 2616.5 (142) 10538.0 (108)
1212 22886.5 (50) 6528.0 (102) 1540.5 (60) 4143.5 (114) 706.0 (77) 2251.0 (54) 3165.5 (78)
1213 22949.5 (16) 2594.0 (53) 4196.5 (30) 9338.0 (61) 1941.0 (45) 7283.0 (23) 4534.0 (26)
1214 25186.0 (17) 8350.0 (65) 2885.5 (30) 4766.0 (58) 3081.0 (32) 4706.0 (19) 6107.5 (30)
1215 25774.0 (26) 21704.0 (53) 3832.0 (27) 14415.0 (63) 2236.0 (63) 5026.0 (33) 25172.5 (32)
1216 24094.5 (18) 18349.0 (67) 4515.0 (37) 13135.0 (82) 1945.5 (30) 3837.5 (16) 10441.5 (44)
1217 24013.0 (44) 12154.5 (124) 7538.0 (73) 10472.5 (124) 3965.0 (74) 5949.0 (49) 9106.0 (77)
1218 19381.5 (106) 10592.0 (144) 4581.0 (100) 9162.5 (184) 800.0 (167) 1873.5 (116) 10008.0 (118)
1511 24304.0 (129) 15283.5 (284) 3317.0 (106) 4320.0 (233) 1676.0 (187) 3462.5 (140) 23393.5 (160)
1512 23429.0 (39) 11999.5 (112) 2663.0 (51) 6769.0 (94) 1539.0 (227) 3204.0 (153) 4142.0 (59)
1513 20726.0 (46) 5607.0 (111) 1080.0 (40) 2537.0 (89) 520.0 (165) 1073.0 (97) 1640.5 (66)
1514 21509.0 (31) 14056.0 (85) 2906.0 (33) 14504.0 (73) 1812.5 (168) 3847.0 (70) 7958.5 (52)
1515 15831.0 (35) 12261.5 (74) 1649.0 (29) 6439.5 (68) 1138.0 (136) 2232.5 (56) 2912.0 (32)
1516 20291.5 (56) 13430.0 (119) 2972.0 (41) 9369.0 (88) 1421.0 (153) 2996.0 (91) 7852.5 (54)
1517 10959.0 (69) 6587.0 (158) 1410.0 (60) 7214.0 (136) 738.0 (185) 1904.0 (101) 2752.0 (88)
1518 20405.5 (154) 6316.0 (257) 2326.0 (125) 6833.0 (248) 1121.0 (193) 2425.0 (165) 1934.0 (205)
1811 15886 3169 1389 1466
1812 9713,5 2715 1234,5 1094
1813 15196 8236 1469 1475
1814 11127 4861 2720,5 3502,5
1815 10549 4330,5 1543 1552
1816 14394 2972,5 1511 1602
1817 8161 4225,5 947 1095
1818 16166 1457,5 1130,5 1163,5
93 
 
6.8.2 Group 2 (PRV-2) 
Table 6.25. Raw data from PRV-2/group 2. Each colour represents a 96-well plate. Light grey = plate 1, dark 
grey = plate 3, yellow = plate 4, green = plate 5, blue = plate 6, purple = plate 7, black = no existing samples, 




Plasma sample PRV1 s1-LM (44) PRV1-u1c (34) PRV3 s1 (54) PRV3 uNS (64) ISAV FP (27) ISAV FP-LM (28) ICP11-LM (29)
1 197.0 (100) 55.0 (188) 76.0 (145) 61.0 (175) 108.0 (154)
2 281.0 (83) 74.0 (135) 116.0 (109) 74.5 (156) 218.5 (126)
3 400.0 (102) 94.0 (157) 111.0 (100) 78.5 (174) 259.0 (114)
4 255.0 (100) 72.0 (217) 106.0 (137) 72.0 (174) 155.5 (140)
5 197.5 (100) 53.0 (188) 88.0 (109) 61.0 (157) 158.0 (134)
6 237.0 (100) 59.0 (262) 87.0 (133) 54.5 (182) 221.0 (153)
7 562.0 (100) 77.0 (171) 128.0 (100) 85.0 (172) 187.5 (122)
No plasma
221 699.0 (107) 343.0 (170) 232.5 (100) 298.5 (168) 541.0 (185) 761.5 (190) 1181.0 (139)
222 546.5 (100) 387.0 (191) 231.0 (109) 363.0 (136) 903.0 (183) 1217.5 (134) 1406.0 (117)
223 578.0 (100) 459.0 (160) 286.0 (109) 428.0 (166) 610.5 (150) 1080.0 (126) 736.0 (115)
224 539.0 (100) 311.0 (193) 216.0 (105) 329.0 (182) 300.0 (239) 604.0 (154) 889.0 (144)
225 715.5 (100) 329.0 (149) 216.5 (100) 247.0 (181) 316.0 (141) 579.5 (118) 663.0 (121)
226 1245.0 (100) 648.0 (177) 314.0 (116) 415.0 (213) 674.0 (179) 1180.5 (150) 1432.5 (128)
227 651.5 (100) 534.0 (153) 262.0 (120) 360.0 (177) 477.0 (181) 835.5 (192) 710.5 (124)
228 668.5 (100) 980.0 (116) 266.0 (103) 328.5 (128) 385.0 (176) 708.5 (174) 762.0 (103)
521 7311.0 (100) 467.5 (178) 725.0 (114) 386.0 (179) 449.0 (195) 757.0 (161) 619.0 (123)
522 928.0 (100) 224.5 (186) 162.5 (100) 214.5 (200) 181.5 (180) 288.0 (132) 646.0 (122)
523 5195.0 (87) 528.0 (173) 373.0 (93) 301.5 (174) 219.0 (135) 386.0 (63) 891.0 (87)
524 6388.5 (72) 457.0 (129) 350.0 (67) 635.5 (126) 194.5 (124) 402.5 (88) 2146.5 (84)
525 4773.5 (84) 502.5 (138) 375.5 (78) 548.5 (148) 669.0 (127) 933.0 (84) 1270.0 (99)
526 7373.0 (31) 433.5 (76) 485.5 (28) 378.5 (88) 473.0 (68) 583.0 (34) 977.0 (35)
527 4660.0 (94) 801.0 (193) 436.5 (102) 470.0 (183) 304.5 (180) 671.0 (127) 1218.0 (154)
528 5470.5 (108) 462.0 (159) 355.0 (114) 540.5 (170) 259.0 (241) 409.5 (156) 1164.5 (100)
821 4077.5 (100) 210.0 (194) 255.0 (103) 420.0 (193) 488.5 (154) 709.5 (156) 873.0 (125)
822 1568.0 (69) 167.0 (156) 185.0 (94) 190.0 (173) 234.0 (137) 438.5 (76) 627.0 (89)
823 2412.0 (49) 1286.5 (144) 256.5 (54) 304.0 (115) 715.5 (92) 1097.0 (61) 1581.0 (67)
824 5385.0 (52) 187.0 (79) 300.5 (42) 497.0 (81) 242.0 (76) 427.0 (41) 554.0 (61)
825 8683.0 (36) 113.0 (72) 349.5 (32) 209.0 (73) 120.0 (91) 241.0 (45) 301.5 (36)
826 4788.0 (25) 213.0 (71) 368.0 (40) 303.5 (64) 245.0 (74) 455.0 (38) 921.0 (39)
827 10447.0 (85) 324.0 (145) 423.0 (71) 337.0 (164) 350.0 (126) 720.0 (57) 998.0 (84)
828 4027.0 (105) 422.5 (162) 377.5 (100) 380.0 (171) 607.0 (240) 979.5 (128) 1234.0 (139)
1021 606.5 (100) 161.5 (182) 340.0 (103) 274.0 (155) 228.0 (199) 364.5 (162) 905.0 (129)
1022 2732.5 (52) 175.0 (137) 206.0 (68) 301.0 (123) 128.0 (96) 155.5 (48) 439.0 (54)
1023 922.0 (42) 323.0 (65) 229.0 (47) 259.0 (65) 325.5 (54) 383.0 (29) 762.0 (41)
1024 2226.0 (22) 215.5 (72) 220.0 (32) 270.0 (48) 190.0 (61) 291.5 (28) 1227.0 (23)
1025 6687.5 (20) 232.0 (66) 309.0 (35) 271.0 (45) 176.5 (58) 347.5 (26) 621.0 (33)
1026 3127.5 (24) 368.5 (46) 233.0 (22) 363.0 (57) 162.5 (56) 286.0 (45) 584.0 (28)
1027 4911.0 (61) 692.0 (107) 568.0 (68) 608.0 (155) 526.5 (126) 998.0 (47) 1981.0 (73)
1028 2510.5 (100) 240.5 (162) 244.0 (110) 312.0 (173) 278.0 (212) 560.0 (134) 888.0 (101)
1221 8056.5 (100) 657.5 (192) 731.5 (114) 652.5 (160) 96.0 (183) 145.0 (130) 756.0 (106)
1222 1156.0 (43) 339.0 (116) 261.0 (51) 371.5 (92) 233.5 (96) 414.0 (52) 574.5 (58)
1223 2041.0 (27) 1917.5 (44) 581.0 (24) 772.5 (58) 334.5 (56) 788.5 (28) 1655.5 (22)
1224 3718.0 (20) 419.0 (69) 413.0 (31) 479.0 (52) 492.0 (27) 726.0 (22) 1083.0 (33)
1225 1451.0 (29) 1094.0 (59) 263.0 (27) 329.0 (41) 186.0 (56) 307.0 (27) 1824.0 (37)
1226 3856.0 (5) 807.0 (51) 678.5 (24) 874.0 (49) 1022.5 (34) 1484.5 (16) 2791.0 (21)
1227 2083.0 (41) 638.0 (82) 328.0 (47) 519.0 (94) 343.5 (64) 546.0 (49) 1339.0 (60)
1228 10746.5 (100) 2073.0 (163) 1036.0 (103) 1025.0 (187) 514.5 (146) 847.0 (89) 1289.0 (125)
1521 5770.0 (101) 1544.0 (188) 452.0 (82) 1140.0 (149) 286.0 (161) 523.0 (86) 2643.5 (108)
1522 1426.0 (71) 326.0 (181) 365.5 (56) 457.5 (148) 220.0 (89) 349.0 (50) 1879.0 (119)
1523 680.5 (38) 292.0 (105) 240.0 (40) 621.0 (93) 175.0 (89) 354.0 (34) 1579.5 (70)
1524 8483.0 (41) 360.5 (88) 460.0 (33) 905.0 (73) 338.0 (79) 707.0 (26) 887.0 (55)
1525 2519.0 (40) 1149.5 (126) 328.0 (33) 981.0 (121) 169.0 (67) 278.0 (25) 1548.0 (73)
1526 1633.0 (61) 807.0 (173) 636.0 (53) 842.5 (130) 540.5 (50) 1029.0 (23) 3234.0 (97)
1527 9025.0 (77) 387.0 (147) 324.0 (55) 335.0 (137) 241.0 (92) 456.0 (34) 469.5 (102)
1528 1110.0 (124) 184.0 (269) 200.0 (86) 266.0 (209) 225.0 (188) 416.0 (81) 692.0 (169)
1821 24392 5465 5670 5885,5
1822 24349 3135 3850 3948
1823 23108 1654,5 1739,5 2088,5
1824 1267 304 426,5 402
1825 1258 179,5 220 214,5
1826 22851 675 554,5 635
1827 23889,5 3716 2204 2577
1828 23275 2457 4832 4248
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6.8.3 Group 3 (PRV-3) 
Table 6.26. Raw data from PRV-3/group 3. Each colour represents a 96-well plate. Light grey = plate 1, dark 
grey = plate 3, yellow = plate 4, green = plate 5, blue = plate 6, purple = plate 7, black = no existing samples, 




Plasma sample PRV1 s1-LM (44) PRV1-u1c (34) PRV3 s1 (54) PRV3 uNS (64) ISAV FP (27) ISAV FP-LM (28) ICP11-LM (29)
1 197.0 (100) 55.0 (188) 76.0 (145) 61.0 (175) 108.0 (154)
2 281.0 (83) 74.0 (135) 116.0 (109) 74.5 (156) 218.5 (126)
3 400.0 (102) 94.0 (157) 111.0 (100) 78.5 (174) 259.0 (114)
4 255.0 (100) 72.0 (217) 106.0 (137) 72.0 (174) 155.5 (140)
5 197.5 (100) 53.0 (188) 88.0 (109) 61.0 (157) 158.0 (134)
6 237.0 (100) 59.0 (262) 87.0 (133) 54.5 (182) 221.0 (153)
7 562.0 (100) 77.0 (171) 128.0 (100) 85.0 (172) 187.5 (122)
No plasma
231 835.5 (100) 622.0 (162) 362.5 (124) 643.0 (200) 565.0 (161) 813.0 (160) 1419.0 (125)
232 775.0 (85) 445.0 (181) 253.0 (100) 407.0 (176) 365.0 (158) 585.0 (138) 960.0 (105)
233 708.0 (43) 753.5 (88) 295.5 (46) 558.0 (98) 581.0 (103) 892.0 (67) 1606.5 (54)
234 896.5 (40) 679.5 (86) 408.5 (46) 588.0 (76) 558.5 (94) 959.0 (56) 1394.0 (55)
235 557.0 (45) 503.0 (63) 247.0 (33) 278.0 (69) 307.5 (86) 583.0 (48) 896.0 (32)
236 450.0 (57) 372.5 (114) 222.0 (61) 335.0 (113) 351.0 (131) 557.0 (105) 1572.0 (65)
237 1053.5 (72) 362.0 (167) 282.0 (69) 462.5 (170) 326.0 (152) 528.5 (110) 467.0 (120)
238 838.5 (100) 370.5 (148) 307.5 (106) 410.5 (192) 389.0 (171) 668.0 (155) 654.0 (139)
531 2250.0 (101) 658.5 (158) 481.5 (100) 819.0 (158) 634.0 (169) 978.0 (142) 2030.0 (128)
532 5538.0 (75) 1051.0 (182) 554.0 (90) 1185.0 (155) 644.0 (186) 894.0 (99) 3605.0 (107)
533 10043.5 (38) 1158.0 (95) 686.0 (59) 802.0 (69) 737.0 (87) 924.5 (66) 2476.5 (62)
534 1085.0 (57) 644.0 (108) 287.0 (47) 562.0 (131) 317.5 (124) 448.5 (72) 1266.5 (56)
535 2714.0 (32) 491.0 (92) 426.5 (38) 974.5 (90) 990.5 (106) 795.0 (59) 2458.0 (37)
536 3767.5 (50) 976.0 (107) 616.5 (58) 915.0 (106) 1127.0 (111) 1683.0 (67) 3618.5 (70)
537 5561.5 (78) 1047.0 (151) 1323.0 (81) 2000.5 (192) 1290.0 (170) 1434.0 (107) 2541.0 (90)
538 2584.0 (108) 778.0 (141) 461.0 (100) 806.0 (149) 557.0 (166) 1018.0 (135) 2404.0 (131)
831 9652.5 (100) 1028.0 (187) 994.0 (105) 1286.0 (189) 2063.0 (159) 2165.5 (140) 1874.0 (119)
832 10527.0 (63) 653.0 (98) 1056.5 (74) 1303.0 (118) 1523.0 (99) 2334.5 (88) 1642.0 (82)
833 22918.0 (39) 2226.0 (86) 3474.5 (52) 3661.0 (85) 3679.0 (84) 9611.0 (56) 4031.0 (51)
834 5834.5 (24) 502.0 (71) 679.0 (33) 1243.5 (68) 698.0 (56) 1355.0 (43) 1464.0 (37)
835 18681.0 (37) 1942.0 (68) 2464.5 (42) 4875.0 (72) 3889.0 (84) 7079.5 (60) 11860.5 (36)
836 9624.0 (27) 445.0 (53) 660.0 (27) 989.5 (52) 740.5 (44) 1514.0 (33) 1464.5 (28)
837 7739.0 (54) 319.0 (133) 440.5 (76) 711.0 (127) 468.0 (121) 844.0 (93) 832.0 (61)
838 5731.5 (100) 1200.0 (158) 942.0 (115) 1463.5 (186) 1985.0 (175) 2706.5 (142) 3220.5 (120)
1031 2980.0 (104) 383.0 (160) 477.5 (100) 700.0 (165) 642.0 (141) 925.5 (148) 1181.0 (124)
1032 10333.0 (53) 800.0 (81) 993.5 (56) 1218.5 (96) 1066.0 (92) 1818.0 (69) 2425.0 (72)
1033 14324.5 (52) 490.0 (96) 692.5 (50) 1179.0 (105) 1280.0 (96) 1860.0 (75) 1342.0 (60)
1034 4608.0 (24) 541.0 (65) 517.0 (41) 1625.5 (70) 590.5 (68) 687.0 (46) 3196.5 (30)
1035 23197.0 (19) 1656.0 (38) 2214.0 (19) 2140.0 (31) 2232.0 (43) 3336.0 (29) 2196.0 (21)
1036 8880.0 (17) 496.0 (49) 653.0 (22) 1243.0 (45) 639.0 (56) 1021.5 (26) 1025.0 (15)
1037 6500.0 (42) 2137.0 (124) 621.0 (47) 979.0 (112) 365.0 (124) 682.0 (60) 565.5 (62)
1038 16068.0 (100) 964.5 (238) 392.0 (101) 268.5 (182) 327.0 (197) 414.0 (149) 391.0 (153)
1231 5542.0 (100) 347.0 (195) 436.0 (126) 728.0 (208) 306.5 (162) 644.0 (127) 1824.0 (135)
1232 7661.5 (34) 1982.0 (115) 482.0 (46) 1373.5 (90) 431.0 (97) 1186.0 (69) 1250.0 (53)
1233 23007.5 (36) 679.5 (84) 723.0 (47) 1103.0 (61) 515.0 (62) 1282.0 (23) 2827.0 (30)
1234 21224.5 (20) 1287.0 (58) 1533.0 (23) 2057.0 (51) 269.0 (41) 557.0 (23) 1438.0 (25)
1235 4401.0 (29) 829.0 (69) 524.0 (30) 713.0 (62) 360.0 (43) 706.0 (31) 1232.0 (46)
1236 2539.0 (32) 1341.5 (24) 425.5 (24) 934.0 (34) 598.0 (63) 1111.5 (40) 2285.0 (18)
1237 7944.0 (41) 1434.0 (107) 589.5 (60) 1465.5 (84) 263.0 (73) 459.0 (40) 1575.0 (48)
1238 2570.0 (85) 389.0 (213) 347.0 (108) 732.0 (198) 333.0 (177) 592.0 (121) 1488.0 (142)
1531 7153.0 (111) 783.5 (236) 286.0 (110) 647.5 (224) 253.5 (92) 477.0 (56) 1148.5 (170)
1532 23311.0 (103) 888.0 (186) 1153.0 (104) 2389.5 (204) 489.0 (55) 1036.0 (31) 2015.0 (134)
1533 2983.5 (58) 208.0 (127) 270.0 (55) 433.5 (112) 389.0 (44) 821.0 (19) 1772.0 (73)
1534 2629.0 (78) 381.0 (217) 323.0 (64) 454.0 (148) 354.0 (37) 667.0 (17) 978.0 (119)
1535 2933.0 (82) 277.0 (153) 275.0 (80) 436.0 (175) 338.0 (17) 742.0 (5) 805.0 (113)
1536 4566.0 (73) 239.0 (185) 377.0 (97) 426.0 (156) 525.0 (51) 1089.0 (23) 568.0 (117)
1537 7820.0 (107) 683.0 (219) 434.0 (95) 539.0 (229) 515.0 (53) 883.5 (26) 2019.0 (145)
1538 9193.5 (168) 298.5 (280) 438.0 (147) 846.0 (279) 499.0 (119) 738.0 (79) 977.0 (261)
1831 2165,5 315 415,5 423,5
1832 4316 417 539,5 480
1833 5693 879 1075 1105
1834 2625,5 177 257,5 241,5
1835 3282 304 504,5 554
1836 2550 570 539,5 606,5
1837 3222 989 549 587
1838 2761 369 477 453
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6.8.4 Group 4 (InPRV-1) 
Table 6.27. Raw data from InPRV-1/group 4. Each colour represents a 96-well plate. Light grey = plate 1, dark 
grey = plate 3, yellow = plate 4, blue = plate 6, purple = plate 7, black = no existing samples, orange = excluded 





Plasma sample PRV1 s1-LM (44) PRV1-u1c (34) PRV3 s1 (54) PRV3 uNS (64) ISAV FP (27) ISAV FP-LM (28) ICP11-LM (29)
1 197.0 (100) 55.0 (188) 76.0 (145) 61.0 (175) 108.0 (154)
2 281.0 (83) 74.0 (135) 116.0 (109) 74.5 (156) 218.5 (126)
3 400.0 (102) 94.0 (157) 111.0 (100) 78.5 (174) 259.0 (114)
4 255.0 (100) 72.0 (217) 106.0 (137) 72.0 (174) 155.5 (140)
5 197.5 (100) 53.0 (188) 88.0 (109) 61.0 (157) 158.0 (134)
6 237.0 (100) 59.0 (262) 87.0 (133) 54.5 (182) 221.0 (153)
7 562.0 (100) 77.0 (171) 128.0 (100) 85.0 (172) 187.5 (122)
No plasma
241 385.0 (84) 66.5 (152) 93.5 (102) 91.0 (146) 175.0 (125)
242 374.0 (45) 57.0 (136) 90.0 (66) 76.0 (123) 100.5 (92)
243 574.0 (36) 64.0 (91) 102.0 (47) 104.0 (67) 366.0 (70)
244 577.0 (51) 77.0 (91) 120.5 (62) 93.0 (85) 141.5 (54)
245 768.5 (48) 179.0 (62) 159.0 (51) 206.0 (79) 428.0 (67)
246 414.0 (39) 75.0 (57) 103.0 (38) 100.0 (58) 224.0 (48)
247 4766.0 (63) 110.0 (121) 148.0 (75) 159.0 (119) 484.0 (73)
248 176.5 (100) 44.0 (170) 69.5 (114) 43.0 (169) 84.5 (136)
541 332.0 (100) 69.5 (202) 90.0 (110) 69.0 (161) 265.0 (126)
542 419.0 (61) 130.0 (111) 204.5 (54) 175.0 (107) 320.0 (81)
543 656.0 (23) 209.0 (42) 315.0 (29) 270.0 (52) 383.5 (48)
544 650.0 (19) 122.0 (29) 198.0 (17) 133.0 (38) 426.0 (27)
545 376.5 (12) 99.0 (21) 96.0 (6) 114.0 (12) 134.0 (29)
546 309.5 (24) 202.0 (47) 212.0 (21) 258.0 (47) 353.0 (35)
547 576.0 (47) 95.5 (72) 134.0 (66) 113.0 (83) 425.0 (71)
548 547.0 (80) 167.0 (158) 171.0 (96) 142.5 (148) 451.0 (121)
841 520.0 (77) 79.0 (183) 106.0 (82) 101.0 (125) 129.0 (97)
842 364.0 (45) 72.0 (85) 109.0 (55) 88.0 (89) 235.0 (59)
843 646.0 (13) 160.0 (31) 264.0 (15) 199.5 (30) 292.0 (16)
844 565.5 (22) 161.0 (57) 346.0 (41) 262.0 (45) 495.0 (29)
845 695.0 (19) 273.0 (33) 389.0 (13) 355.0 (27) 523.0 (21)
846 532.0 (14) 100.0 (35) 134.5 (30) 135.0 (36) 686.0 (14)
847 199.0 (34) 55.0 (62) 80.0 (50) 50.0 (53) 111.0 (43)
848 260.5 (72) 76.0 (174) 93.0 (91) 69.0 (151) 231.0 (134)
1041 442.0 (69) 100.0 (140) 132.5 (104) 106.0 (130) 579.0 (97)
1042 920.0 (43) 97.5 (52) 131.0 (33) 125.0 (73) 1050.0 (47)
1043 1474.5 (20) 244.0 (45) 220.0 (21) 194.0 (38) 301.0 (31)
1044 407.0 (20) 149.0 (42) 164.5 (34) 227.0 (41) 659.0 (28)
1045 956.0 (25) 105.0 (51) 139.0 (23) 133.0 (48) 624.0 (28)
1046 748.0 (18) 121.0 (36) 156.0 (17) 146.0 (37) 1123.0 (23)
1047 771.0 (37) 312.0 (82) 316.0 (31) 327.5 (66) 906.5 (54)
1048 703.5 (60) 90.5 (132) 149.0 (89) 97.0 (129) 300.0 (79)
1241 1298.0 (111) 343.0 (177) 183.0 (100) 232.0 (189) 148.5 (146) 210.5 (108) 583.5 (122)
1242 2583.0 (51) 254.5 (72) 923.0 (63) 527.0 (94) 203.5 (106) 423.0 (49) 3117.5 (64)
1243 2291.0 (29) 369.0 (79) 425.0 (28) 1502.0 (67) 427.5 (50) 794.0 (27) 1877.0 (48)
1244 1175.5 (22) 202.0 (34) 272.0 (24) 478.5 (48) 265.0 (29) 499.0 (16) 625.5 (22)
1245 611.0 (22) 172.0 (54) 192.0 (33) 264.0 (63) 164.0 (45) 228.0 (27) 693.0 (31)
1246 815.0 (36) 571.0 (40) 284.0 (31) 742.0 (36) 246.0 (57) 483.5 (44) 1962.0 (16)
1247 867.0 (61) 320.0 (159) 237.0 (79) 400.5 (126) 194.0 (81) 459.0 (53) 1553.0 (73)
1248 906.0 (100) 469.0 (217) 528.0 (101) 704.0 (183) 388.0 (108) 469.0 (85) 1065.0 (131)
1541 2205.0 (100) 770.5 (158) 974.0 (100) 1175.0 (163) 533.5 (136) 747.5 (50) 1682.0 (101)
1542 1273.0 (87) 322.5 (138) 337.0 (79) 935.5 (146) 308.0 (52) 539.0 (22) 1295.0 (100)
1543 1623.5 (50) 542.0 (98) 617.0 (51) 839.0 (120) 647.0 (41) 832.0 (14) 1239.0 (60)
1544 2106.0 (57) 856.5 (78) 614.0 (52) 1351.0 (89) 623.0 (47) 1581.0 (18) 2624.5 (72)
1545 787.0 (59) 269.0 (86) 269.0 (38) 433.0 (106) 353.0 (23) 510.5 (8) 771.0 (71)
1546 1144.0 (45) 384.0 (95) 518.0 (51) 812.0 (78) 780.0 (39) 1097.0 (15) 1013.0 (61)
1547 1118.0 (86) 359.0 (135) 486.0 (87) 732.0 (125) 533.0 (61) 1004.0 (29) 1822.5 (98)
1548 1912.0 (105) 468.0 (202) 394.5 (94) 457.5 (176) 258.0 (126) 443.5 (56) 758.0 (133)
1841 407,5 296 303 300
1842 682,5 433 485,5 563,5
1843 469 227,5 279 267
1844 548 391,5 484 509,5
1845 12791 1298 970 1189
1846 11882,5 1777 1613 1823,5
1847 14677 3120 3452 3468
1848 12872 3864 2731 3214
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6.8.5 Group 5a (Negative group not introduced to shedders) 
Table 6.28. Raw data from Mock (group 5a). Each colour represents a 96-well plate. Light grey = plate 1, dark 
grey = plate 3, yellow = plate 4, blue = plate 6, purple = plate 7, black = no existing samples, orange = excluded 
samples due to low bead count 
 
 
Plasma sample PRV1 s1-LM (44) PRV1-u1c (34) PRV3 s1 (54) PRV3 uNS (64) ISAV FP (27) ISAV FP-LM (28) ICP11-LM (29)
1 197.0 (100) 55.0 (188) 76.0 (145) 61.0 (175) 108.0 (154)
2 281.0 (83) 74.0 (135) 116.0 (109) 74.5 (156) 218.5 (126)
3 400.0 (102) 94.0 (157) 111.0 (100) 78.5 (174) 259.0 (114)
4 255.0 (100) 72.0 (217) 106.0 (137) 72.0 (174) 155.5 (140)
5 197.5 (100) 53.0 (188) 88.0 (109) 61.0 (157) 158.0 (134)
6 237.0 (100) 59.0 (262) 87.0 (133) 54.5 (182) 221.0 (153)
7 562.0 (100) 77.0 (171) 128.0 (100) 85.0 (172) 187.5 (122)
No plasma
251 548.0 (100) 74.0 (165) 110.0 (111) 95.0 (164) 159.0 (105)
252 384.0 (43) 73.0 (103) 109.0 (64) 99.0 (91) 122.5 (66)
253 184.0 (29) 51.5 (52) 70.5 (30) 57.5 (64) 77.5 (52)
254 446.5 (24) 68.5 (66) 95.0 (33) 104.0 (55) 663.0 (36)
255 408.0 (9) 104.0 (59) 133.0 (15) 113.0 (34) 348.0 (18)
256 354.5 (42) 70.0 (63) 92.0 (45) 79.0 (65) 212.0 (50)
257 712.0 (61) 96.0 (91) 141.0 (64) 149.0 (129) 296.0 (76)
258 345.0 (100) 70.0 (201) 99.0 (121) 72.0 (212) 111.0 (160)
551 374.5 (72) 61.0 (199) 91.0 (96) 67.0 (155) 276.5 (130)
552 333.0 (27) 64.0 (83) 85.0 (39) 71.0 (73) 213.0 (55)
553 322.0 (11) 101.0 (46) 99.0 (12) 144.0 (34) 170.0 (28)
554 292.0 (17) 68.0 (57) 101.0 (18) 91.5 (30) 185.5 (22)
555 574.0 (21) 88.0 (44) 133.0 (27) 170.5 (28) 519.5 (20)
556 1003.0 (31) 116.0 (51) 143.0 (35) 365.0 (60) 187.0 (42)
557 431.0 (36) 93.0 (85) 92.0 (36) 93.5 (48) 300.0 (36)
558 454.0 (91) 131.0 (169) 191.0 (103) 122.0 (174) 316.0 (119)
851 453.5 (90) 68.5 (166) 112.0 (97) 100.5 (160) 306.0 (125)
852 514.0 (30) 67.5 (60) 105.5 (40) 66.0 (49) 353.0 (47)
853 311.0 (21) 62.0 (54) 95.0 (22) 69.0 (39) 202.0 (27)
854 565.0 (16) 61.0 (35) 85.0 (19) 78.0 (42) 139.0 (24)
855 552.0 (26) 118.0 (47) 113.0 (29) 105.5 (34) 220.5 (42)
856 290.0 (19) 62.0 (34) 113.0 (16) 81.0 (36) 211.5 (20)
857 191.0 (47) 53.0 (104) 84.5 (48) 65.0 (110) 227.0 (62)
858 319.0 (109) 70.0 (174) 96.0 (94) 80.0 (177) 179.0 (137)
1051 765.5 (100) 129.5 (200) 213.5 (82) 183.0 (159) 362.0 (104)
1052 532.0 (44) 106.0 (114) 110.0 (48) 93.0 (78) 283.0 (60)
1053 919.0 (23) 96.5 (50) 142.0 (38) 128.5 (52) 276.0 (32)
1054 949.0 (26) 123.0 (56) 232.5 (44) 221.0 (58) 585.0 (50)
1055 883.0 (31) 98.0 (63) 150.0 (33) 117.0 (58) 529.5 (26)
1056 643.0 (21) 79.0 (63) 126.0 (21) 126.0 (54) 385.0 (43)
1057 535.0 (63) 89.0 (155) 139.0 (64) 132.5 (110) 267.0 (79)
1058 178.0 (101) 37.0 (180) 50.0 (100) 43.0 (141) 172.0 (121)
125a1 682.5 (100) 530.5 (170) 292.0 (117) 446.5 (188) 226.0 (177) 337.0 (155) 1666.0 (108)
125a2 975.5 (44) 232.0 (141) 266.5 (62) 641.5 (104) 185.5 (96) 335.0 (51) 2081.0 (61)
125a3 5406.0 (31) 1074.0 (65) 943.0 (37) 2509.5 (62) 569.0 (81) 1416.0 (49) 2723.0 (37)
125a4 1393.0 (27) 365.0 (49) 290.5 (30) 530.0 (35) 226.0 (101) 457.0 (43) 2765.0 (31)
125a5 2142.0 (28) 325.5 (38) 467.5 (34) 512.5 (54) 434.5 (82) 975.0 (69) 1994.0 (25)
125a6 965.5 (22) 264.0 (59) 283.0 (24) 552.0 (53) 226.0 (102) 373.0 (67) 1684.0 (35)
125a7 1018.0 (48) 310.0 (155) 314.5 (76) 513.0 (129) 246.5 (108) 439.0 (69) 1205.0 (76)
125a8 635.5 (100) 153.0 (162) 190.0 (127) 260.0 (157) 171.0 (154) 283.0 (133) 439.5 (142)
155a1 398.0 (29) 161.5 (72) 181.0 (34) 322.5 (52) 211.0 (120) 380.0 (43)
155a2 515.0 (89) 110.0 (182) 135.0 (89) 261.0 (157) 188.5 (40) 341.0 (20) 1239.0 (127)
155a3 880.5 (102) 385.0 (197) 209.0 (100) 427.0 (186) 522.0 (11) 887.5 (8) 2165.5 (128)
155a4 1066.5 (100) 299.0 (156) 296.0 (121) 459.0 (143) 200.0 (29) 279.5 (16) 2400.0 (118)
155a5 912.0 (139) 149.0 (152) 169.0 (100) 414.0 (161) 169.0 (19) 317.0 (7) 2060.0 (142)
155a6 979.0 (8) 287.0 (25) 253.5 (12) 509.0 (21) 241.5 (38) 328.5 (16)
155a7 1208.5 (18) 462.5 (42) 349.0 (20) 855.0 (42) 353.0 (67) 977.0 (19)











6.8.6 Group 5b (Negative group introduced to shedders) 
Table 6.29. Raw data from Mock infected with shedders 10 wpc (group 5b). Each colour represents a 96-well 
plate. Light grey = plate 1, dark grey = plate 3, yellow = plate 4, blue = plate 6, purple = plate 7, black = no 
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Abstract: Heart and skeletal muscle inflammation (HSMI), caused by infection with Piscine orthoreovirus-1
(PRV-1), is a common disease in farmed Atlantic salmon (Salmo salar). Both an inactivated whole virus
vaccine and a DNA vaccine have previously been tested experimentally against HSMI and demonstrated
to give partial but not full protection. To understand the mechanisms involved in protection against HSMI
and evaluate the potential of live attenuated vaccine strategies, we set up a cross-protection experiment
using PRV genotypes not associated with disease development in Atlantic salmon. The three known
genotypes of PRV differ in their preference of salmonid host species. The main target species for PRV-1 is
Atlantic salmon. Coho salmon (Oncorhynchus kisutch) is the target species for PRV-2, where the infection
may induce erythrocytic inclusion body syndrome (EIBS). PRV-3 is associated with heart pathology and
anemia in rainbow trout, but brown trout (S. trutta) is the likely natural main host species. Here, we tested
if primary infection with PRV-2 or PRV-3 in Atlantic salmon could induce protection against secondary
PRV-1 infection, in comparison with an adjuvanted, inactivated PRV-1 vaccine. Viral kinetics, production
of cross-reactive antibodies, and protection against HSMI were studied. PRV-3, and to a low extent PRV-2,
induced antibodies cross-reacting with the PRV-1 σ1 protein, whereas no specific antibodies were detected
after vaccination with inactivated PRV-1. Ten weeks after immunization, the fish were challenged through
cohabitation with PRV-1-infected shedder fish. A primary PRV-3 infection completely blocked PRV-1
infection, while PRV-2 only reduced PRV-1 infection levels and the severity of HSMI pathology in a few
individuals. This study indicates that infection with non-pathogenic, replicating PRV could be a future
strategy to protect farmed salmon from HSMI.
Keywords: heart and skeletal muscle inflammation; Piscine orthoreovirus; vaccine; atlantic salmon;
antibodies; immune response
1. Introduction
Infections represent a constant challenge and threat against fish health and welfare
in aquaculture. Modern farming of Atlantic salmon (Salmo salar) is characterized by high-
density populations, rapid growth, short production cycles, and artificial adaptation to
Vaccines 2021, 9, 230. https://doi.org/10.3390/vaccines9030230 https://www.mdpi.com/journal/vaccines
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sea water. This life cycle does not ensure natural pathogen exposure in early life or the
natural training of the fish innate immune system [1]. When transferred to the sea, the
untrained immune system may not be ready to handle the novel repertoire of pathogens.
High-density populations increase infection pressure, and transportation and handling
procedures increase disease susceptibility due to stress [2]. In Atlantic salmon aquaculture,
vaccines have been effective in protecting the fish from many diseases, but several viral
diseases remain unsolved challenges [3]. One of the viral diseases of concern in European
Atlantic salmon aquaculture is heart and skeletal muscle inflammation (HSMI) caused by
Piscine orthoreovirus (PRV) [4,5].
PRV particles are non-enveloped with a double-layered protein capsid and a seg-
mented double-stranded RNA genome [6]. PRV is a common virus infection in salmonids,
and PRV-1 is the genotype associated with HSMI in farmed Atlantic salmon [5,7]. PRV
is ubiquitous in the sea water phase of salmonid aquaculture [8] and is also emerging
in fresh water facilities. However, PRV-1 is found to a lower extent in salmonids in the
wild [9,10]. PRV-1 was first described in 2010 [4], whereas HSMI emerged in Norway and
Scotland a decade earlier [11,12]. The causality between PRV-1 and HSMI was proven
experimentally in 2017 using highly purified virus to induce disease [5]. PRV-1 is proposed
to infect Atlantic salmon via the intestinal tract [13], followed by a massive infection of red
blood cells and high plasma viremia [14,15]. Following the peak infection in red blood cells,
the virus infects cardiomyocytes, which may result in an inflammatory response dominated
by cytotoxic T-cells in the heart [16,17]. This inflammatory response is a hallmark of HSMI.
In Atlantic salmon populations, the disease usually gives a moderate mortality that in
severe cases may accumulate to 20% [11]. The relative high frequency of outbreaks makes
HSMI a significant problem for the salmon farming industry. The PRV-1 infection becomes
persistent in Atlantic salmon, and based on PRV prevalence in farm escapees [10], near
90% of Norwegian farmed salmon are PRV-infected in the marine phase, while near 100%
of a small number of escaped Atlantic salmon were reported infected in Washington and
British Columbia [18]. The long-term effects of PRV-1 infection are disputed, but the virus
has been associated with the worsening of black spots in the skeletal muscle [19], a signif-
icant quality problem for the salmon production industry. This association is, however,
disputed [20]. PRV-1 is also found in Canadian aquaculture, but few cases of HSMI have
been reported [21], and HSMI has not been reproduced experimentally using Canadian
isolates [22–24]. Different PRV-1 isolates with genetic variation have been shown to differ
in the ability to induce HSMI [7]. PRV-1 has also been reported to infect other salmonid
species [25].
Two additional genotypes of PRV, PRV-2 and PRV-3, have been described. They both
infect salmonids, but with a different ability to infect and cause disease in the various
salmonid species. PRV-2 infects coho salmon (Oncorhynchus kisutch) in Japan, causing
erythrocytic inclusion body syndrome (EIBS) [26]. The main host species of PRV-3 may
be wild brown trout (S. trutta) [27], but disease has only been found in farmed rainbow
trout (O. mykiss), where PRV-3 is associated with heart inflammation and anemia [28–30].
Nucleotide alignment shows 80% (PRV-2) and 89% (PRV-3) identity to PRV-1 [31]. PRV-3
has previously been shown to infect Atlantic salmon experimentally, but without induc-
ing HSMI [29]. Current information on PRV subtypes and distribution was recently
reviewed [32].
No vaccines have been marketed against HSMI, but two different experimental vac-
cination approaches have been published. An inactivated whole virus vaccine, based
on purified virus, was shown to give partial protection against HSMI, but less efficient
protection against infection and virus replication [33]. Although promising, this approach
has been hampered by the problem of producing PRV-1 for vaccine development, as no cell
lines efficiently produce viral progeny [34]. A DNA vaccine approach has also been tested,
and partial protection against HSMI was reported for a vaccine combining non-structural
PRV-1 proteins with outer capsid antigens [35]. Although with some protective effects
against HSMI, none of these vaccines have been able to block PRV-1 infection.
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PRV-1 infection has been reported to induce strong innate antiviral responses in
infected red blood cells [36]. Expression analysis of adaptive immune response genes
has indicated that both humoral and cellular responses are induced [37], and it has been
shown that infected fish produce specific antibodies against the outer capsid spike protein
σ1 [38], predicted to be the receptor-binding protein [39]. The cellular immune response
initiated by PRV-1 in Atlantic salmon is strongly associated with HSMI development,
and the typical HSMI myocarditis is dominated by an influx of cytotoxic T-cells [16,17].
However, this response is also associated with virus eradication from heart tissue, making
cellular immunity a two-edged sword in HSMI [16,40].
The purpose of this study was to determine if PRV-2 or PRV-3 infection in Atlantic
salmon could provide protection against a consecutive PRV-1 infection and HSMI. We
compared the protection induced by PRV-2 and PRV-3 to an inactivated PRV-1 vaccine, and
characterized immune responses, including the production of cross-reactive PRV-specific
antibodies. The results show that PRV-3 infection in Atlantic salmon, in contrast to PRV-2,
blocks a secondary infection with PRV-1, and that cross-protective antibodies may be one
of the mechanism involved.
2. Materials and Methods
2.1. Experimental Trial and Sampling
The trial was performed at the Aquaculture Research station at Kårvika, Troms,
Norway, approved by the Norwegian Animal Research Authority, and performed in
accordance with the recommendations of the current animal welfare regulations: FOR-
1996-01-15-23 (Norway).
The PRV-1 infection material was prepared from two frozen blood cell pellets (−80 ◦C)
with PRV-1 qPCR ct values of 17.6 and 16.4, harvested from a PRV-1-infected Atlantic
salmon from a previous experimental trial [5]. The virus isolate (PRV-1 NOR2012-V3621 [5])
originated from an HSMI outbreak in mid-Norway in 2012 and had been passaged in prior
experimental trials, all resulting in HSMI. The PRV-3 infection material was a blood pellet
that originated from a Norwegian outbreak in 2014 (PRV-3 NOR2014, [28]) and has been
passaged twice experimentally in rainbow trout [30]. The mock-blood cell lysate originated
from control fish from an Atlantic salmon experimental trial. The blood cell lysate from
PRV-1, PRV-3 and mock was prepared by diluting the blood pellet (plasma removed prior
to freezing) 1:10 in L15-medium, sonicating five times at 20 kHz for 10 s with 1 min rest in
between and centrifuging at 3000× g for 10 min before the collection of the supernatant.
The PRV-2 infection material (PRV-2, [26]) originated from a frozen spleen sample from
a Coho salmon. The tissue sample was homogenized in L15 medium as described for
the blood pellets. The inactivated PRV-1 material was prepared from a batch of purified
PRV-1 particles (PRV-1 NOR2012, 5.35 × 109 copies /mL) by PHARMAQ AS, as described
in a previously published trial [33]. In short, the batch was formalin-inactivated and
prepared as a water-in-oil formulation where the water phase (containing PRV antigens)
was dispersed into a mineral oil continuous phase containing emulsifiers and stabilizers.
At the start of the trial, a total of 630 fish (Salmo salar L) were divided into four
experimental groups of 75 fish and one mock control group of 125 fish, while 190 naïve fish
from the same group were kept for use as transmission controls and future virus shedders.
The experimental fish were kept in freshwater (10 ◦C, 24:0 light:dark cycle, >90% O2) and
injected intraperitoneally (ip) with 0.2 mL of immunization material described above. Eight
fish were sampled prior to Injection Week 0, and from each of the five experimental groups
Week 2 and 5. Five weeks after the start of the experiment, 12 naïve fish labelled by tattoo
pen were added to each of the tanks containing fish infected with PRV-1, PRV-2 and PRV-3
to monitor transmission of virus. At Weeks 8 and 10, eight experimental fish and six
transmission control fish were sampled from each of these groups. At Week 8, 140 naïve
fish in a separate tank were injected ip with 0.2 mL of a newly prepared batch of PRV-1
blood cell lysate (PRV-1 NOR2012, same origin and preparation method) and left for two
weeks. After Sampling Week 10, 35 fish remained in each of the experimental groups, and
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70 fish in the mock-infected control group. The mock group fish were divided into two
tanks of 35 fish each, and three experimental tanks (PRV-2, PRV-3, InactPRV-1) and one of
the mock-tanks were added to an equal number (35) of tattoo-labelled pre-infected PRV-1
shedder fish. No shedders were added to the original PRV-1 tank, and the other mock
group was kept as a negative control. The number of tanks included in the experiment was
now 6, and eight fish from each group were sampled on Weeks 12, 15 and 18. No fish died
during the experiment.
At each sampling, blood was drawn from the caudal vein on BD Medical Vacutainer
heparin-coated tubes (BD Medical, Mississauga, ON, USA). Hearts were sampled on 10%
formalin for histology and samples from the heart tip and spleen were sampled on 0.5 mL
of RNALater (Qiagen, Hilden, Germany) in separate bar-coded microtubes (FluidX Ltd.,
Manchester, UK) along with additional organ samples not analyzed here. Blood samples
were stored at 4 ◦C for a maximum of 6 h, centrifuged (3000× g for 5 min at 4 ◦C), and
plasma and cell pellets were separated into different microtubes and stored at −80 ◦C.
RNALater samples were stored at 4 ◦C for 24 h followed by freezing at −20 ◦C. Formalin
samples were stored at RT for 24 h, after which formalin was changed to 70% ethanol, and
thereafter stored cold (4 ◦C).
2.2. RNA Preparation and RT-qPCR for Virus and Host Response Gene Analyses
Tissue samples from the spleen and heart (25 mg) on RNALater (Qiagen) were trans-
ferred to 0.65 mL Qiazol lysis reagent (Qiagen) with a 5 mm steel bead and homogenized
in a TissueLyzer II (Qiagen) for 2 × 5 min at 25 Hz followed by chloroform inclusion, and
the aqueous phase was collected. RNeasy Mini QIAcube Kit (Qiagen) was used as per the
manufacturer guidelines for automated RNA isolation. RNA concentrations were quanti-
fied using the Nanodrop ND-100 spectrophotometer (Thermo Fisher Scientific, Waltham,
MA, USA). RNA was eluted in RNase-free water and stored at −80 ◦C until further use.
For the PRV subtype expression analysis, i.e., PRV-1 and PRV-3, one-step RT-qPCR was
performed using an Agilent Brilliant III Ultra Fast kit (Agilent Technologies, Santa Clara,
CA, USA) with 100 ng (5 µL of 20 ng/µL) RNA per reaction in duplicates of 15 µL total
reaction volume. The template was previously denatured at 95 ◦C for 5 min. Cycling
parameters were set to 10 min for 50 ◦C, 3 min at 95 ◦C, and 40 cycles for 5 s at 95 ◦C
and 10 s at 60 ◦C. The cut-off value was set to 35 and samples were run with positive
and no template controls (NTC). For PRV-2 expression analysis, a Quantitect SYBR Green
(Qiagen) RT-qPCR kit (catalogue number 204243) was used according to manufacturer
instructions. A total of 100 ng RNA with prior denaturation at 95 ◦C for 5 min was used
in duplicates in 15 µL of total reaction volume. Thermal conditions were 50 ◦C for 30
min, 95 ◦C for 15 min, and 40 cycles with 94 ◦C for 15 s, 60 ◦C for 30 s and 72 ◦C for 30 s.
Specificity of the assay was confirmed by melting curve analysis. The same threshold level
and positive controls were used together with NTCs. Probes and primer sequences are
given in Supplementary Table S1.
For Immune gene expression, 400 ng total spleen RNA per sample was reverse tran-
scribed to cDNA using the QuantiTect Reverse Transcription Kit with gDNA wipeout
buffer (Qiagen). For qPCR, cDNA corresponding to 5 ng RNA was analyzed with Sso
Advanced Universal SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) and 10 pmol
of forward and reverse target-specific primers in a 10 µL volume in duplicate wells on a
384 well plate. The amplification program (15 s 95 ◦C, 30 s 60 ◦C) was run for 40 cycles
in a CFX Touch Real-Time PCR Detection System (Bio-Rad), followed by a melt point
analysis. The results were analyzed using the software CFX Manager, version 3.1.1621.0826.
The expression cycle threshold level was normalized against the elongation factor (EF) 1α
reference gene (∆Ct). The ∆∆Ct method was used to calculate relative expression levels
and fold induction compared to samples from the uninfected control samples.
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2.3. Bead-Based Immunoassay
MagPlex®-C Microspheres (Luminex Corp., Austin, TX, USA) #12, #21, #27, #29, #34,
#36, #44, #62 and #64 were coated with antigens using the Bio-Plex Amine Coupling
Kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instructions. The N-
Hydroxysulfosuccinimide sodium salt and N-(3-Dimethylaminopropyl)-N’-ethylcarbod
used for the coupling reaction were from Sigma-Aldrich. For each coupling reaction, 6-24 µg
of recombinant protein was used. The proteins used were recombinant PRV µ1l [41], lipid-
modified PRV σ1 (LM-PRVσ1), unmodified infectious salmon anemia virus fusion protein
(ISAV-FP), and lipid-modified ISAV-FP (LM-ISAV-FP) [39]. The bead concentrations were
determined using the Countess automated cell counter (Invitrogen, Carlsbad, CA, USA).
Coupled beads were stored in black Eppendorf tubes at 4 ◦C for up to 10 weeks. Incubations
were performed at room temperature and protected from light on a HulaMixer rotator
(Thermo Fisher Scientific) at 15 rpm.
The immunoassay was performed as described earlier (8). Briefly, Bio-Plex Pro™ Flat
Bottom Plates (Bio-Rad) were used. Beads were diluted in phosphate buffered saline (PBS)
containing 0.5% bovine serum albumin (BSA) (Bio-Rad Diagnostics GmbH, Dreieich, Germany)
and 0.05% azide (Merck, Darmstadt, Germany) (PBS+) and 2500 beads of each bead number
were added to each well. AntiSalmonid-IgH monoclonal antibody (clone IPA5F12, Cedar-
lane, Burlington, ON, Canada) diluted 1:400 in PBS+ was used as an unconjugated anti-IgM
heavy chain monoclonal antibody. Biotinylated goat AntiMouse IgG2a antibody (Southern
Biotechnology Association, Birmingham, AL, USA) diluted 1:1000 in PBS+ was used as a sec-
ondary antibody, and Streptavidin-PE (Invitrogen) diluted 1:50 in PBS+ was used as the reporter
flourochrome. Plates were read using two different Bio-Plex 200 (Bio-Rad) machines as part
of a validation plan. The DD-gate was set to 5000–25,000, and between 20 and 100 beads from
each population were read from each well. The reading was carried out using a low (standard)
photomultiplier tube (PMT) setting. The results were analyzed using the Bio-Plex Manager 5.0
and 6.1 (Bio-Rad). All samples were analyzed in duplets on each of the two different Bio-Plex
200 (Bio-Rad) machines. The data used originated from one machine, but no differences were
observed during validation. The data were given in mean fluorescence intensity (MFI), based on
secondary antibody binding to beads, and were corrected for binding to control beads without
antigen: MFI (antigen-containing beads) −MFI (control beads) = MFI (sample data).
2.4. Histopathology
Formalin-fixed hearts were paraffin embedded and routinely processed. The sections,
3–4 µm, were stained with hematoxylin and eosin (H&E, Merck, Kenilworth, NJ, USA) and
studied under microscope. The slides from Experimental Weeks 15 and 18 (n = 96) were
blinded to the study groups and scored by an experienced fish pathologist using a visual
analogue scale from 0 to 3 as previously described [11].
2.5. Statistical Analysis
All statistical analyses were performed within GraphPad Prism 8.1.1 (GraphPad
Software Inc., La Jolla, CA, USA). Ct values of the target groups (PRV-2, PRV-3 and
Inact. PRV-1-injected fish exposed to PRV-1 shedder fish at 10 weeks post injection) were
compared to the PRV-1 control group by using the non-parametric Mann–Whitney test
due to the small sample size (n = 8) in each group. p-values of p ≤ 0.05 were considered
as significant.
3. Results
3.1. PRV Immunization Trial
The trial was performed as outlined in Figure 1. Initially (Week 0), Atlantic salmon
with a mean weight of 41.3 g (+/− 5.8 g) were grouped and injected intraperitoneally
(ip) with cell or tissue lysates containing infective PRV-1, PRV-2 or PRV-3, uninfected
blood lysate (mock), or purified, inactivated and adjuvanted PRV-1 [33]. At 10 weeks, the
mean weight of the injected fish was 107.6 g (+/− 18.4 g) with no significant difference
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between groups (Supplementary file S2). At this timepoint, PRV-1-infected shedder fish
were added to the remaining fish in the groups injected with PRV-2, PRV-3, inactivated
PRV and half of the mock group to test the effects of immunization. Neither the initial
ip challenge/immunization nor the cohabitant challenge led to mortality in any of the
treatment groups, and there was no loss of fish or aberrant clinical observations during the
experimental period. At the end of the experiment in Week 18, the fish mean weight was
193.6 g (+/− 29.5 g), with no statistically significant difference between groups.
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3.2. Replication and Transmission of PRV Genotypes in Atlantic Salmon
The RNA loads of PRV-1, PRV-2 and PRV-3 were monitored by the RT-qPCR of spleen
samples through the experi ental period (Figure 2, Supplementary file S2). The spleen
was chosen for analysis since PRV replicates in red blood cells, and spleen has been shown
to reflect the levels of PRV infection in blood [42] better than, e.g., kidney. PRV-1 showed
maximum replication during the first 5 weeks, as expected from previous trials (median
Ct 14.79, interquartile range (IQR) Ct 14.12–15.37 (Figure 2A)), and persisted in spleen
through the 18 weeks of the study with median PRV-1 levels above a Ct level of 20 at all
sampling time points. Five weeks after injection, naïve fish were added to tanks of fish
injected with PRV-1, PRV-2 and PRV-3 to study the transmission of the injected virus. The
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naïve cohabitants added to the PRV-1 group at Week 5 were all infected 3 and 5 weeks
later (Experimental Week 8 and 10, not analyzed at later time points). PRV-2 levels were
generally low and reached the highest level after 2 weeks (median Ct of 26.7, IQR Ct
25.99–27.08), after which the infection declined. After 18 weeks, PRV-2 was detected in
only one out of eight sampled fish. No naïve cohabitants added to the PRV-2 tank Week 5
were infected (Figure 2B). PRV-3 levels increased up to Week 5 (median Ct of 19.19, IQR Ct
18.02–20.75), then declined until Week 18 (Figure 2C). The added naïve cohabitants were
not infected. No cross-infection was observed between the tanks, and no replication was
observed in the fish injected with inactivated PRV-1, as monitored on Weeks 2, 5 and 10
(Supplementary Figure S1, Supplementary File S2).
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Figure 2. Development of infection with PRV-1, -2 and -3. Levels of PRV-1 (A), PRV-2 (B) and PRV-3 (C) as detected in
spleen with specific RT-qPCR assays targeting the S1 genome segment in the respective viruses and trial groups. The figures
show individual Ct values and median (line) at each sampling from 2 to 18 weeks post injection (wpi). Gray dots show
virus levels in naïve cohabitants added to the tank at 5 wpi and removed at 10 wpi (5 weeks after exposure). Relative levels
of PRV-1, -2 and -3 in heart at 15 and 18 weeks post infection (D).
To explore if there was any persistence of PRV2 and PRV3 in hearts at the end of
the trial, we compared RNA loads of PRV-1, PRV-2 and PRV-3 in heart samples at 15 and
18 weeks (Figure 2D). Whereas PRV-1 levels in heart were below Ct 25, PRV-2 was only
detected (median 34.87, IQR Ct 34.31–37.24) in the heart in two fish at 15 weeks after
infection, and one fish at 18 weeks. PRV-3 was detected at low levels in 50% of the fish
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hearts at both time points. Except for two fish at 15 weeks, all PRV-3-positive fish had Ct
levels above 30 in the heart.
3.3. Production of Anti-PRV Antibodies
Using a bead-based multiplexed immunoassay based on recombinant PRV-1 spike
protein σ1 and outer capsid protein µ1c [39], the ability of the viruses to induce cross-
binding antibodies in plasma (IgM) was explored for the period 2 to 10 weeks after virus
injection (Figure 3, Supplementary file S4). PRV-1 infection induced the production of PRV-
1-specific antibodies against the viral proteins σ1 and µ1 after 8 and 10 weeks (Figure 3A)
and induced unspecific antibodies binding to non-PRV antigens. PRV-2 induced low
levels of PRV-1 σ1 binding antibodies as detected at Weeks 5 and 8, declining at Week
10 (Figure 3B), in line with a low PRV-2 replication in the fish. PRV-3 infection induced
intermediate levels of PRV-1 σ1 binding antibodies, with lower background binding to
non-PRV antigens (Figure 3C). Inactivated PRV-1 did not induce detectable production of
antibodies binding to PRV-1 σ1 (Figure 3D).
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Figure 3. Production of anti-PRV antibodies. Magnetic beads coated with recombinant lipid-modified (LM)-PRV-1-σ1,
PRV-1 µ1c, infectious salmon anemia virus fusion protein (ISAV-FP) or LM-ISAV-FP in a multiplexed assay were used to
measure PRV-specific and unspecific antibodies in blood plasma sampled from fish in the PRV-1 (A), PRV-2 (B), PRV-3 (C)
and InactPRV-1 (D) injected groups in the first 10 weeks post injection (wpi). MFI: edian fluorescence intensity. The results
from beads coated with PRV antigens are shown in red, and beads with non-PRV antigens in gray/black.
3.4. Innate and Cellular Immune Responses
In order to explore which immune responses were activated in the fish at the time of
exposure to PRV-1 shedder fish (10wpi), spleen RNA samples were analyzed for transcript
markers of cellular cytotoxic immunity (Figure 4, Supplementary file S5): CD8α, IFN-γ
and Granzyme A (Figure 4A), and innate interfero -mediated antiviral respo ses: viperin,
myxovi us esistance gene (Mx), and interferon-stimulated gene (ISG)15 (Figure 4B). These
genes have previously been shown to be induced in spleen after infection with PRV-1 [37].
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PRV-1 infection induced both cellular and innate immune responses in spleen, whereas
infection with PRV-2, PRV-3 or inactivated adjuvanted PRV-1 showed no or minor induction
of the cellular and selected innate antiviral response genes.




Figure 4. Cellular and innate antiviral immune responses 10 weeks after immunization (wpi). Cellular responses CD8α, 
IFNγ and Granzyme A (A) and innate antiviral responses viperin, myxovirus resistance gene (Mx) and interferon-stimu-
lated gene (ISG)15 (B) were analyzed by RT-qPCR in spleen, normalized for the reference gene EF1α and shown as 2−ΔΔCt 
levels. Gene expression in spleen samples from fish injected with PRV-1 (red), PRV-2 (blue), PRV-3 (green), inactivated 
PRV (yellow) and mock lysate (gray) are shown. 
3.5. Protection from PRV Infection and HSMI 
Infection with PRV-1 was monitored in all groups from 12 to 18 wpi (Figure 5A,B, 
Supplementary file S2). The mock-injected + PRV-1-exposed group acted as a positive con-
trol and was infected with PRV-1 after two weeks, peaking 5 weeks later (Experimental 
Week 15) at median Ct levels of 15 in the spleen and median Ct levels of 17 in the heart. 
Fish that had been immunized with PRV-2 showed a delayed and variable PRV-1 infection 
level at 15 and 18 weeks ranging from Ct 15 to 30 in the heart and Ct 10 to 24 in the spleen. 
Surprisingly, the highest PRV-1 infection levels in the PRV-2 group ranged beyond the 
levels in the positive controls, indicating that PRV-2 increased susceptibility to PRV-1 in-
fection in some individuals. A similar partial protection was seen in the fish immunized 
with inactivated, adjuvanted PRV-1 (InactPRV-1), but without the replication boost seen 
in some fish in the PRV-2 group. In fish infected with PRV-3, the PRV-1 infection was 
completely blocked, except for two individuals showing high Ct levels in the spleen, one 
of which also had detectable PRV-3 in the heart. 
Hearts from fish sampled at 15 and 18 weeks after PRV-1 infection by shedders, and 
the corresponding uninfected control group, were prepared for histopathology and 
scored for tissue changes consistent with HSMI (score system 0–3 [11], Figure 6, Supple-
mentary file S6). At 15 weeks, heart pathology was seen only in the PRV-1 group infected 
ip at the beginning of the trial (five of eight fish had mild lesions, i.e., a score of 1). HSMI-
like lesions were present in all individuals in the mock + PRV-1 control group (positive 
control) at Week 18, with a median HSMI pathology score of 2.5 (1.5–2.5). For the PRV-2 
+ PRV-1 group, the median pathology score was reduced to 2 (six out of eight fish had 
lesions), and for the PRV-3 + PRV-1 group pathology was completely absent in all eight 
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out heart lesions. The group infected with PRV-1 ip Week 0 showed a median pathology 
score of 1 (six out of eight fish had mild lesions), 18 weeks after infection. 
Figure 4. Cellular and innate antiviral immune responses 10 weeks after immunization (wpi). Cellular responses CD8α,
IFNγ and Granzyme A (A) and innate antiviral r sponses viperin, myxovirus esistance gene (Mx) and int rferon-stimulated
gene (IS )15 (B) were analyze by RT-qPCR in spl en, normalized for the reference gene EF1α and shown as 2−∆∆Ct levels.
Gen expression in sple n samp es from fish injected with PRV-1 (red), PRV-2 (blue), PRV-3 (green), inactivated PRV (yellow)
and mock lysat (gray) are shown.
3.5. Protection from PRV Infection and HSMI
Infection with PRV-1 was monitored in all groups from 12 to 18 wpi (Figure 5A,B,
Supplementary file S2). The mock-injected + PRV-1-exposed group acted as a positive
control and was infected with PRV-1 after two weeks, peaking 5 weeks later (Experimental
Week 15) at median Ct levels of 15 in the spleen and median Ct levels of 17 in the heart.
Fish that h d been immunized with PRV-2 showed a delay d a d variable PRV-1 infection
level at 15 and 18 weeks ranging from Ct 15 to 30 in the heart and Ct 10 to 24 in the spleen.
Surprisingly, the highest PRV-1 infection levels in the PRV-2 group ra ged beyond the levels
in the positive controls, indicating that PRV-2 increased susceptibility to PRV-1 infection
in some individuals. A similar partial protection was seen in the fish immunized with
inactivated, adjuvanted PRV-1 (InactPRV-1), but without the replication boost seen in some
fish in the PRV-2 group. In fish infected with PRV-3, the PRV-1 infection was completely
blocked, except for two individuals showing high Ct levels in the spleen, one of which also
had detectable PRV-3 in the heart.
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Figure 5. Development of PRV-1-infection after exposure by cohabitation. The level of PRV-1 after infection with PRV-1
shedders at 10 weeks was monitored by RT-qPCR at Weeks 12, 15 and 18 in the spleen (A) and Weeks 15 and 18 in the heart
(B). Each dot represents an individual Ct value with a line (median) at each sampling. Dot color: Fish pre-injected with
PRV-2 (Blue), PRV-3 (green), Inactivated PRV-1 (Yellow), or mock (grey), then secondary infected with PRV-1 where marked.
Statistical analyses were performed by comparing each target group with the PRV-1 control group at each time point using
the Mann–Whitney test. Asterisk shows significant difference (*** p < 0.001); wpi = weeks post immunization.
Hearts from fish sampled at 15 and 18 weeks after PRV-1 infection by shedders, and
the corresponding uninfected control group, were prepared for histopathology and scored
for tissue changes consistent with HSMI (score system 0–3 [11], Figure 6, Supplementary
file S6). At 15 weeks, heart pathology was seen only in the PRV-1 group infected ip at
the beginning of the trial (five of eight fish had mild lesions, i.e., a score of 1). HSMI-like
lesions were present in all individuals in the mock + PRV-1 control group (positive control)
at Week 18, with a median HSMI pathology score of 2.5 (1.5–2.5). For the PRV-2 + PRV-1
group, the median pathology score was reduced to 2 (six out of eight fish had lesions), and
for the PRV-3 + PRV-1 group pathology was completely absent in all eight fish (a score of
0). Six out of eight fish from the InactPRV-1 + PRV-1 group were also without heart lesions.
The group infected with PRV-1 ip Week 0 showed a median pathology score of 1 (six out of
eight fish had mild lesions), 18 weeks after infection.
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3.6. Immune Responses after Challenge of Immunized Salmon
The specific antibody response (Figure 7A, Supplementary file S4) and cellular cyto-
toxic immune gene activation—Granzyme A, IFNγ (Figure 7B,C, Supplementary file S5)—
were monitored after the PRV-1 challenge at Experimental Weeks 12–18 (two to eight weeks
after exposure to shedder fish). The positive control group showed specific and unspecific
antibody production and induction of Granzyme A and IFNγ levels in the spleen. The
PRV-1-induced antibody response tended to be higher in some fish in the PRV-2 immunized
group and lower in fish immunized with inactivated PRV-1. Both observations were in
line with the PRV-1 levels found in the spleen. Both groups induced Granzyme A and
IFNγ transcripts in fish with high PRV-1 loads, but not in individuals with low PRV-1
loads. In the fish immunized with PRV-3, the antibody levels declined from Week 10 to 18,
and since the fish were protected against PRV-1 infection, the antibodies observed most
likely resulted from the initial immunization with PRV-3. No regulation of cytotoxic T-cell-
associated immune genes was seen. The antibody levels in this group can be compared to
the group infected with PRV-1 at Week 0, which showed even higher levels of anti PRV-1
σ1 antibodies during Weeks 12–18. In contrast, whereas fish that were PRV-1 infected Week
0 still had induced levels of Granzyme A in their spleens, the PRV-3-injected group did not.




Figure 7. Immune responses in the spleen after PRV-1 challenge of immunized fish. (A) Magnetic 
beads coated with recombinant lipid-modified PRV antigens (LM-PRV-1σ1, PRV-1 µ1c), and non-
PRV antigens (ISAV-FP or LM-ISAV-FP), used in a multiplexed assay to measure antibodies from 
diluted blood plasma sampled from fish in the trial groups. Levels of fluorescent secondary anti-
body bound to the beads (median fluorescence units, MFI) carrying PRV-antigens (red) and non-
PRV antigens (gray/black) were assayed. (B) Gene expression of Granzyme A. (C) Gene expression 
of IFNγ in spleen samples from fish injected with PRV-1 (red), PRV-2 + PRV-1 (blue),  PRV-3 + 
PRV-1 (green), InactPRV-1 + PRV-1 (yellow), mock negative control, and mock + PRV-1 positive 
control groups (black). 
4. Discussion 
We clarified the potential of the PRV genotypes PRV-2 and PRV-3 to cross-protect 
against PRV-1 and HSMI, compared them with an inactivated PRV vaccine, and studied 
some of the possible protective mechanisms involved. Cross-protection induced by re-
lated low virulent virus variants was the first successful immunization strategy more than 
200 years ago. It was then found that smallpox was prevented by previous exposure to a 
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combinant lipid-modified PRV antigens (LM-PRV-1σ1, PRV-1 µ1c), and non-PRV antigens (ISAV-FP or LM-ISAV-FP), used in a
multiplexed assay to measure antibodies from diluted blood plasma sampled from fish in the trial groups. Levels of fluorescent
secondary antibody bound to the beads (median fluorescence units, MFI) carrying PRV-antigens (red) and non-PRV antigens
(gray/black) were assayed. (B) Gene expression of Granzyme A. (C) Gene expression of IFNγ in spleen samples from fish injected
with PR -1 (red), PRV-2 + PRV-1 (blue), PRV-3 + PRV-1 (green), InactPRV-1 + PRV-1 (yellow), mock negative control, and mock +
PRV-1 positive control groups (black).
4. Discussion
We clarified the potential of the PRV genotypes PRV-2 and PRV-3 to cross-protect
against PRV-1 and HSMI, compared them with an inactivated PRV vaccine, and studied
some of the possible protective mechanisms involved. Cross-protection induced by related
low virulent virus variants was the first successful immunization strategy more than
200 years ago. It was then found that smallpox was prevented by previous exposure to a
low virulent pox virus infecting cows [43]. This strategy was used for several years before it
was published by Jenner in 1796. A cross-protective approach to immunization introduces
many uncertain factors. The theoretical ability of the low virulent virus to cause low-grade
disease, develop into virulence over time, or cause disease in other species requires initial
mapping and testing. Nevertheless, a replicating mimic of the disease-causing virus itself
has th potential of b ing the ultimate inducer f efficient immune pr tection, as this will
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set off the exact mechanisms used to fight the virus. The rationale for this study is to
increase our understanding of cross-protective mechanisms, aiming for the design of more
efficient future vaccination approaches.
Although the three PRV genotypes mainly cause disease in different salmonid species,
evidence of cross-species infection exists. PRV-1 infect coho salmon, Chinook salmon, and
rainbow trout in addition to Atlantic salmon [25], and PRV-3 infects rainbow trout and
coho salmon in addition to brown trout [27]. Our observations of experimental infection of
Atlantic salmon with PRV-3 confirmed those of a previous study where it was observed that
PRV-3 replicated and persisted over a period of 16 weeks and transmitted less efficiently to
naïve cohabitants, compared to PRV-1 [29]. Infection with PRV-2, however, is less studied
in other species than farmed coho salmon. Here, we show that PRV-2 can infect and
replicate in Atlantic salmon after injection, although not as efficiently as PRV-1 and PRV-3.
This ability of both PRV-2 and PRV-3 to infect and replicate in Atlantic salmon calls for
awareness of all three viruses in aquaculture and breeding.
As previously shown in several previous experimental challenge studies [5,15,44], the
PRV-1 genetic variant used in this trial, originating from a Norwegian disease outbreak,
induces HSMI in Atlantic salmon. The same ability to cause HSMI experimentally has not
been found for Canadian PRV-1 genetic variants [22,23]. The differences in pathogenicity
induced by PRV-1 variants was demonstrated experimentally in 2020 [15], and shown
to be associated with genetic differences within four out of the ten genetic segments of
PRV. Properties of the outer capsid and virus dissemination in the host was suggested as
determinants of pathogenicity [15]. Considering the overall similarities between the PRV
genotypes at the amino acid level, PRV-1 is more similar to PRV-3 (90% identity) than to
PRV-2 (80%) [31]. The most prominent genetic differences were found in the segment S1,
encoding the outer clamp protein σ3 and the non-structural protein p13, encoded by an
internal open reading frame. These proteins have both been suggested to be implicated in
the pathogenicity of PRV [6,45,46], σ3 for promoting virus replication by dsRNA binding
and inhibition of the dsRNA-activated protein kinase PKR [47] and p13 for inducing
cytotoxicity [45]. The σ3 and p13 proteins are among the least conserved between the
PRV genotypes. For PRV2, σ3 and p13 aa identities to PRV-1 homologues are 69.7 and
62.9%, and for PRV-3 the identities are 79.1 and 78.2%, respectively [31]. The rather low
aa conservation could potentially be of importance for the host-specific pathogenicity
differences of these viruses, or their ability to interact with each other during infection.
When focusing specifically on the amino acid sequence of the outer capsid protein
σ1 (S4) from PRV-1, used as antigen in the bead-based immunoassay [39], the identity is
82% with PRV-3 and only 67% with PRV-2 (NCBI database). Since σ1 is considered to be
the receptor-binding protein of PRV [6], its sequence variation may explain the species
specificity, and the lack of transmission to naïve cohabitants in Atlantic salmon. The higher
amino acid identity between PRV-1 and PRV-3, which is in line with their main host species
being more closely related, consequently gave a more efficient infection and replication of
PRV-3 compared to PRV-2 in Atlantic salmon. A higher rate of virus replication and higher
amino acid identity for σ1 as well as for other virus proteins could explain the higher
level of cross-binding antibodies detected after PRV-3 infection and thus the higher cross-
protecting effect. Although the genetic diversity in PRV-1 is generally not associated with
the σ1 gene, it is possible that cross-protection could be different against the genotypes.
In this trial, histological analyses were performed only in the late phase of the trial,
i.e., after 18 weeks. At that time, PRV-2 was eradicated from the heart, and PRV-3 levels
were low, with Ct values above 30 in 50% of the fish and the remaining fish virus being
negative. Compared to this, 100% of the fish injected with PRV-1 at the start of the trial
were still virus positive in the heart after 18 weeks, with Ct-levels around 20. We cannot
completely rule out that heart inflammation occurred at some point after injection with
PRV-2 and PRV-3. In a former study on PRV-3 in Atlantic salmon, minor inflammatory foci
were detected in the PRV-3-infected hearts [29], but these findings were not comparable,
neither to the inflammation induced by PRV-3 in rainbow trout hearts nor to HSMI in
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Atlantic salmon. Infection and pathological changes in other organs, such as the liver and
kidney, earlier shown to be sites for PRV replication [21,48,49], or pathological changes at
earlier time points in heart cannot be ruled out either, as this was not explored here.
Based on analyses of spleen and heart, PRV-2 appears to be eradicated a few weeks
after infection in Atlantic salmon compared to PRV-1 and PRV-3. PRV-2 loads in spleen
were similar to those of PRV-3 two weeks after infection, but after 5 weeks PRV-2 levels
declined, whereas PRV-3 and PRV-1 levels increased. PRV-3 is reported to be successfully
cleared in rainbow trout after infection, not moving into persistence like PRV-1 in Atlantic
salmon [29,30]. However, PRV-3 appeared to persist for at least 18 weeks in Atlantic salmon
in our study, and also for 16 weeks in a former study [29]. This may indicate that persistence
is related to host factors in farmed Atlantic salmon.
In the magnetic bead-based assay used to detect anti-PRV antibodies, the PRV-1 LM-σ1
antigen has earlier been found to be the most efficient antigen for antibody detection [39].
PRV-3 triggered the production of antibodies that were able to cross-bind to PRV-1 LM-σ1.
PRV-1 infection has previously been reported to also trigger the production of polyreactive
antibodies that bind to non-PRV control antigens [39]. Similarly, we observed high levels
of background binding to the ISAV-F-protein control antigens after PRV-1 infection. The
production of polyreactive antibodies start at the same time as the more specific antibodies
but decrease earlier. The polyreactive antibody response was not seen after PRV-2 or PRV-3
infection. This could be linked to the much higher innate antiviral response triggered by
PRV-1, which correlated with the replication efficiency or load of virus for this genotype,
compared to the other genotypes. This phenomenon will be subject to further study.
Low levels of antibodies binding to PRV-1 σ1 was observed in blood from PRV-2-
injected individuals as well, but only in a short time frame while the virus was still present.
Although this low antibody level did not lead to protection from PRV-1 and HSMI, the
specificity against PRV antigens and association with virus eradication is notable.
The inactivated, adjuvanted PRV-1 vaccine did not induce any measurable antibodies
against PRV-1 σ1. Still, the inactivated PRV-1 vaccine lowered PRV-1 infection levels after
secondary challenge, and protected six out of eight individuals from HSMI, in line with
previous findings [33]. The mechanism behind this effect is not clear, as neither innate
immune activation nor cellular immune activation was revealed through the analyses
performed here. We cannot rule out if an early immune activation was triggered by the
adjuvant or if antibody-based protection targeting PRV-1 antigens other than PRV-1 σ1
is involved [6]. It is also possible that the inactivation procedure may have changed the
structure of the σ1 protein in the inactivated viral particle, as it is in an exposed position in
the outer capsid.
The PRV-3 pre-exposure totally blocked PRV-1 infection. Cross-protective antibodies
are likely to be one explanation but are most likely not the only one. Several fish had very
low levels of detectable antibodies in plasma after 10 weeks, but PRV-1 infection was still
completely blocked in these fish. The analysis of expressed antiviral immunity genes and
indicators of cellular adaptive immunity (cytotoxic cell markers) did not indicate that these
mechanisms were triggered by PRV-3 beyond 10 weeks, at least not in spleen, which was
tested. The almost total infection block may lead us to think that protective mechanisms
have been induced also at mucosal surfaces, although PRV-3 was given ip and not as a
bath exposure. In general, orthoreoviruses enter through respiratory and gastrointestinal
mucosal surfaces. Although PRV-1 is reported to infect via the intestinal wall [13], it may
use other ports of entry as well. The infection route of PRV-3 has not been studied but could
be assumed similar to that of PRV-1. This could point to a mucosal protection mechanism
involved in the blockage of PRV-1 infection by PRV-3, which would be a highly desired
effect of a future vaccine. Such a PRV-1-blocking effect was not obtained with previous
PRV-2 exposure or the inactivated PRV-1 vaccine. It should be noted that PRV-3, but not
PRV-2, persisted in the spleen of all fish when they were exposed to PRV-1, and further
until the end of the study (18 weeks). It may be that the almost full protection and blocking
of PRV-1 infection is dependent on the presence of PRV-3.
Vaccines 2021, 9, 230 16 of 20
All PRV isoforms infect red blood cells, and PRV-1 is shown to strongly induce
interferon-regulated antiviral genes in these cells [50]. Thus, the blocking of secondary
PRV-1 infection could be a result of red blood cells in an antiviral state. This would be
reflected in analysis of spleen antiviral responses. However, very little innate antiviral
immune response was induced by PRV-3 in Atlantic salmon although fish were still infected
with the virus after 10 weeks. This is remarkably different to a PRV-1 infection, which
induces long-lasting antiviral responses. PRV-3 is also reported earlier to induce antiviral
responses in rainbow trout [29,30], but not in Atlantic salmon [29]. This difference could be
linked to the observed differences in pathogenicity in the two species, but this is still not
confirmed and will be further explored.
For PRV-2, 50–80% of the fish had cleared the virus between 10 and 18 weeks after
infection. In this group, we found a contradictory effect on PRV-1 infection and HSMI.
As two out of eight fish did not develop HSMI, there was no effect on the remaining
six. In addition, PRV-1 levels were lower in some fish, but strongly boosted in others. It
appeared that PRV-1 may have replicated more efficiently in some of the individuals that
had eradicated PRV-2, compared to individuals that had not. Like for PRV-3, we did not
detect innate antiviral immune responses to PRV-2 infection 10 weeks after infection.
PRV-1 induces cytotoxic T-cell (CTL) activity in Atlantic salmon [17,37], which is
strongly associated with HSMI pathology [16], and also heart inflammation in rainbow
trout infected with PRV-3 [30]. Here, there is clear evidence that PRV-1 induces a strong
regulation of innate antiviral and cytotoxic immune response genes 10 weeks after infection,
which is not induced by PRV-2 or PRV-3, and which is likely to be decisive for HSMI pathol-
ogy. The role of CTL activity in vaccine effects and long-term protection against viruses in
salmonids is not much studied, but specific cytotoxicity against the salmonid alphavirus
(SAV) has recently been explored after vaccination with an adjuvanted inactivated SAV
vaccine, in comparison with SAV infection [51]. There, it was clearly demonstrated that
while SAV infection induced specific cytotoxicity, only unspecific cytotoxic activity was
induced by the vaccine [51]. It would, in a follow-up study, be interesting to compare spe-
cific CTL activity in the period after PRV-2 and PRV-3 infection to explore any correlation
with the ability to cross-protect against PRV-1.
This study illustrates some potential pitfalls in using replicating viruses for vaccine
purposes. They may be very efficient, like PRV-3, which completely blocks PRV-1 infec-
tion. However, PRV-3 itself persists in the fish, which may have unknown long-term
consequences.
This study also indicates that antibodies against the putative receptor-binding protein
σ1 may be an important protective measure. PRV-3, but not PRV-2, induced the production
of anti-σ1 antibodies. This could be due to the higher replication rate of PRV-3 to PRV-2 in
Atlantic salmon and the higher identity between the σ1 protein of PRV-1 and -3. A protec-
tive effect could eventually be verified in a passive immunization test by administration of
purified serum immunoglobulin from PRV-3-infected fish to PRV-1 experimentally infected
fish. The long-term protective effects of these antibodies will be subject to follow-up ex-
periments, as we could observe a decline after > 15 weeks of PRV-3 infection. If plasma
antibodies are also involved in blocking infection at mucosal surfaces is an open question.
PRV-2 replicates at low levels in Atlantic salmon and is eventually cleared, which
normally could be considered beneficial properties of a “live” replicating vaccine. However,
the replication must be at a level sufficient to induce an effective immune response. Here,
only minor innate and cellular responses were found at the transcript level. However,
there may be effects at the post-transcriptional or post-translational levels that we did not
monitor. PRV-2 caused contradictory results by protecting some fish from HSMI but causing
even higher susceptibility to PRV-1 infection in others. The large individual differences
could possibly be due to host genetics, leading to a different ability to present antigen. This
study also confirms the partial efficiency of the inactivated PRV-1 vaccine published earlier;
although, it is still without a clear answer to the main mechanism of protection.
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Besides the obvious pitfalls in immunizing Atlantic salmon against HSMI with PRV-3,
a virus pathogenic to rainbow trout [28], there are also additional concerns associated
with a live attenuated vaccination approach. Segmented RNA viruses may reassort or
recombine if two related genotypes infect the same cell [52], creating new viruses with
unpredictable properties, potentially pathogenic.
Future vaccine production can provide us with reverse genetic approaches and viruses
tailored by synthesis and gene editing. Combined with thorough long-term studies of
risks and effects of the different vaccine approaches and a higher repertoire of ways to
measure vaccine effect, this will hopefully ensure safe and effective attenuated vaccines in
the future.
5. Conclusions
This work show that PRV-1, PRV-2 and PRV-3 replicate in Atlantic salmon, and can
induce production of antibodies that bind to the PRV-1 σ1 antigen. Only PRV-1 in-fection
induce unspecific antibodies, long-lasting expression of antiviral response genes and
cytotoxic genes in spleen in Atlantic salmon, which could be associated with the ability
to cause HSMI. When compared to vaccination with an inactivated PRV-1 vaccine, PRV-3
infection provides full protection from PRV-1 introduced ten weeks later, and development
of HSMI. In comparison, inactivated PRV-1 vaccine and PRV-2 infection does not prevent
PRV-1 infection and only partially protects against HSMI. This work indicates that a
replicating attenuated vaccine approach could protect against HSMI.
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